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Neurological disorders are a major public health problem and are expected to 
rise dramatically together with the higher life expectancy and the shift towards an 
ageing society. Current therapeutic options can only ameliorate some of the 
symptoms and there are no effective treatments to target pathological 
mechanisms and stop disease progression. The human brain complexity hampers 
the understanding of the brain functioning at the molecular, cellular, and 
pathophysiological levels for many neurological disorders. This highlights the need 
for new brain models, which can contribute to unveil molecular mechanisms of 
neurological disorders, identify therapeutic targets and evaluate preclinically new 
therapies in a more adequate and predictive basis, withstanding its successful 
translation to the clinics. Despite their undeniable value, traditional animal models 
diverge from humans at biochemical and genetic levels. Moreover, 2D in vitro cell-
based models do not mimic important aspects of brain cellular heterogeneity, 
architecture and microenvironment.  
The main goal of this thesis was the development, validation and interrogation 
of 3D in vitro brain models for disease modeling and drug discovery. These models 
should include the presence of differentiated and functional human neurons and 
astrocytes, able to recapitulate the neuron-astrocyte interactions present in human 
brain, and mimic the endogenous microenvironment without the confounding 
effects of an exogenous matrix. To accomplish this, we took advantage of agitation-
based culture systems to promote cellular aggregation and neural differentiation 
into neurospheroids. This strategy allows neural cells to establish cell-cell and cell-
extracellular matrix (ECM) interactions and generate complex 3D networks within 
the neurospheroids.  
For drug screening applications, the human NTera2 (NT2) cell line was chosen 
to develop neurospheroids, since it provides an unlimited number of cells, with less 
expensive and time-consuming differentiation protocols. The development of a 




neurospheroids enriched in mature and functional human neurons and astrocytes 
is described in chapter 2. Toxicity assessment of prototypical neurotoxicants, 
combining endpoints based on neuronal- and astrocytic-specific gene expression 
and functionality in 3D, validated this brain cell model as a powerful tool to 
evaluate human neuronal and astrocytic toxicity. The potential of the NT2-derived 
neurospheroids for neuroprotection assessment was further validated. 
Implementation of an in vitro neuroprotection assay combining the human neuron-
astrocyte co-culture neurospheroids with a cell viability endpoint is described in 
chapter 3. The neuroprotection assay setup was applied to several chemical and 
naturally-synthesized compounds and revealed several candidates with 
neuroprotective effect against an oxidant lesion. The robustness and simplicity of 
these assays enabled the use of complex 3D brain cell models as a platform to 
identify neurotoxic agents and to identify and validate drug candidates. This 
highlights the potential of 3D human brain cell models for drug testing, including 
both neurotoxicity and neuroprotection assessment.  
For disease modelling, patient-specific induced pluripotent stem cells (iPSC) 
were used, as these can be differentiated in vitro into relevant somatic lineages 
with the genetic background of the patients. In chapter 4, the development of a 
Mucopolysaccharidosis type VII (MPS VII) human disease model, able to 
recapitulate the neuronopathic form of the disease is described. MPS VII is an 
orphan, ultra-rare, lysosomal storage disease (LSD) caused by a deficiency in β-
glucuronidase enzymatic activity, which leads to an abnormal accumulation of 
glycosaminoglycans (GAGs) in the lysosomes of many tissues, including in the brain. 
For healthy and MPS VII iPSC-derived neural progenitor cells (NPC) 3D neural 
differentiation we took advantage of a strategy previously implemented in our 
laboratory using software-controlled perfusion stirred-tank bioreactors. The results 
demonstrated that neural differentiation of human MPS VII iPSC-NPC recapitulate 
major disease features, specifically GAGs accumulation. MPS VII neurospheroids 




disturbance in MPS VII neuronal network activity and network functional 
connectivity, when compared with neurospheroids derived from iPSC of a healthy 
donor. This MPS VII human brain cell model can potentially contribute to elucidate 
the cellular processes responsible for disease progression and brain dysfunction 
and be applied for in vitro assessment of appropriate pharmacological treatments. 
The tools developed, namely the 3D neurospheroid culture system combined with 
the neuronal connectivity assay, have potential to assess neurological defects in 
other LSD and neurological disorders with variable phenotypes. 
The work developed in this thesis provides simple and versatile in vitro approaches 
to generate human brain cell models for disease modeling and drug discovery that 
recapitulate human neuron-astrocyte interactions. Furthermore, the strategies 
described herein can be applied to other sources of neural cells or to iPSC from 















As doenças neurológicas consituem um problema de saúde pública grave e 
prevê-se que a sua incidência aumente em paralelo com o aumento da esperança 
média de vida e o consequente envelhecimento da população. Os tratamentos 
disponiveis atualmente apenas aliviam alguns dos sintomas, não existem 
tratamentos efetivos, direccionados aos mecanismos patológicos e que impeçam a 
progressão das doenças. A elevada complexidade do cérebro humano dificulta a 
compreensão do seu funcionamento a nivel molecular, celular e patofisiológico. 
Isto demonstra a necessidade de desenvolver novos modelos celulares que 
contribuam para desvendar os mecanismos moleculares envolvidos no 
desenvolvimento e progressão das doenças neurológicas, identificar alvos 
terapêuticos e avaliar novas terapias de forma mais adequada e preditiva, 
garantindo o sucesso na sua translação para a clinica. Apesar da sua importância, 
os modelos animais usados tradicionalmente divergem dos humanos a nivel 
bioquimico e genético. Além disso, os modelos celulares bidimensionais (2D) não 
mimetizam aspectos importantes do cérebro humano, tais como a sua 
heterogeneidade celular, arquitectura e microambiente.  
O objectivo principal desta tese é o desenvolvimento, validação e interrogação 
de modelos celulares de cérebro, com aplicação na descoberta de fármacos e em 
modelos de doenças neurológicas. Estes devem incluir neurónios e astrócitos 
humanos, diferenciados e funcionais, capazes de recapitular as interacções 
neurónio-astrócito existentes no cérebro humano e mimetizar o microambiente 
endógeno, sem a perturbação de uma matriz exógena. Foram usados sistemas de 
cultura agitados para promover a agregação celular e a diferenciação neural. Esta 
estratégia permite às células nos neuroesferóides estabelecer interacções célula-
célula e célula-matriz e gerar redes neuronais tridimensionais complexas.  
Para aplicações em testes de fármacos, foi escolhida a linha celular Ntera2 
(NT2), uma vez que permite obter um número ilimitado de células, com protocolos 




bioprocesso robusto e escalonavél, que permitiu a produção de neuroesferóides 
enriquecidos em neurónios e astrócitos humanos, maturos e funcionais, é descrito 
no capitulo 2. A avaliação da toxicidade de compostos neurotóxicos prototípicos, 
combinando endpoints baseados na expressão génica e na funcionalidade neuronal 
e astrocitica, permitiu validar este modelo como uma metodologia eficaz para 
avaliar toxicidade em neurónios e astrócitos humanos. A possibilidade dos 
neuroesferóides serem utilizados para avaliação de neuroprotecção foi também 
avaliada. A implementação de um ensaio in vitro para avaliar neuroprotecção, 
combinando a co-cultura de neurónios e astrócitos humanos em neuroesferóides e 
um endpoint de viabilidade celular, é descrita no capitulo 3. Este ensaio foi aplicado 
a diversos compostos, quimicos e sintetizados naturalmente e revelou vários 
candidatos com efeito neuroprotector contra uma lesão oxidativa. A robustez e a 
simplicadade destes ensaios potencia o uso de modelos celulares 3D mais 
complexos como plataforma para identificar compostos neurotóxicos e novos 
fármacos. Isto demonstra o potencial da aplicação de modelos celulares neurais 
para teste de fármacos, incluindo avaliação de neurotoxicidade e de 
neuroprotecção.  
Para desenvolvimento de um modelo de doença, foram usadas células 
estaminais pluripotentes induzidas (iPSC), uma vez que estas podem ser 
diferenciadas in vitro em linhagens somáticas relevantes para o fenótipo da doença 
com os antecedentes genéticos dos pacientes. No capitulo 4 é descrito o 
desenvolvimento de um modelo celular humano que recapitula a forma 
neuronopática da doença Mucopolissacaridose tipo VII (MPS VII). A MPS VII é uma 
doença lisossomal de sobrecarga (DLS), orfã e ultra-rara, causada por uma 
deficiência na actividade do enzima β-glucuronidase, que leva à acumulação de 
glicosaminoglicanos (GAGs) nos lisosomas de diversos tecidos, incluindo no 
cérebro. Para diferenciação de células progenitoras neurais (NPC) derivadas de iPSC 
de um dador saudável e de outro com MPS VII, foi aplicada uma estratégia já 




Os resultados demonstraram que o modelo neural de MPS VII, derivado de iPSC-
NPC humanas, recapitula as principais caracteristicas da doença, nomeadamente a 
acumulação de GAGs. Os neuroesferóides da doença revelaram uma 
sobreexpressão do gene astrocitico GFAP e distúrbios na funcionalidade da rede 
neuronal e na sua conectividade, quando comparados com os neuroesferóides 
derivados do dador saudável. Este modelo celular humano de MPS VII pode 
contribuir para elucidar os mecanismos celulares responsáveis pela progressão da 
doença e pela disfunção cerebral e ser aplicado na avaliação de tratamentos 
farmacológicos adequados para a doença. As metodologias desenvolvidas, 
nomeadamente o sistema de cultura de neuroesferóides, combinado com o ensaio 
de avaliação da funcionalidade e conectividade neuronal, podem ser aplicados na 
avaliação de defeitos neurológicos em outras DLS e doenças neurológicas com 
fenótipos variáveis.  
O trabalho desenvolvido nesta tese fornece abordagens simples e versáteis 
para gerar modelos in vitro de células neurais humanas, com aplicação em ensaios 
pré-clínicos, que recapitulam as interações neurónio-astrócito presentes no 
cérebro humano. Para além disso, esta estratégia pode ser aplicada a outras fontes 
de células neurais ou a células de outras doenças neurológicas, para avaliar 
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1. Neuroscience research: need for CNS modeling  
Neurological disorders are a major public health problem and are expected to 
rise dramatically together with the increase in life expectancy and the shift towards 
an ageing society. Around 450 million people currently suffer from mental 
disorders and the forecasts indicate that by 2050 the number will triple (WHO 
Mental Disorders Fact Sheet, 2017). Neurological disorders represent significant 
economic and social burdens and high costs for healthcare systems, accounting for 
as much as 45% of the annual health budget in Europe (DiLuca et al., 2014; Harper, 
2014; Rosemann, 2015). Current treatments for most neurological disorders only 
ameliorate some of the symptoms, alleviating patient’s mental impairment. 
Despite major and continuously growing investment, there are no effective 
disease-modifying treatments available to target pathological mechanisms and stop 
disease progression (Calcoen et al., 2015; Payne et al., 2015). Drug development 
pipeline have proven lengthy, costly and relatively unproductive process (Fig. 1.1) 
with a high number of late-stage failures and attrition rates around 90% (Calcoen et 
al., 2015; Hay et al., 2014). This is even worst for central nervous system (CNS) 
drugs, which are more likely to fail in Phase III drug development than non-CNS 
drugs, mainly due to lack of efficacy (Kesselheim et al., 2015). On average, the 
overall success rate is of 4.1%, but for example, in Alzheimer’s disease (AD) drug 
development, from 2002 to 2012, 413 clinical trials have been performed, mainly 
with drugs to improve cognition and disease-modifying small molecules or 
immunotherapies, with an overall success rate of only 0.4% (Calcoen et al., 2015; 






Figure 1.1: Drug discovery pipeline in the pharmaceutical industry. The different stages of drug 
development process (drug discovery, preclinical research, clinical trials and regulatory approval); 
typically only 1 in 10 000 compounds are approved and the process costs more than 1 billion euro 
overall. 3D cell models can represent a complementary tool in preclinical research, offering increased 
predictive capacity, when compared to 2D cell-based assays. The use of these models can be parallel 
to animal models, reducing the dependency on animal models, costs and time. Adapted from Kunz-
Schughart et al., (2004) and from http:// www.researchamerica.org/ advocacy-action/ issues-
researchamerica-advocates/bench-bedside-drug-development-pipeline. 
This highlights the need for novel preclinical models that enable new therapies 
to be developed and tested in a more adequate and predictive context, reducing 
the number of drugs that will fail in late-stages clinical trials (Fig. 1.1). To do so, the 
understanding of the pathophysiological bases for many neurological disorders is 
essential. However, the high degree of complexity of the human brain and its poor 
accessibility in vivo makes it difficult to investigate specific biochemical and cellular 
mechanisms. While of undeniable value, animal models and several in vitro cell-
based models fail to precisely recapitulate the clinical pathophysiological state, 





accounted for the fact that animal and in vitro models do not mimic important 
aspects of the in vivo brain cellular composition, architecture and 
microenvironment. Animal models have been widely used to study genetic and 
pathological mechanisms of neurodegenerative diseases and to test new 
therapeutic drugs (Breslin and O’Driscoll, 2013; Fitzgerald et al., 2015). While 
mimicking brain tissue complexity, at biochemical and genetic levels there are 
differences between species and many human diseases resulting from complex 
interactions between genes and environmental factors can not be recapitulated in 
animals (Payne et al., 2015). Indeed, concordance between rodents and human 
toxicity can be very low with rodents being predictive of human toxicity in less than 
half of the cases (Olson et al., 2000). The transcriptional profile of AD mouse 
models is not similar to human AD (Hargis and Blalock, 2018) and these models do 
not reflect the extensive neuronal loss seen in the human condition (LaFerla and 
Green, 2012). Consequently, numerous drugs that demonstrated efficacy in the 
animal models have not shown efficacy when translated to the clinic. In fact, 
around 500 neuroprotective therapies that were successfully developed in rodent 
models of stroke, failed at some stage when translated to humans, with only one 
treatment being approved (O’Collins et al., 2006; Sena et al., 2010). Furthermore, 
human in vitro models for neurological disorders are commonly based on neuronal-
like cell lines, mainly tumor-derived, but these do not recapitulate the cell 
heterogeneity of human brain and its microenvironmental features and are not 
genetically matched to the patient (Choi and Tanzi, 2012; Ross and Akimov, 2014). 
The recent advances in cell reprogramming technologies and pluripotent stem cell 
(PSC) neural differentiation strategies, allowing obtaining neural cells with the 
genetic background of the patient, provided unique opportunities to investigate 
important aspects of brain function, development and disease pathogenesis at 
cellular level. Therefore, given our poor understanding of the pathogenesis of 





in vitro models, it is clear that there is a high demand to develop brain cell models 
that can withstand a successful translation of drugs to the clinics.  
2. Human cell sources for CNS modeling 
Human cell sources available for the derivation of neural cells for CNS modeling 
can be divided into two main categories: (1) primary cultures of human brain cells 
and (2) immortalized cell lines and in vitro differentiation of neural cells (Fig. 1.2). 
 
Figure 1.2: Different cell sources available for the derivation of human neural cells. Neural 
progenitor cells (NPC) or neural cells can be isolated directly from human fetal or adult brains. NPC 
are able to keep to some extent their self-renewal and multipotent capacities and can be 
differentiated into neural cells. Embryonic stem cells, isolated from blastocyst inner cell mass, and 
induced pluripotent stem cells, can be committed towards the neural lineage through neural 
induction protocols, generating neural progenitor cells, which can be further differentiated into 
neural cells. Somatic cells can be reprogrammed into induced pluripotent stem cells or directly 
reprogrammed into neural progenitor cells or terminally-differentiated neural cells. Immortalized cell 
lines are usually derived from tumor cells and some of these present ability to differentiate towards 
neural lineage into neural-like cells by addition of neurotrophic factors. Adapted from Conti and 





2.1. Primary cultures 
Human brain cells isolated from fetus, can be maintained in vitro as primary 
cultures, including one or several brain cell types (Darbinyan et al., 2013; Mattson 
and Rychlik, 1990; Ray et al., 2014), or ex vivo as organotypic slice cultures, keeping 
the in situ cellular organization and three-dimensional (3D) tissue architecture 
within the slice (Humpel, 2015). The first cell culture of human neurons isolated 
from live adult brain was recently reported (Spaethling et al., 2017), with 
identification of 5 distinct cell types in culture: oligodendrocytes, microglia, 
neurons, endothelial cells and astrocytes and cell-type- and individual-specific 
transcriptional hierarchies were identified. Although it is a very valuable resource, 
the use of human brain tissue is limited due to the lack of availability and ethical 
concerns. Additionally, human brain tissue to study development and early defects 
in neurological disorders is not readily available, as brain biopsies from living 
patients are limited, and autopsy material is normally representative of later 
disease stages and limits sample quality (Darmanis et al., 2015). The use of 
terminally-differentiated cell types isolated from the CNS, as neurons, is also 
limited due to the impossibility of expansion in vitro. To overcome these issues, 
self-renewing multipotent neural stem cells (NSC) can be isolated from specific 
niches in fetal or adult brain tissue and expanded and terminally differentiated in 
vitro into neurons and glia cells (Conti and Cattaneo, 2010; Simão et al., 2014). 
Primary NSC have a limited self-renewal capacity in vitro due to the low level of 
expression of telomerase, which is required for continuous cell proliferation 
(Ostenfeld et al., 2000). Moreover, NSC differentiation potential, temporal 
development and phenotype varies with the tissue age, in vitro expansion and 
culturing method (Conti and Cattaneo, 2010; Zhang, 2006). Altogether, these 
aspects highlight the great limitations in the use of primary cell sources from CNS 





2.2. Immortalized cell lines and in vitro differentiation of 
neural cells  
Historically, the first hypothesis to overcome the difficulties associated with the 
use of primary cultures of brain cells was to establish immortalized cell lines. These 
can be from tumoral origin or immortalized in vitro by transfection of oncogenes. 
The advantages include being easy to obtain and allowing expansion of large 
numbers of cells. However, most of immortalized cell lines, as the widely used 
neuroblastoma cell lines, have the disadvantage of continuous proliferation, as 
they not generate post-mitotic cell-types and therefore do not allow the 
recapitulation of the neuronal development occurring in the CNS, as well as the 
organ-specific structural and functional features (Conti and Cattaneo, 2010; Gupta 
et al., 2012). The majority of the cell lines can be induced in vitro to differentiate in 
a more neuronal-like phenotype, usually by removal of specific growth factors or 
addition of neurotrophic factors. The human neuroblastoma cell line SH-SY5Y, 
which grows continuously as an undifferentiated cell population with neuroblast-
like morphology, can be differentiated towards neuronal-like cells, with retinoic 
acid (RA) or specific neurotrophic factors, such as brain-derived neurotrophic factor 
(BDNF) (Shipley et al., 2016). SH-SY5Y cells have been used for neurotoxicity and 
neuroprotection testing in vitro and to understand the mechanisms of action of 
neurotoxic chemicals, such as okadaic acid and antidepressant drugs (Choi et al., 
2011; Del Barrio et al., 2011). Also, Parkinson’s disease (PD) and AD-associated 
neuronal defects have also been modeled using neuroblastoma cell lines (Dodel et 
al., 2011; Fang et al., 2006; Presgraves et al., 2004). However, these models 
comprise immature neuronal-like cells and do not take into account the multiple 
cell types involved in the brain pathology and their interactions, which contribute 
to the disease.  
Neural progenitor cells (NPC) can be immortalized in vitro, usually by 
transfection of oncogenes, to overcome its limited self-renewal capacity due to 





and differentiated in neural cells. The human fetal NPC Lund mesencephalic cell 
line (LUHMES), immortalized by a tetracycline-controlled v-myc gene, can be 
differentiated into morphologically and biochemically mature dopamine-like 
neurons, following exposure to tetracycline, glial cell line-derived neurotrophic 
factor (GDNF) and dibutyryl cyclic adenosine monophosphate (cAMP). LUHMES 
were used for neurotoxicity testing and for PD modeling (Scholz et al., 2011; Zhang 
et al., 2014), either in co-culture with astrocytic cells (Efremova et al., 2015) or in a 
3D culture setup (Smirnova et al., 2016), in an attempt to increase the level of 
mimicry of the human brain of the model. NPC immortalized in vitro by 
overexpression of the myc family transcription factors (ReNcell cells) were 
differentiated into the three neuronal lineages by removal of growth factors and 
addition of neurotrophic factors (Donato et al., 2007). A high-throughput screening 
assay for evaluation of chemical compounds effects was implemented using this 
ReNcell line (Breier et al., 2008) and differentiated neuronal cells were applied in 
AD modeling, based on overexpression of human b-amyloid precursor protein 
(APP) or APP and presenilin 1 (PSEN1), containing familial AD mutations (Choi et al., 
2014). This 3D culture of differentiated neurons in Matrigel has been reported to 
recapitulate amyloid and tau pathologies with robust extracellular deposition of β-
amyloid, and detection of aggregates of phosphorylated tau in neuronal cell soma 
and neurites (Choi et al., 2014). Notably, this was the first cell-based model able to 
recapitulate key features of AD pathophysiology in vitro, which have not been 
previously observed in mouse models and in in vitro 2D culture systems. The largely 
studied NTera-2 (NT2) cell line, a pluripotent cell line derived from a malignant 
embryonic carcinoma (Pal and Ravindran, 2006; Pleasure and Lee, 1993), upon 
exposure to RA, can be differentiated into neural cells, including neurons and 
astrocytes (Bani-Yaghoub et al., 1999; Goodfellow et al., 2011; Pleasure and Lee, 
1993; Terrasso et al., 2015). NT2-derived neurons maintain a post-mitotic neuronal 
phenotype, with axons and dendrites elaborating processes and synaptic contacts 





GABAergic neurons (Coyle et al., 2011; Podrygajlo et al., 2009). NT2-derived 
astrocytic cells show phenotypic and functional markers, such as glial fibrillary acid 
protein (GFAP), the glutamate transporters GLAST and GLT-1 and the glutamine 
synthase (GS) enzyme (Goodfellow et al., 2011; Hill et al., 2012). NT2 cell line has 
been widely used to model specific neural functions (Goodfellow et al., 2011; Hill et 
al., 2012) and for neurotoxicity studies (Hill et al., 2008; Stern et al., 2013) due to its 
easy expansion in vitro and the simple neural differentiation protocol. In 
comparison with other cell lines, NT2-derived neural cells can attain a high degree 
of maturation, making them an useful human brain cell source. We promoted 
neural differentiation of NT2 cells as aggregates, generating neurospheroids that 
were mainly composed of functional neurons and astrocytes and were further 
applied for drug testing (Simão et al., 2016; Terrasso et al., 2017, 2015).  
Several technological advances are nowadays allowing the derivation of 
human neural cells from different cell sources, such as embryonic stem cell (ESC) 
and induced pluripotent stem cells (iPSC). First human ESC lines were derived by 
Thomson and colleagues in 1998, providing a new starting point to attain 
recapitulation of tissue development in vitro and to generate a wide variety of cells 
types. A decade ago, reprogramming human somatic cells into iPSC by the 
introduction of four embryonic transcription factors (Oct4, Sox2, Klf4 and c-Myc) 
was firstly published by Yamanaka and colleagues (Takahashi et al., 2007). This 
technology opened the possibility of generating PSC with the genetic background 
of patients, which could then be induced to differentiate towards relevant somatic 
lineages, including the neural lineage (Chambers et al., 2009; Fernandes et al., 
2015; Shi et al., 2012).  
Initially ESC were differentiated towards the neural lineage via embryoid 
bodies (EB) formation (Dhara and Stice, 2008; Zhang et al., 2001), but more 
recently directed differentiation factors have been employed to differentiate ESC 
and iPSC into neural cells (Chambers et al., 2009; Shi et al., 2012). NPC can be 





bone morphogenetic protein (BMP) signaling by its antagonist noggin (Gerrard et 
al., 2005). RA and nerve growth factor (NGF) were found to be potent enhancers of 
neuronal differentiation, eliciting extensive outgrowth of processes and the 
expression of neuron-specific molecules (Schuldiner et al., 2001). Directed ESC or 
iPSC differentiation to enriched populations of specific neuronal subtypes can also 
be achieved. Derivation of midbrain dopaminergic neurons was induced by 
sequential application of the patterning molecules Sonic hedgehog (SHH), 
Fibroblast growth factor 8 (FGF8), BDNF, GDNF, transforming growth factor type β 
(TGF-β), dibutyryl cAMP and ascorbic acid (Perrier et al., 2004; Zhang and Zhang, 
2010). Human iPSC-derived dopaminergic progenitor cells, differentiated by floor 
plate induction protocol, using BDNF, GDNF, cAMP and ascorbic acid, were grafted 
into the brain of a primate model of PD (Kikuchi et al., 2017). The authors reported 
that cells survived and functioned as mature midbrain dopaminergic neurons, 
extended dense neurites into the host striatum, indicating that human iPSC-derived 
dopaminergic progenitors are clinically applicable for the treatment of patients 
with PD (Kikuchi et al., 2017). Enriched populations of forebrain GABAergic neurons 
were obtained using purmorphamine and SHH interchangeably for neuroepithelia 
patterning (Ma et al., 2012). Human iPSC generated from Huntington’s disease 
patient were differentiated into striatal GABAergic neurons by combining 
morphogens and neurotrophins SHH, BDNF, dibutyryl cAMP and valpromide that 
contain the same CAG repeat expansion as the mutation in the HD patient (Zhang 
et al., 2010). The generation of a culture enriched in ESC-derived astrocytes was 
first reported by Gupta and colleagues (2012) by combining BMP-mediated Smad 
and LIF-mediated JAK-STAT signaling. These astrocytes promoted the protection of 
ESC-derived neurons against oxidative insults (Gupta et al., 2012). One year later, a 
chemically defined xeno-free medium was developed for fast generation of 
astrocytes from NSC derived from PSC (Shaltouki et al., 2013). Astrocytes 
differentiated by this culture method have been reported to display similar gene 





primary astrocytes (Shaltouki et al., 2013). Human iPSC from healthy individuals 
and patients with early-onset familial AD or late-onset sporadic form of AD were 
differentiated into astrocytes by addition of FGF2, ciliary neurotrophic factor and 
BMP2 (Jones et al., 2017). These astrocytes expressed functional markers, including 
GFAP, GLT-1 and GS, comparable to that of adult astrocytes in vivo, and AD 
astrocytes exhibited a pronounced pathological phenotype, with a significantly less 
complex morphological appearance than healthy astrocytes and aberrant 
expression and localization of GLT-1 and GS (Jones et al., 2017).  
 To shortcut the differentiation process from PSC, somatic cells can be directly 
reprogrammed into a terminally differentiated neural cell types, skipping all 
developmental precursor cell stages, or into an intermediate progenitor stage, such 
as multipotent NSC (Mertens et al., 2016; Pang et al., 2011). Payne and colleagues 
reported that a combination of four transcription factors (Brn2, Ascl1, Myt1l and 
NeuroD1) was enough to convert human fibroblasts into induced neurons (iN) that 
expressed multiple neuronal markers and matured to form synapses and generate 
action potentials. A minimal set of three transcription factors (Mash1, also known 
as Ascl1, Nurr1 and Lmx1a) was described to directly generate functional 
dopaminergic neurons from mouse and human fibroblasts (Caiazzo et al., 2011). 
Direct neuronal conversion, contrary to iPSC reprogramming, does not revert 
putative cellular aging markers. Therefore, these iN could be important tools to 
develop models of sporadic, late-onset neurodegenerative diseases, as aging is one 
of the most important risk factor for these disorders. Contrary, differentiation of 
neural cells from PSC recapitulates human neural development, potentially 
allowing studying neurodevelopmental diseases, impossible to address with iN 
(Mertens et al., 2016). For the generation of induced NSC (iNSC), human fibroblasts 
were directly reprogrammed with a single factor, Sox2 (Ring et al., 2012). Induced 
oligodendrocyte progenitor cells (iOPC) were generated by direct lineage 
conversion of mouse fibroblasts using different sets of three transcription factors, 





2013). Embryonic and postnatal mouse fibroblasts were recently convert into 
astrocytes (iastrocytes) by three transcription factors involved in defining the 
astroglial cell fate, NFIA, NFIB, and SOX9 (Caiazzo et al., 2015). Small molecules can 
also be used to directly convert mouse and human fibroblasts into functional 
astrocytes without genetic manipulation (Tian et al., 2016). Direct neural 
reprogramming could be a more efficient strategy, in terms of time and costs than 
neural differentiation of iPSC. Still, iN are post-mitotic cells that cannot be 
expanded in vitro, which is a major disadvantage (Mertens et al., 2016). Thus, 
applications that require large numbers of neural cells may favor iNSC or iPSC-
based strategies. 
The widespread implementation of iPSC was accelerated by the knowledge 
accumulated with the ESC field and the fact that iPSC bypass the ethical concerns 
underlying the use of tissue from embryonic origin. With the recent advances in 
gene editing tools, such as CRISPR-Cas9, new strategies to precise genetic 
manipulations to introduce or to correct disease-associated mutations in iPSC are 
available, allowing accurate functional analysis (Doudna and Charpentier, 2014; 
Hockemeyer and Jaenisch, 2016). Recently, a set of isogenic stem cell lines 
containing PD-associated mutations in α-synuclein was generated by CRISPR-Cas9 
gene editing (Arias-Fuenzalida et al., 2017). iPSC rapidly became a valuable tool for 
modelling human neurological disorders and for drug testing. For example, 
neurotoxicity of the chemotherapeutic drugs paclitaxel, vincristine and cisplatin 
was evaluated in iPSC-derived neurons that showed morphological disruption, 
decreased neurite outgrowth, decreased cellular viability and apoptosis (Wheeler 
et al., 2015). iPSC technology has also been widely applied for disease modeling, 
potentially contributing to elucidate early disease mechanisms and progression of 
neurological disorders. Indeed, disorders such as AD (Israel et al., 2012; Kondo et 
al., 2013), Down syndrome (Briggs et al., 2013), autism spectrum disorder (ASD) 
(DeRosa et al., 2010) and schizophrenia (Brennand et al., 2011) have been modeled 





relevant to the disease, such as accumulation of β-amyloid and phosphorylated tau 
protein (Israel et al., 2012; Kondo et al., 2013). Down syndrome iPSC-derived neural 
cultures showed a two-fold bias towards glial lineages and were up to two times 
more sensitive to oxidative stress-induced apoptosis than healthy neural cultures 
(Briggs et al., 2013). Schizophrenia iPSC-derived neurons showed reduced neuronal 
connectivity together with decreased neurite number, postsynaptic density protein 
95 (PSD-95) levels and glutamate receptor expression (Brennand et al., 2011). Also, 
the neuronopathic forms of lysosomal storage diseases (LSD), such as 
mucopolysaccharidosis (MPS) IIIB (Lemonnier et al., 2011), MPS IIIC (Canals et al., 
2015) and Pompe disease (Higuchi et al., 2014) were modeled employing human 
iPSC lines. The knowledge generated contributed to understanding disease 
mechanisms and to the treatment of these rare diseases (Borger et al., 2017). 
Further, this demonstrates that patient-specific iPSC can be used to model features 
of neurological disorders in vitro, for analyzing disease pathogenesis and evaluating 
drugs. Still, some limitations of iPSC-based disease modeling must be circumvent. 
These limitations include the time, costs and labor required for iPSC 
reprogramming and neural differentiation. Further, improve the maturity of neural 
cells differentiated from PSC is another of the challenges the field is facing. It is 
required to develop PSC neural differentiation strategies that allow obtaining fully 
mature and functional neural cells, which age in culture in order to mimic late-
onset neurodegenerative diseases phenotypes.  
3. Cell fate determinants: patterning and differentiation 
towards neural lineage 
In vivo, following implantation of the blastocyst and gastrulation, 3 distinct 
germ-layers are generated: endoderm (that gives rise to internal organs), 
mesoderm (that gives rise to bone, muscle, heart and vasculature) and ectoderm 
(that gives rise to the nervous system and the skin). Neurodevelopment is 





cell fate from embryonic ectoderm. Three main events characterize early 
neurodevelopment: (1) neural induction through specification of the embryonic 
ectoderm to form the neural plate, mainly composed of neuroepithelial (NE) cells; 
(2) neurulation through serial morphogenetic transformations, including cell 
division, morphological changes and migration, to generate the neural tube along 
the developing embryo; and (3) neural patterning through expansion and division 
of the neural tube into functionally and spatially distinct neuraxial regions; NE cells 
originate radial glia (RG) cells, which maintain their epithelial characteristic (Price et 
al., 2011; Zirra et al., 2016). Further differentiated cell types, such as intermediate 
progenitors and terminally differentiated distinct neural subtypes, are generated 
from self-renewing asymmetric divisions of RG cells, through concerted molecular 
programs in specific regions of the nervous system. Once neurons are produced, 
they migrate outwards to their final locations, extend axons to target other 
neurons and begin forming the neural network (Kelava and Lancaster, 2017; Zirra 
et al., 2016).  
Neurogenesis precedes gliogenesis, with radial glial serving as NSC substrate 
for both cell types and as scaffold for migration. Neurons and oligodendrocytes 
develop following a step-wise process: (a) stem cells are specified towards the 
neural lineage; (b) NSC migrate away from the germinal centers; (c) NSC exit cell 
cycle and (d) undergo terminal differentiation during which a given cell type 
initiates its physiological function (Molofsky and Deneen, 2015). Whether 
astrocytes follow the same pattern of development as neurons and 
oligodendrocytes has not yet been established (Molofsky and Deneen, 2015). 
However, it has become increasingly clear that the same patterning factors that 
control neuronal subtype generation also play an instructive role in astrocyte 
differentiation and regulate astrocyte subtype generation (Molofsky and Deneen, 
2015). 
During embryogenesis, germ-layer specification is highly dependent on TGF-β 





through a number of SMAD proteins downstream effectors (Pauklin and Vallier, 
2015). Non-neural identities are promoted by BMP and Activin/Nodal signaling. 
Combined gradients of Nodal and BMP within the primitive steak control 
endoderm and mesoderm germ layer specification, whilst blocking neuroectoderm 
formation (Pauklin and Vallier, 2015; Zirra et al., 2016). BMP4 and its downstream 
effectors Smad1/5/8 interact with mesoderm regulators to repress endoderm 
markers, induced by Nodal and the downstream Smad2/3 that directly controls the 
transcriptional activity of a broad number of endoderm genes (Pauklin and Vallier, 
2015). Furthermore, Smad1/5/8 and Smad2/3 bind to the same region of Nanog 
promoter, suggesting that these might compete to modulate the expression of key 
pluripotency markers.  
Differentiation of PSC into neural cells requires the combination of mitogens 
and morphogens that mimic the in vivo developmental cues to specify cell identity. 
Insights from developmental neurobiology provided a conceptual framework to 
rationalize media composition for the directed differentiation of human PSC 
towards the neural lineage: the ectoderm produces BMPs to promote epidermal 
differentiation, while neural inducing regions antagonize BMPs to permit neural 
induction. Based on these mechanisms, Chambers and colleagues (2009) developed 
the most widely adopted approach for neural conversion of PSC, termed the dual-
Smad inhibition protocol. The need for an intermediate EB stage is bypassed and 
the efficiency of generation of neural rosettes increased greatly by applying both 
Nodal and BMP4 antagonists in combination, for inhibition of downstream SMAD 
proteins. This protocol was further modified by addition of retinoids, improving the 
efficiency of specification towards a forebrain identity (Shi et al., 2012). Still, 
current approaches for directed differentiation of human PSC often fail to capture 
the dynamic and overlapping nature of the neurodevelopmental processes (Zirra et 
al., 2016). In vivo, the stem cell niche is regulated by multiple factors, such as the 
differentiating cell types and secreted signaling molecules, extracellular matrix 





mechanical forces such as tension, rigidity and even fluid flow (Murrow et al., 
2017). Nevertheless, the precise mechanisms by which individual components 
regulate the niche are still largely unknown.  
The role of extracellular cues, including ECM and other microenvironmental 
factors, in cell growth and differentiation is now beginning to be understood. The 
mechanical properties of the ECM, such as the stiffness or the elasticity, affect the 
adhesion and the interactions between the cells and the matrix, thus affecting cell 
morphology and resulting in the transduction of signals that can regulate cell 
differentiation (Guilak et al., 2009). Structurally, the ECM provides binding sites to 
neural cells and facilitates its organization into distinct CNS regions. Chemically, it is 
a source of diverse molecular signals that guide cellular growth, activity and 
survival. During CNS development, specific ECM components are dynamically 
regulated in a temporal and spatial manner to facilitate neurogenesis, neural cell 
migration and differentiation and axonal growth and guidance (Lau et al., 2013). 
The neural ECM of healthy brain tissue is a complex mixture of proteins, mainly 
composed by hyaluronan, proteoglycans (PGs) and tenascins (Fig. 1.3).  
 
Figure 1.3: Major components of brain extracellular matrix (ECM). ECM components are mainly 
arranged into perineuronal nets that are condensed around cell bodies and dendrites of neurons or 






The chondroitin sulfate PGs (CSPGs) aggrecan, versican, neurocan and 
brevican are the primary organizational component of the brain ECM. These PGs 
bind tenascin glycoproteins, which act as linkers and provide binding sites to the 
cells (Hopkins et al., 2015; Lau et al., 2013). Hyaluronan is a negatively charged 
glycosaminoglycan (GAG), thereby attracting cations and charged proteins and 
increasing the hydration of brain tissue (Hopkins et al., 2015). Brain ECM is 
distributed within the perineuronal nets (PNNs) and the neural interstitial matrix, 
which consists of ECM components in the brain parenchyma that are not as tightly 
associated as in the PNNs (Fig. 1.3) (Lau et al., 2013). PNNs compose most of the 
brain ECM and are a condensed layer of a mesh-like matrix consisting mainly in 
PGs, tenascin r and link proteins, located around neuronal cell bodies and proximal 
dendrites. PNNs prevent random synapse formation and are thought to be critical 
for synaptic plasticity (Hopkins et al., 2015; Lau et al., 2013). Enzymatic degradation 
of CSPGs or destabilization of PNNs was shown to enhance neuronal activity and 
synaptic plasticity after CNS injury (Soleman et al., 2013). 
4. Culture strategies for CNS modelling and drug screening 
Typical strategies for culturing neural cells for CNS modelling rely on 
monolayer systems (2D). These, although easy to manipulate, fail to recapitulate 
the in vivo microenvironment and lack the structural architecture of the tissue, in 
many cases precluding the establishment of physiologically-relevant cell-cell and 
cell-ECM interactions (Breslin and Driscoll, 2013; Fitzgerald et al., 2015; Picollet-
D’hahan et al., 2016). Contrasting with 2D, three-dimensional (3D) culture systems 
allow cells to establish a network of cell-cell and cell-ECM interactions in all planes, 
which affects cell morphology, polarity, cell signaling and gene expression 
(Pampaloni et al., 2007).  
As mentioned previously, precise control of stem cell differentiation and tissue 
architecture is essential for development, organogenesis and tissue homeostasis. 





that recapitulate key aspects of the tissue of origin, such as the presence of 
multiple differentiated cell types, cell migration and activation of developmental 
gene expression programs (Murrow et al., 2017). This 3D environment can be 
relevant not only for neuronal maturation, functionality and signaling, but also for 
the penetration and action of drugs (Kim et al., 2004), potentially improving the 
outcome of cell-based assays in drug screening.  
A vast number of distinct 3D culture strategies have been developed and 
employed in the last years. Nonetheless, several limitations need to be circumvent 
to take advantage of the full potential of 3D cultures. The 3D culture strategies can 
be divided in two main categories: (1) scaffold-dependent cultures, employing 
scaffolds based on natural or synthetic biomaterials as cell supportive matrixes and 
(2) scaffold-free cultures, in which cells were allowed to self-assemble into 
aggregates without an exogenous matrix. 
4.1. Scaffold-dependent cultures 
Aiming at recreating the in vivo cues such as mimicking tissue structure, 
mechanical and biochemical properties, a wide range of synthetic and biologically-
derived materials have been used as scaffolds for 3D culture (Pampaloni et al., 
2007; Picollet-D’hahan et al., 2016). These are mainly hydrogels and include 
biologically inert polymers, such as alginate, agarose or chitosan, or biologically 
active polymers, such as collagen or hyaluronan (Picollet-D’hahan et al., 2016). 
Biological active external cues (e.g. RGD adhesion domains) can also be 
incorporated in the scaffold in order to further enhance cell adhesion to the matrix, 
cell migration, cell differentiation and cellular functions (Guilak et al., 2009). For 
example, by controlling the density of the ligand ephrin-B2 along a soluble 
biopolymer, NSC differentiation was enhanced in vitro and in vivo, and ephrin-B1 
conjugates strongly enhance PSC differentiation toward a dopaminergic phenotype 
(Conway et al., 2013).  
Two main strategies can be followed for cell incorporation in the scaffold: (1) 





within the scaffold material, allowing them to spontaneously organize. Both 
strategies have already been applied for 3D culture of neural cells and generation 
of neural tissue-like structures (Irons et al., 2008; Lancaster et al., 2013). More 
recently, the field has been extended to more sophisticated scaffolding methods 
that include microfabrication, microfluidics and 3D bioprinting (Picollet-D’hahan et 
al., 2016). The combination of cellular supporting matrices and microfluidics 
technology, which controls physical and chemical conditions (e.g. temperature, gas 
tension, medium and soluble factors composition and precise control of fluid flow 
and shear stress) at microscale level, allows the generation of organ-on-chip 
models (Sackmann et al., 2014). These can potentially enhance the differentiation, 
function, and long-term survival of many cell types. The 3D bioprinting approaches 
allow creating complex and layered scaffolds able to sustain cell survival, 
proliferation and neural differentiation (Devillard et al., 2014; Lozano et al., 2015). 
Although presenting a great potential in recreating the natural physical and 
structural environment of living tissues, biologically active scaffold components can 
profoundly affect the properties of the culture and cell phenotype, which can lead 
to confounding effects specially when modeling disease. Further, scaffold-
dependent culture methods are difficult to control in terms of diffusion of gases 
and nutrients (Kelava and Lancaster, 2017; Ranga et al., 2016; Serra et al., 2012). 
These methods are laborious, require technical knowledge and equipment and the 
analysis of most biological readouts is challenging, making difficult its applicability 
in high-throughput screenings (Hopkins et al. 2015).  
Ideal 3D scaffolds should provide native spatial arrangement, adequate 
biomechanical properties and biocompatibility. The mechanical properties of the 
scaffold should match the CNS tissue characteristics, not affect, or affect positively, 
cell differentiation and ensure efficient neurite outgrowth and neural connectivity. 
Cell culture on hydrogel surfaces with variable moduli indicated that softer gels 
(100–500 Pa) favour neuronal differentiation while harder gels (1–10 kPa) favour 





neurodegenerative disorders such as AD so, when modeling disease, stiffer 
scaffolds should be chosen to better mimic the pathological state (Franze et al., 
2013). Still, the ideal 3D scaffold cannot be defined due to the lack of knowledge on 
disease-induced ECM changes. 
4.2. Scaffold-free cultures 
Scaffold-free methods take advantage of the capability of some cell types to 
self-assemble into aggregates, without the support of an exogenous scaffold. This 
allows cells to produce their own ECM without the confounding effects of an 
exogenous matrix, which can overlook the biochemical and biophysical 
contribution of the endogenous ECM factors. 
Conditions in which the adhesive forces between the cells are greater than for 
the substrate are required for cells to aggregate. Cell aggregation can be facilitated 
by buoyancy or stirring. Thus, cell spheroids can be generated in static systems by 
forced floating methods, such as low-adherence culture surfaces and hanging-drop 
methods, or in agitation-based culture systems, such as shake flasks, spinner flasks, 
rotary wall vessels and stirred-tank bioreactors. 
In low adherence surfaces and in the hanging drop method, no adherence cue 
is provided to the cells, cell aggregation is forced and is strongly dependent on cell-
cell contacts. Depending on the heterogeneity of the initial cell population and its 
aggregation capacity, some lack of reproducibility could exist and control of tissue 
size is difficult, while being also time-consuming and cumbersome aggregation 
methods (Picollet-D’hahan et al., 2016). Moreover, these systems provide low mass 
transfer properties and inherently it is difficult to maintain long-term cultures and 
the scalability of the system is very low, precluding many applications. 
Agitation-based culture systems allow the generation of more homogenous 
cultures, presenting improved mass transfer properties over static culture systems. 
Cell aggregation is highly dependent not only on the cell type but also on system 
hydrodynamics. The geometry of the vessel, the stirring rate, and the type and size 





therefore, are important to optimize when aiming at promoting cell aggregation 
and culturing aggregates (Kinney et al., 2011). The stirring creates shear, which may 
increase the number of cell-cell contacts and promote cell aggregation and aid in 
controlling the size of the aggregates (Kehoe et al., 2010). However, stirring can 
also subject the cells to shear stress, which can negatively impact cell physiology. 
To minimizing detrimental effects of shear stress, impellers able to suspend cells 
and mix the fluid gently and operating at lower stirrer speed were developed for 
PSC culture (Marks, 2003; Olmer et al., 2012). 
Software-controlled stirred-tank bioreactors allow monitoring and controlling 
physical and chemical culture parameters, such as hydrodynamics, temperature, 
pH and dissolved oxygen. Furthermore, operation in a perfusion mode allows a 
stable flow of nutrients and differentiation/ neurotrophic factors, while clearing the 
cell debris and toxic byproducts at a controlled rate and maintaining the cells 
within the vessel (Simão et al., 2016). The major disadvantages of stirred tank 
bioreactors are the requirement for technical knowledge and specialized 
equipment, which is costly. 
Efficient neuronal differentiation of PSC and NSC spheroids can be performed 
in scaffold-free 3D cultures, attaining increased neuronal differentiation efficiencies 
with reduced culture times, when compared to static 2D cultures (Chandrasekaran 
et al., 2017; Simão et al., 2014; Terrasso et al., 2015). We recently showed that 
iPSC-derived NSC cultured in a stirred suspension culture system self-assemble into 
aggregates, and differentiate into the three neural lineages, neurons, astrocytes 
and oligodendrocytes (Simão et al., 2016; Simão et al., 2018). Neurospheroids 
proteome and transcriptome dynamics revealed significant changes at cell 
membrane and ECM composition during neural differentiation, with an enrichment 
in PGs typical of brain ECM (Simão et al., 2018). These results demonstrate that 
iPSC-NSC 3D neural differentiation recapitulates extracellular space dynamics, with 






With current advances in automation, microscopy imaging, and processing of 
large amount of data, cellular spheroids are being increasingly employed for in vitro 
drug testing and disease modelling. Spheroid aggregation can be easily automated 
in scalable agitation-based culture systems and, therefore, scaling-up cellular 
spheroid-based assays to feed high-throughput neurotoxicity testing platforms is 
feasible. Alternatively, to generate larger spheroid amounts, a scale-out approach 
can be followed simply multiplying the number of parallel cultures performed. This 
approach can be cost-, space- and labour-intensive but provides some advantages 
over scale-up approaches, such as the reduction of scale-up risks, better costs 
control and flexible process designs and validation strategies. 
5. Brain in vitro models for neuroscience research 
Neuroscience research has relied on animal models for many years, with 
rodents being the most popular. However, as above mentioned, animals fail to 
precisely recapitulate the human pathophysiological state. There are differences 
between species and many human diseases result from complex interactions 
between genes and environmental factors that can not be recapitulated in animals, 
as referred in section 1. Additionally, animal models are not suitable for high-
throughput screening platforms, precluding its use in early stage drug 
development. 
The first human cell models used for neuroscience research were brain 
organotypic slice cultures or neuronal-like cell lines, mainly tumor-derived. Brain 
organotypic slices preserve cellular organization and architecture but post-mortem 
human tissue is scarce and the culture is technically difficult and highly variable 
(Walsh et al., 2005). Cell lines are a renewable source of neural-like cells and less 
complex models, technically easier to work with, but do not recapitulate the 
environmental features of native neurons, as discussed in section 2.2 above.  
In recent years, there is growing evidence that combining PSC-derived neural 





brain cell models for disease modeling and drug discovery with higher physiological 
and pathophysiological relevance. While methods for neural induction of human 
PSC were developed, the field of the 3D cultures of human brain cells grew 
exponentially. Several 3D culture strategies have been explored with the ultimate 
goal of achieving the desired level of mimicry of specific features of the human 
brain. These include the generation of: brain organoids (cell aggregates embedded 
into Matrigel (Choi et al., 2014; Lancaster et al., 2013) or other synthetic matrices 
capable of support tissue morphogenesis (Ranga et al., 2016)), scaffold-free 
cultures of neural-like tissue in air-liquid interface (Preynat-Seauve et al., 2009), 
and the brain spheroids cultures (Birey et al., 2017; Paşca et al., 2015; Rigamonti et 
al., 2016; Simão et al., 2016).  
Brain organoids are self-organized 3D structures derived from stem cells that 
can recapitulate multi-lineage differentiation and aspects of in vivo architecture, 
functionality and genetic signature of the original in vivo tissue (Dutta et al., 2017). 
Organoids can be derived from PSC, mimicking embryonic developmental 
processes, or from adult stem cells, as neural stem cells (Dutta et al., 2017; Murrow 
et al., 2017). Usually Matrigel is employed as extracellular supportive matrix. 
Several researchers have already generated brain organoids from human PSC, 
capable of recapitulating to some extent the composition, cell diversity and 
architecture of the fetal brain, to model diseases as microcephaly and infectious 
diseases (Lancaster et al., 2013; Qian et al., 2017). The spontaneous nature of 
organoids self-organization results in variability in morphology and composition 
between various areas of the tissue-like structure and between different batches, 
occasionally with formation of non-neural entities. This leads to issues with 
reproducibility and suitability for high-throughput screening with robust and 
reliable readouts (Kelava and Lancaster, 2017; Lancaster et al., 2013; Quadrato et 
al., 2017). To increase reproducibility and improve architecture of forebrain 
organoids, Lancaster and colleagues (2017) used poly(lactide-co-glycolide) 





organization and generate elongated EBs. Upon neural differentiation these 
modelled the radial organization of the cerebral cortex and allowed the study of 
neuronal migration (Lancaster et al., 2017). Individual organoids can reach up to 4 
mm in diameter (Kelava and Lancaster, 2017), which is one of the major limitations 
of these 3D models; supply of oxygen and nutrients is insufficient to the center of 
the organoids, limiting the presence of healthy cells to the surface of the tissue. 
This is an important hurdle to overcome in the near future.  
One of the disadvantages of these scaffold-dependent culture strategies is the 
use of Matrigel an extract of the ECM secreted by the Engelbreth-Holm-Swarm 
mouse sarcoma cell line, with characteristics similar to a basement membrane. This 
undefined matrix has low mechanical flexibility and high batch-to-batch variation 
and therefore can produce a source of variability in experimental results (Kleinman 
and Martin, 2005). Moreover, basement membrane properties are different from 
mature brain ECM, which contain low levels of basement membrane constituents 
collagen, laminin and fibronectin. Nowadays, synthetic matrices capable of support 
tissue morphogenesis are being developed to replace the widely used hydrogels 
such as Matrigel (Lemke et al., 2017; Ranga et al., 2016). Ranga and colleagues 
(2016) showed that defined modular synthetic 3D matrices can be used to explore 
the role of the ECM in the development of complex 3D neuroepithelial cysts. The 
authors demonstrated that key steps of early neural morphogenesis, such as the 
specification of cytoskeletal-mediated symmetry-breaking events that lead to 
neural tube-like patterning along the dorsal-ventral axis, can be precisely controlled 
by the extracellular microenvironment (Ranga et al., 2016).  
Scaffold-free neural cultures have also been developed and improved in last 
years (Birey et al., 2017; Mariani et al., 2012; Paşca et al., 2015; Preynat-Seauve et 
al., 2009; Simão et al., 2016). An air-liquid interface-based culture for 3D PSC 
expansion and neural differentiation, spontaneously guided by endogenous 
developmental cues and in the absence of added growth factors, allowed 





developing brain (Preynat-Seauve et al., 2009). Employing a method previously 
described for neural differentiation of ESC that involves formation of serum-free, 
floating EB-like, quick aggregates (SFEBq) (Eiraku et al., 2008) and a cell-replating 
step on Matrigel, Mariani and colleagues generated iPSC-derived 3D structures 
containing polarized RG, intermediate progenitors and layer-specific cortical 
neurons (Mariani et al., 2012). Further improvements generated a SFEBq neural 3D 
culture with organoid’s transcriptome similar to those of the human dorsal 
telencephalon during early fetal development, recapitulating the second trimester 
of the developing forebrain (Mariani et al., 2015). These organoids were used to 
model ASD, employing iPSC derived from ASD patients. ASD organoids presented 
increased production of inhibitory neurons caused by increased FOXG1 gene 
expression, identifying this gene as a molecular signature of idiopathic ASD and a 
potential drug target (Mariani et al., 2015).  
By combining the dual-Smad inhibition protocol with the SFEBq approach, 
eliminating the cell replating in Matrigel and maintaining the cell aggregates in 
floating conditions, Paşca and colleagues (2015) generated cortical and dorsal or 
ventral forebrain spheroids with multiple rosette-like structures and homogeneous 
morphology, able to differentiate into several neural and glial identities within a 3D 
context (Birey et al., 2017; Paşca et al., 2015). To recapitulate a more elaborated 
developmental process, the saltatory migration of interneurons observed in the 
fetal forebrain, the authors assembled the dorsal and ventral forebrain spheroids 
into 3D structures that they referred to as brain assembloids (Birey et al., 2017). 
Moreover, these brain assembloids were used to model Timothy syndrome, a 
neurodevelopmental disorder caused by mutations in the CaV1.2 calcium channel. 
The authors reported that interneurons displayed abnormal migratory saltations, 
which were not possible to detect in other 3D brain cell models that do not allow 
for the recapitulation of saltatory migration of interneurons (Birey et al., 2017).  
In a different approach, our group employed agitation-based culture systems to 





neurospheroids from fetal NPC (Simão et al., 2014) and from the NT2 cell line 
(Serra et al., 2009; Terrasso et al., 2015). We showed applicability of these 
neurospheroids for neurotoxicity testing and for modeling neural functionality and 
neuron-astrocyte interactions (Simão et al., 2018, 2016, 2014, Terrasso et al., 2017, 
2015).  
Further optimization of the available models is still required as the native 
microenvironment includes not only the endogenous ECM, but also other cell 
types, such as vascular and immune cells, which directly contribute to this 
microenvironment (Dutta et al., 2017). The embryonic brain begins to develop in 
the absence of vasculature, but later brain development requires blood vessels to 
provide a neural progenitor niche (McCauley and Wells, 2017). Mimicking vascular 
networks in vitro will provide not only oxygen and nutrients to the center of the in 
vitro tissue-like structures, even those with larger diameters, but also support 
neural differentiation by providing a basement membrane where neural cells can 
attach their basal processes, as occur in vivo (Kelava and Lancaster, 2017). 
Incorporation of microglia cells in the neural models will provide an opportunity to 
study the interactions between these cells and other neural cell types during brain 
development and understand the role of microglia in neurodegenerative diseases 
and drug action mechanisms. Recent reports point to the role of microglia in 
contributing both to tissue injury and repair. Several neurodegenerative disorders 
involve synapse loss and emerging evidence from mouse models suggest that 
microglia can mediate this loss (Hong and Stevens, 2016). It is becoming 
increasingly recognised that microglial aging and senescence is linked to functional 
changes that can contribute to the development of dystrophic microglia and an 
increase of microglia-mediated neuroinflammatory responses, which in turn can 
contribute to the progression of neurodegenerative diseases such as AD, PD, and 
ALS (Hong and Stevens, 2016; Spittau, 2017). For example, in AD context, any loss 
or decrease in phagocytic ability of microglial cells would result in the extracellular 





al., 2015). Recently, the generation of microglia-like cells from PSC has been 
described and these cells have been incorporated in a 3D organotypic neural 
environment, responding to cellular damage (Muffat et al., 2016) and providing 
new tools to study the role of microglia in disease. 
The onset of most neurodegenerative diseases occurs during the later stages 
of life, with exception to familiar forms in which a particular mutation reduces the 
age of onset. The challenges to model sporadic diseases are enormous. Currently, 
to mimic in vitro late onset sporadic neurodegenerative diseases, exogenous 
chemicals are used to induce cellular stress and/ or aging. However, this may also 
induce mutational changes and lead to changes in cell phenotype that are not 
disease-related, affecting the recapitulative capacity of the model (Payne et al., 
2015). Thus, other of the major challenges the field is facing is to improve the 
maturity and aging of the neural cell types differentiated in vitro. It is essential to 
develop strategies to further mature 3D brain tissue-like structures to allow the 
generation of endogenous cellular diversity with truly mature and functional 
neuronal networks that will age along culture time. This will allow the study of 
brain functions that rely on complex cellular interactions and mature and 
functional neural networks as well as late-onset diseases. 
Essentially, when generating new model systems for neuroscience research, it 
is extremely important to take into account the balance between complexity and 
heterogeneity and the desired goal. Simpler and homogeneous model systems, 
easier to scale-up, are more suited for screening approaches while more complex 
systems are more suited to perform neurobiological studies, where the 
recapitulation of the interactions between several cell types and the 
microenvironment is essential for the recreation of the pathophysiology.  
6. Lysosomal storage diseases – Mucopolysaccharidosis 
type VII 
LSD are a group of over 50 rare metabolic disorders caused by lysosomal 





Lysosomal dysfunction is mainly due to the absence or deficiency of a lysosomal 
enzyme; defects in the post-translational modifications, in the metabolic trafficking 
or in the activity of the lysosomal enzyme can occur (Borger et al., 2017; Khan et 
al., 2016; Lemonnier et al., 2011). These defects can lead to numerous metabolic 
alterations, including storage of undigested metabolic products and impaired 
endocytosis, sorting, digestion of cellular and extracellular products and exocytosis 
(Alroy et al., 2014a; Vitner et al., 2010). Further, interruption of intracellular 
trafficking can result in a variety of pathogenic cascades, including alteration of 
calcium homeostasis, oxidative stress, inflammation and altered autophagy (Alroy 
et al., 2014b; Vitner et al., 2010). LSD generally occur at a frequency of 1 in 4000 
live births (Borger et al., 2017) and represent the major cause of 
neurodegeneration in infants and children (Lemonnier et al., 2011). Near two thirds 
of LSD patients present some neurological defect, although the clinical 
manifestations are heterogeneous and defects appear at different ages and 
progress at different rates (Fraldi et al., 2016). LSD have been a major focus of rare 
disease research, with a growing interest due the recent evidence implicating 
lysosomal dysfunction in aging and age-related neurodegenerative diseases 
(Carmona-Gutierrez et al., 2016; Fraldi et al., 2016). Clinical features depend on the 
cell types affected and the organs involved and the level of residual enzyme 
activity. LSD are classified according to the major storage compound, thus disorders 
with accumulation of glycosaminoglycan fragments are classified as 
mucopolysaccharidoses, and those dominated by lipid storage as lipidoses. More 
than 30 % of all lysosomal diseases are MPS and there are nine subtypes of MPS 
described, each caused by a deficiency in one of the enzymes responsible for the 






Figure 1.4: Stepwise degradation of glycosaminoglycans (GAGs). Example of heparan sulfate 
catabolism. The scheme illustrates the 9 enzymatic activities required for the sequential catabolism of 
GAGs to lead to a complete degradation of its chain. The deficiency in the activity of one of these 
enzymes generates a pathological condition called mucopolysaccharidosis (MPS, in blue). There are 9 
different MPS, depending on the deficient enzyme. MPS VII (in red) is caused by a deficiency in β-D-
glucuronidase. Adapted from Kowalewski et al.(2012).  
MPS type VII (MPS VII; Sly syndrome) is an ultra-rare neuronopathic form of 
MPS, with an estimated frequency of ~1: 2 000 000. It has an autosomal recessive 
inheritance pattern and is characterized by a deficiency in the activity of β-D-
glucuronidase (β-gluc; EC 3.2.1.31; Fig 1.4) (Montaño et al., 2016; Tomatsu et al., 





hepatosplenomegaly, cardiac abnormalities, recurrent pulmonary infections, 
skeletal dysplasia and early death. However, the phenotypic consequences in 
patients are extremely variable, ranging from late-onset milder forms with fewer 
manifestations, mild skeletal abnormalities and near-normal intelligence to early-
onset severe forms with non-immune hydrops fetalis at birth and a few months of 
life expectancy (Montaño et al., 2016; Tomatsu et al., 2009). Up to now, 49 disease-
causing mutations have been identified along the β-GUS gene and these include 
mainly missense mutations, but also nonsense mutations, deletions and splice-site 
mutations (Khan et al., 2016; Montaño et al., 2016). β-gluc catalyses the hydrolysis 
of β-D-glucuronic acid residues from the non-reducing terminal of GAGs (Khan et 
al., 2016) (Fig. 1.4). Deficient β-gluc activity leads to the progressive abnormal 
accumulation of partially degraded chondroitin sulfate, dermatan sulfate and 
heparan sulfate GAGs within the lysosomes of the majority of the cell types, 
affecting many tissues, including the brain (Montano et al., 2016). In the brain, 
GAGs accumulation is followed by the secondary accumulation of GM2 and GM3 
gangliosides (Archer et al., 2014). While no clear connection was established 
between the primary lysosomal accumulation of GAGs and the secondary 
accumulation of GM2 and GM3 gangliosides it is possible that GAGs accumulation 
can lead to the overall dysfunction of the lysosomal system and to the storage of 
multiple substrates and several mechanisms can be hypothesized. These could 
include alterations in normal trafficking or fusion of vesicles, which can result in a 
compromised movement of a variety of materials for further degradation or the 
inhibition of lysosomal enzymes by the accumulating GAGs or by other changes in 
lysosomal environment, such as a pH alteration, leading to reduced degradation of 
additional substrates. 
In addition to lysosomal GM2 and GM3 gangliosides accumulation, there are 
several other secondary pathological processes that have been identified in MPS, 
including disturbance of the vesicular network (e.g. blocking of autophagy and 





vesicle trafficking), of the mitochondrial function (oxidative stress, apoptosis), and 
of the signalling response (TLR4, TGF-β pathway) and inflammation (cytokines, 
chemokines), amongst others (Plotegher and Duchen, 2017; Salazar et al., 2016). 
GAGs breakdown products could activate TLR4 signalling pathway due to its 
structural similarity with the canonical ligand of TLR4, LPS, thus inducing a pro-
inflammatory response and the release of cytokines such as MIP1α and TNFα 
(Ballabio and Gieselmann, 2009; Xing et al., 2015).  
During many years palliative therapies were the only resource for MPS VII 
patients. Intravenous enzyme replacement therapies (ERT) were alternatives to 
change the course of the mild phenotype of the disease in mouse models and in 
human clinical trials, while requiring infusions at regular intervals and not 
appropriately addressing all disease phenotypes and being ineffective in some 
organs, including the brain (Giugliani et al., 2016; Montaño et al., 2016). In 2017, 
FDA approved MEPSEVII from UltraGenix, a recombinant human β-GUS 
replacement therapy for MPS VII. Nevertheless, ERT has no impact on the 
neuronopathic phenotypes, as the infused recombinant enzyme is unable to cross 
the blood-brain barrier (BBB; Borger et al., 2017). Therefore, the treatment of 
neurological defects associated with MPS VII still representing an unmet medical 
need (Giugliani et al., 2016; Montaño et al., 2016). Gene therapy represents the 
ultimate treatment for monogenic diseases and several studies demonstrated 
positive effects in MPS VII. It has been shown that intracerebral injections of 
adeno-associated vectors (Giugliani et al., 2016) or canine adenovirus (Ariza et al., 
2014; Cubizolle et al., 2013) could reverse cognitive impairment. The potential of ex 
vivo gene therapy was also recently demonstrated by the transplant of genetically 
corrected NSC differentiated in vitro from iPSC isolated from a MPS VII patient in a 
mouse model of MPS VII (Griffin et al., 2015).  
Whereas the primary effects of MPS disorders are well described, the 
limitation of the current animal models hampered the study of cascades of events 





Thus, the development of novel disease-relevant human models that better mimic 
human brain cells and its interactions and microenvironment has the potential to 
provide further insight to the mechanisms of disease onset and progression and 
new tools to accurately identify potential therapeutic targets and evaluate 
promising drug candidates. 
7. Aims and Scope of the thesis 
The development of 3D cell models that recapitulate features of the human 
brain can potentially contribute to unveil specific neurological disease mechanisms, 
to identify potential therapeutic targets and to accurately evaluate promising drug 
candidates. The main goal of this thesis was the development, characterization and 
interrogation of 3D neural cell models for disease modeling and drug discovery, in 
which phenotypic and functional features of human brain tissue would be 
recapitulated, namely functional neuron-astrocytes interactions (Fig 1.5). We 
hypothesized that (1) concomitant neuronal and astrocytic differentiation in a 3D 
context would allow neural cells to mature and establish functional neuron-
astrocyte interactions, generating complex 3D networks; and (2) the establishment 
of neuron-astrocyte interactions would contribute to recapitulate disease 
mechanisms in which those have impact. Therefore, this thesis focused on 3D 
neural differentiation of human stem cells, exploring agitation-based cultured 
systems to promote stem cell aggregation and concomitant differentiation in to 
neuronal and astrocytic lineages. 
In Chapter 2, we employed the NT2 cell line for the establishment of a 
differentiation strategy to obtain a co-culture of neurons and astrocytes 
(neurospheroids), building up on a bioprocess for 3D neuronal differentiation 
previously implemented at our laboratory. The process was optimized to achieve 
mature and functional cells, as demonstrated by the establishment of neuron-





were implemented to distinguish between neuronal and astrocytic toxicity within 
neurospheroids. 
 
Figure 1.5: Thesis aims and its discrimination by chapter. NT2 – Ntera2/ clone D1 cell line; MPS VII – 
Mucopolysaccharidosis type VII; iPSC-NPC – induced pluripotent stem cells-derived neural progenitor 
cells. 
In Chapter 3, the applicability of NT2 neurospheroids to assess the 
neuroprotective effect of drug candidates was evaluated. The implementation of 
an in vitro neuroprotection assay, which combines neurospheroid culture with a 
cell viability endpoint, is described and several drug candidates were tested as a 
proof-of-concept. 
In Chapter 4 the goal was to establish and interrogate a disease model in 
which establishment of neuron-astrocyte interactions would potentially contribute 
to the recapitulation of disease features. MPS VII patient-derived iPSC were used as 
cell source for neural differentiation. The recapitulation of disease features, neural 
gene expression and neuronal network functionality were evaluated in MPS VII 
neurospheroids.  
Finally, in chapter 5, results obtained along this work were further discussed, 
integrating thesis outcomes with state-of-the-art literature in the fields addressed 
throughout the previous chapters. 
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There is an urgent need for new in vitro strategies to identify neurotoxic agents 
with speed, reliability and respect for animal welfare. Cell models should include 
distinct brain cell types and represent brain microenvironment to attain higher 
relevance. The main goal of this study was to develop and validate a human 3D 
neural model containing both neurons and glial cells, applicable for toxicity testing 
in high-throughput platforms. To achieve this, a scalable bioprocess for neural 
differentiation of human NTera2/cl.D1 cells in stirred culture systems was 
developed. Endpoints based on neuronal- and astrocytic-specific gene expression 
and functionality in 3D were implemented in multi-well format and used for 
toxicity assessment. The prototypical neurotoxicant acrylamide affected primarily 
neurons, impairing synaptic function; our results suggest that gene expression of 
the presynaptic marker synaptophysin can be used as sensitive endpoint. 
Chloramphenicol, described as neurotoxicant affected both cell types, with 
cytoskeleton markers’ expression significantly reduced, particularly in astrocytes. In 
conclusion, a scalable and reproducible process for production of differentiated 
neurospheroids enriched in mature neurons and functional astrocytes was 
obtained. This 3D approach allowed efficient production of large numbers of 
human differentiated neurospheroids, which in combination with gene expression 
and functional endpoints are a powerful cell model to evaluate human neuronal 







Human brain is a critical target organ of xenobiotics due to its developmental, 
structural and functional features that make it an extremely complex organ with 
highly elaborate physical, communicative and metabolic interactions between 
neurons and glial cells (Allen and Barres, 2009; Moors et al., 2009).  
Given the insufficient information available on neurotoxicity and the growing 
number of chemicals to be tested, new testing strategies are required to identify 
neurotoxic agents with speed, reliability and respect for animal welfare. Moreover, 
generate in vitro tests with an increased high-throughput is needed to provide 
mechanistic data and evaluate more efficiently the toxics that may cause adverse 
effect in humans (Breier et al., 2010; Breslin and O’Driscoll, 2013; Tralau and Luch, 
2012).  
Numerous studies demonstrated that screens focusing solely on the direct 
effect of compounds on isolated neurons may not model consistently the basic 
Central Nervous System (CNS) functions and environment and will overlook 
potentially important neuroprotective and/or neurotoxic activities that act via 
astrocytes or other non-neuronal cells (Chen and Swanson, 2003; Gupta et al., 
2012; Sofroniew and Vinters, 2010). Moreover, cell differentiation and tissue 
development and homeostasis in vivo are strongly dependent on cell spatial 
arrangement, essential for correct trafficking and communication between neurons 
and astrocytes and directional cues, so extracellular context profoundly affects cell 
behavior (Irons et al., 2008). Neurospheres, free-floating aggregates of neural 
progenitors (Conti and Cattaneo, 2010), allow formation of a complex 3D network 
of cell-cell and cell-extracellular matrix interactions, being potentially relevant in 
the penetration and action of drugs (Breslin and O’Driscoll, 2013). Despite research 
with neurospheres largely focused on their application for neuronal regeneration in 
CNS diseases, a few studies utilized neurospheres for in vitro developmental 
toxicity studies, providing support for their use in neurotoxic compounds 
identification (Breier et al., 2010). Furthermore, differentiated neurospheroids 




fabrication procedures have been described by our laboratory and others (Brito et 
al., 2012; Moors et al., 2009; Serra et al., 2009), using different cell sources, 
however, none of these systems generates neurospheroids enriched in functional 
astrocytes. Since the use of human origin tissues is limited due to availability issues, 
an insufficient potential to generate the necessary number of cells and ethical 
concerns, efforts should focus on creating affordable and sensitive methods to 
develop alternative human-cell based in vitro models that closely reconstruct the in 
vivo situation for investigation of neurotoxic effects in human neural cells (Hill et 
al., 2008; Moors et al., 2009).  
A wide range of cell systems have been under investigation for their suitability 
for inclusion in neurotoxicity test batteries (Mori and Hara, 2013). In recent years, 
protocols have been developed for the isolation and in vitro culture of human 
neural stem cells (NSC) or neural progenitor cells as well as for the derivation of 
human neurons and astrocytes from pluripotent stem cells (PSC), both embryonic 
(ESC) and induced (iPSC) (Molofsky et al., 2012; Mori and Hara, 2013). Although the 
use of the latter holds great promise and remarkable advances have been made in 
expansion, differentiation and characterization, numerous challenges must be 
overcome before the use of this technology can be widespread (Mori and Hara, 
2013; Serra et al., 2010).  
Human pluripotent embryonic carcinoma cell lines, such as NTera-2/cloneD1 
(NT2), represent an alternative that can provide an unlimited number of cells, with 
less time-consuming and well characterized neuronal differentiation protocols 
(Brito et al., 2007; Serra et al., 2009). NT2-derived neurons have been shown to be 
a valuable model for in vitro developmental neurotoxicity testing (Laurenza et al., 
2013; Stern et al., 2013), demonstrating advantages regarding the identification of 
potential neurotoxicants. A few works described astrocytic differentiation of NT2 
cell line, based on RA neural induction and increased differentiation times, in 2D 





The present work focused on the development of a robust process for 
generation of a human 3D cellular model, enriched in functional neurons and 
astrocytes and suitable to feed high-throughput neurotoxicity studies, using the 
human pluripotent NT2 cell line as cell source. Having as starting point a scalable 
process based on stirred suspension culture system previously developed by us for 
NT2 neuronal differentiation (Serra et al., 2009, 2007), we have extended 
differentiation in order to allow astrocytic differentiation and maturation. The 
feasibility of using these differentiated neurospheroids as 3D human neural cell 
model for high-throughput neurotoxicity testing was attained by performing 
neurotoxicity assays in multi-well formats. The effect of neurotoxic compounds in 
differentiated neurospheroids was evaluated by gene expression and functional 
endpoints, allowing distinguishing between neuronal and astrocytic toxicity. 
2. Materials and Methods 
2.1. Cell culture and 2D differentiation 
Undifferentiated NT2 cells from American Type Culture Collection (ATCC) were 
routinely cultivated in DMEM (Invitrogen) supplemented with 10% (v/v) fetal 
bovine serum (FBS, Invitrogen) and 1% (v/v) penicillin-streptomycin (P/S, 
Invitrogen), as previously described (Brito et al., 2007). 
2.2. Stirred suspension culture 
NT2 cells were cultured in stirred suspension culture systems in a humidified 
atmosphere of 5% CO2 in air, at 37◦C. Undifferentiated NT2 cells were inoculated as 
single cell suspension in a silanized 125 mL spinner vessel (from Wheaton) 
equipped with ball impeller, at a density of 6.7 × 105 cell/mL in 75 mL DMEM, 10% 
FBS, 1% P/S. On day 2, 50 mL of fresh medium were added and cells allowed to 
aggregate for additional 2 days in vitro (DIV). After this aggregation period, at day 3 
differentiation induced by RA was initiated, by performing 50% medium exchange 
which was repeated every2–3 days for 3 weeks (until 24DIV). The medium 
composition during this period was DMEM supplemented with 10% FBS, 1% P/S 




and 20 M retinoic acid (RA, Fig. 2.1a). Following this period (from 24DIV onwards), 
the medium was composed by DMEM, 5% FBS, 1% P/S. Cultures were maintained 
up to 50DIV and applied in neurotoxicity assays (from 38 to 50 DIV). The agitation 
rate was increased along culture to avoid aggregate clumping and to control 
aggregate size (from initial 40 rpm, to 60 rpm during RA induction phase and up to 
100 rpm by the end of this period). 
 
Figure 2.1: Neurospheroid culture. (a) Schematic workflow of stirred suspension culture. Cells were 
inoculated in a stirred suspension culture system and aggregated for 3 days. Neural differentiation 
was induced by retinoic acid (RA) for 3 weeks (3–24 DIV), followed by 2 weeks (until 38 DIV) without 
RA. Neurotoxicity studies were performed between 38 and 50 DIV. Images representative of the 
culture status at the indicated time points: fluorescent live/dead assay using fluorescein diacetate for 
identification of live cells (green) and propidium iodide for identification of dead cells (red). (b) 
Aggregate diameter profile along culture time; data are mean ± SD of three independent cultures. 
***indicate significant difference with P < 0.001 by one-way ANOVA analysis with Tukey’s post 
multiple comparison test. 
2.3. Neurotoxicity assays  
Neurospheroids were collected between 38-50 DIV, distributed in 96 or 6 well 





concentrations of test compounds, for 48–72 h, before carrying out the assay 
endpoints. Six wells were used per toxicant concentration and medium was used as 
untreated control. The induced toxicity of tert-buthyl hydroperoxide (tBHP;0.008–2 
mM), acrylamide (Acr; 1 µM-1 mM) and chloramphenicol (39 µM–10 mM) (all 
purchased from Sigma-Aldrich) was evaluated by performing dose-response curves 
using cell viability as end-point, measured by the Presto blue viability assay 
(Invitrogen),based on resazurin reduction, following the manufacturer’s 
instructions (calibration curves with neurospheroids Fig. 2.2). Based on these 




Figure 2.2: Neurotoxicity assays – dose-response curves. (a) Calibration curve performed to validate 
Presto blue cell viability assay. 5 to 20 neurospheroids were distributed per well, with 6 replicates per 
neurospheroids number and incubated for 72 hours before carrying out Presto blue cell viability 
assay. (b) Dose-response curve of 1 μM–1M acrylamide induced lesion for 72 hours in differentiated 
neurospheroids, determined by Presto blue assay. (c) Dose-response curve of 39 μM-10 mM 
chloramphenicol induced lesion for 48 hours in differentiated neurospheroids, determined by Presto 
blue assay; data are mean ± SD of three independent experiments. 




2.4. Astrocytic functionality 
Neurospheroids were collected at 38DIV, distributed in 6-well plates and 
incubated with DMEM without glutamate (Glu) and glutamine (Gln; Invitrogen). Glu 
transporters and Gln synthetase (GS) activities were stimulated adding 5 mM Glu 
(Sigma) to culture medium. As control medium was added to empty wells and 
processed together with those containing neurospheroids. Samples were collected 
at 0, 24, 48 at 72 h and Glu and Gln concentrations in culture medium were 
evaluated using a YSI 7100 MBS equipment (YSI Incorporated, USA). 
2.5. Synaptic vesicle trafficking assay  
Synaptic vesicles trafficking assay was based in Gaffield, 2006. Neurospheroids 
were plated in poly-d-lysine (PDL) – coated glass coverslips and incubated with 100 
mM KCl buffer (5 mM HEPES-NaOH, pH 7.4; 10 mM glucose; 2.5 mM calcium 
chloride; 1 mM magnesium chloride; 100 mM potassium chloride; 37 mM sodium 
chloride) for 5 min. Afterwards, 100 mM KCl buffer was removed and 
neurospheroids incubated with 10 M FM-1-43 dye (Invitrogen)in 5 mM KCl buffer 
(5 mM HEPES-NaOH, pH 7.4; 10 mM glucose;2.5 mM calcium chloride; 1 mM 
magnesium chloride; 5 mM potassium chloride; 37 mM sodium chloride) for 15 
min. Neurospheroids were washed for 1 min with 5 mM KCl buffer with ADVASEP-
7(Sigma), followed by three washes with 5 mM KCl buffer. Exocytosis was 
stimulated with 100 mM KCl buffer and samples were visualized live using a 
fluorescence microscope (Leica DMI6000) in order to monitor the decreasing of 
fluorescence intensity overtime. Fluorescence intensity was measured using ImageJ 
software version 1.47m (http://rsbweb.nih.gov/ij/). 
2.6. Fluorescence microscopy 
Neurospheroids were collected at several time points and processed for 
immunofluorescence staining according to Serra et al. (2009). Briefly, 
neurospheroids were fixed in 4% (w/v) paraformaldehyde (Sigma) solution in PBS 





antibodies used for cell characterization were: anti-nestin (Millipore), anti-βIII-
tubulin (βIII-Tub, Millipore), anti-microtubule associated protein 2 (MAP2, 
Millipore), anti-synaptophysin (Syn, Millipore), anti-Glu descarboxilase 65/67 
(GAD65/67, Chemicon), anti-vesicular Glu transporter 1 (VGluT1, Abcam), anti-glial 
fibrillary acidic protein (GFAP, DAKO), and anti-Glu transporter 1 (GLT-1, Millipore). 
Secondary antibodies were goat anti-mouse IgG-AlexaFluor 594, goat anti-mouse 
IgG-AlexaFluor 488 and goat anti-rabbit IgG-AlexaFluor 594 (Invitrogen). Cell nuclei 
were counterstained with 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen). 
Preparations were visualized using a point scan confocal (Leica SP5) microscope. 
Merge between channels, maximum z-projections and orthogonal projections, as 
well as linear brightness and contrast adjustments of the images, were created 
using the ImageJ software version 1.47m. The number of positively labeled cells 
was quantified by counting 10–20 randomly selected fields of at least three 
independent experiments. 
2.7. Western blot 
Neurospheroids were lysed in TX-100 lysis buffer (50 mM Tris, 5 mM EDTA, 150 
mM NaCl, 1% Triton X-100 and 1× complete protease inhibitors cocktail (Roche)) 
and protein quantification was carried out using the Micro BSATM Protein Assay Kit 
(Thermo Scientific). Protein samples were subjected to a gel electrophoresis using a 
NuPAGE 4-12% Bis–Tris Gel with MES running buffer (Invitrogen) and 
electrophoretically transferred to polyvinylidene difluoride (PVDF) membrane. 
Membranes were blocked with PBS with 0.1% (w/v) Tween 20 and 5% non-fat dried 
milk powder (blocking solution) for 1 h, followed by incubation with primary 
antibodies overnight at RT, diluted in blocking solution with 0.1% sodium azide and 
then with secondary antibodies (horseradish peroxidase-conjugated, ECL anti-
mouse IgG or anti-rabbit IgG; GE Healthcare) diluted 1:5000 in blocking solution, for 
2 h at RT. Anti-α-tubulin antibody (Millipore) was used as control to confirm equal 
loading of total protein. Membranes were developed using Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare) and visualized using a 




ChemiDocTM XRS+ System (BioRad). Primary antibodies used for protein detection 
were anti- βIII-Tub, anti-syn, anti-GFAP, anti-GAD65/67 and anti-VGluT1 described 
above as well as anti-tyrosine hydroxylase (TH, SantaCruz Biotechnology). 
2.8. qRT-PCR 
Real-time quantitative PCR analysis (qRT-PCR) was performed as described in 
Brito et al. (2012). Briefly, total RNA was extracted with High Pure RNA Isolation kit 
(Roche) and quantified using a NanoDrop 2000c (ThermoScientific). Reverse 
transcription was performed with Transcriptor High Fidelity cDNA Synthesis kit 
(Roche), using Anchored-oligo(dT)18 Primer. qRT-PCR analysis was performed in a 
LightCycler 480 Multiwell Plate 96 (Roche), according to Light-Cycler 480 SYBR 
Green I Master Kit (Roche). cDNA was diluted 1:2 and primers were used in a 
concentration of 5 M, in20 L reactions; each sample was performed in triplicates. 
The list of used primers and its sequence is presented in Table 1. Cycles threshold 
(Ct’s) and melting curves were determined using LightCycler 480 software, version 
1.5 (Roche) and results were processed using the 2−ΔΔCt method for relative gene 
expression analysis (Brito et al., 2012; Livak and Schmittgen, 2001). Changes in 
gene expression were normalized using the house-keeping gene RPL22 (coding for 
ribosomal protein L22) as internal control. 
2.9. Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5 software. Data are mean 
± SD from at least three independent experiments performed in triplicates (qRT-
PCR) or six replicates (neurotoxicity assays). One-way ANOVA analysis with Tukey’s 
post multiple comparison test was performed to assess differences between time 
points (aggregate’s diameter and qRT-PCR) or treated and control in neurotoxicity 
assays. Statistical significance was indicated as follows *P < 0.05, **P < 0.01, and 






Table 2.1:  List of primers used in NT2 neurospheroids qRT-PCR analysis. 
 
3. Results 
3.1 Characterization of 3D neural cultures along differentiation 
in stirred culture systems  
NT2 neuronal and astrocytic differentiation as 3D aggregates in stirred 
suspension systems was optimized in order to obtain a very reproducible and 
robust process, without significant batch-to-batch variation: typically cultures with 
high concentration of aggregates were obtained (888 ± 194 aggregates/mL by 
38DIV) which maintained their structural integrity along the entire culture period, 
with high cell viability and no evidences of necrotic core formation, as indicated by 
generalized FDA staining and few PI-positive cells scattered through the aggregates 
(Fig. 2.1a).  
Aggregate size gradually increased until 24DIV (end of the RA induction period) 
and was kept stable during the remaining time of the cultures (Fig. 2.1b), with an 
average diameter of 179.0 ± 76.5 µm. Initially, neurospheroids had a ragged 




appearance; however, as differentiation progressed the aggregate shape became 
uniform, forming compact and spherical structures (Fig. 2.1a, 24DIV), typical of 
neurospheroid cultures (Serra et al., 2009). In order to accurately characterize the 
NT2-derived 3D neural model, cultures were monitored along the differentiation 
process, including phenotypic and functional assessment of neurons and 
astrocytes. Along differentiation the expression of neuronal marker βIII-tubulin was 
upregulated (Fig. 2.3a), with an eight-fold increase in gene expression at 10DIV, 
compared to undifferentiated cells.  
Thereafter, maintenance of high levels of expression was observed, indicating 
an efficient differentiation into the neuronal lineage. In accordance, the expression 
of nestin, a marker of undifferentiated NT2 cells and early neuroepithelial 
progenitors, was downregulated in differentiated cultures (two-fold decrease 
at38DIV), while an initial four-fold increase was observed at 10DIV, probably 
corresponding to the proliferation of nestin+ neural progenitors (Michalczyk and 
Ziman, 2005). 
 
Figure 2.3: Characterization of the neuronal population in neurospheroids. (a) qRT-PCR analysis of 
βIII-tubulin and nestin gene expression; fold increase in gene expression of neuro-spheres along 
culture relatively to NT2 undifferentiated cells; data are mean ± SD of two independent 





post multiple comparison test. (b) qRT-PCR analysis of synaptophysin gene expression; fold increase in 
gene expression of neurospheroids at 24 and 38 DIV normalized for NT2 undifferentiated cells; data 
are mean ± SD of three independent cultures. (c) Detection of βIII-tubulin (βIII-tub) and synaptophysin 
(syn) by Western blot analysis; β-tub was used as loading control. (d) Immunofluorescence 
microscopy of neurospheroids (38 DIV); scale bar: 20 µm; MAP2 (red) and DAPI (blue). (e) 
Immunofluorescence microscopy of neurospheroids (38DIV); scale bar: 20 µm; Synaptophysin (green) 
and DAPI (blue). For (d) and (e) data are from one representative experiment of three independent 
cultures. (f) Relative decrease in fluorescence intensity evaluated by FM-1-43 dye assay performed for 
undifferentiated aggregates at 3DIV and neurospheroids at 38DIV. 
At 38DIV, an extensive network of MAP2+ cells was detected throughout the 
neurospheroids (Fig. 2.3d), indicating that mature neurons were present in culture 
at this time point. Concomitantly, synaptophysin, a presynaptic vesicle 
glycoprotein, was detected in a typical vesicular pattern across the differentiated 
neurospheroids (38DIV, Fig. 2.3e), with a 10-fold increase in synaptophysin gene 
expression (Fig. 2.3b). Although synaptophysin was already detected at 24DIV, 
protein levels increased till 38DIV (Fig. 2.3c). The neurotransmitter-specific 
phenotype of neurons in differentiated neurospheroids was further evaluated. By 
38DIV, high expression levels of the GABAergic marker GAD67 were observed, as 
well as gene expression of the dopaminergic marker TH and cholinergic marker 
ChAT (Fig. 2.4a). These correlated with the detection of VGluT1, GAD65/67 and TH 
proteins (Fig. 3b). Immunofluorescence co-localization allowed identification of βIII-
tubulin+/GAD65/67+ GABAergic neurons (Fig. 2.4c), as well as βIII-tubulin+/VGluT1+ 
glutamatergic neurons (Fig. 2.4d). Moreover, VGluT1 was detected in a vesicular 
punctate pattern (inset in Fig. 2.4d), suggesting its localization in presynaptic 
vesicles (Alonso-Nanclares and Defelipe, 2005). These results indicated that the 
two main neurotransmitters in human brain – Glu and GABA (γ-aminobutyric acid) 
– were present in NT2 differentiated neurospheroids, as well as dopaminergic and 
cholinergic neurons. 





Figure 2.4: Characterization of neurotransmitter phenotype of neuronal population in 
neurospheroids. (a) qRT-PCR analysis of ChAT, GAD67 and TH gene expression; fold increase in gene 
expression of neurospheroids at 24 and 38 DIV relatively to NT2 undifferentiated cells; data are mean 
± SD of three independent cultures;***indicate significant difference with P < 0.001 by one-way 
ANOVA analysis with Tukey’s post multiple comparison test. (b) Detection of TH, VGluT1 and 
GAD65/67 by Western blot analysis; β-tubulin (β-tub) was used as loading control. (c) 
Immunofluorescence microscopy of neurospheroids (38 DIV); scale bar: 20 µm; βIII-tubulin (βIII-tub) 
(red), GAD65/67 (green) and DAPI (blue). (d) Immunofluorescence microscopy of neurospheroids 
(38DIV); scale bar: 20 µm; βIII-tubulin (red), VGluT1 (green) and DAPI (blue). For (b), (c) and (d) data 
are from one representative experiment of three independent cultures. 
In terms of astrocytic differentiation, expression of GFAP significantly increased 
from 24 to 38DIV (Fig. 2.5a). In accordance, GFAP protein reached detectable levels 
by 38DIV (Fig. 2.5b), with GFAP+ cells homogeneously distributed across the 
neurospheroids (Fig. 2.5c) and being 77.5 ± 4.9% of total cells in culture. These 
results indicated that the extended period implemented (Fig. 2.1a) was essential to 
obtain NT2 astrocytic cells expressing GFAP. Expression of the astrocytic markers 





these cells (Cantini et al., 2012). Expression of S100- β increased during 
differentiation until 38DIV (Fig. 2.5a). 
 
Figure 2.5: Characterization of astrocytic population in neurospheroids. (a) qRT-PCR analysis of 
GFAP, S100-β, GLAST and GLT-1 gene expression; fold increase in gene expression of neurospheroids 
along culture relatively to NT2 undifferentiated cells; data are mean ± SD of three independent 
cultures. Asterisks indicate significant difference (*P < 0.05, **P < 0.01 and***P < 0.001) by one-way 
ANOVA analysis with Tukey’s post multiple comparison test. (b) Detection of GFAP by Western blot 
analysis; β-tubulin (β-tub) was used as loading control (c) Immunofluorescence microscopy of 
neurospheroids (38DIV); scale bar: 20 m; βIII-tubulin (green), GFAP (red) and DAPI (blue). (d) 
Immunofluorescence microscopy of neurospheroids (38DIV); scale bar: 20 µm; GLT-1 (red) and DAPI 
(blue). For (b), (c) and (d) data are from one representative experiment of three independent cultures. 
Upregulation of the two main Glu transporters, GLAST and GLT-1, was observed 
until 17DIV, with maintenance of high levels of expression thereafter (Fig. 2.5a), 
with GLT-1+ cells detected at 38DIV (Fig. 2.5d). Altogether, these results indicated 
that culture time extension besides the 3-weeks RA induction was essential to 
attain differentiated neurospheroids, which by 38DIV were enriched in GFAP+ 
astrocytes, as well as MAP2+ mature neurons with several neurotransmitter 
phenotypes. Neurospheroids from 38DIV onwards were referred as differentiated 
neurospheroids (Fig. 2.1a) and applied in neurotoxicity studies. 




3.2. Characterization of 3D neural cell cultures by neuronal and 
astrocytic-specific endpoints 
Neuronal and astrocytic specific functional endpoints were implemented in 
differentiated neurospheroids in multi-well plate format. To assess neuronal 
synaptic activity, the ability of differentiated neurospheroids to respond to 
depolarizing stimuli was evaluated using the fluorescent probe FM-1-43 which 
allows labeling and monitoring synaptic vesicle exocytosis (Gaffield and Betz, 2006). 
Undifferentiated aggregates (3DIV) and differentiated neurospheroids (38DIV) 
were loaded with FM-1-43 dye and loss of fluorescence upon a depolarizing 
stimulus triggered a steeply decrease in fluorescence intensity of differentiated 
neurospheroids, when compared to undifferentiated aggregates (Fig. 2.3f), 
suggesting that these neurospheroids contained mature neurons with functional 
synaptic terminals able to fuse the synaptic vesicles with the plasma membrane 
and perform exocytosis and neurotransmitters release. Concerning astrocytic 
features, a four-fold increase in GS gene expression was observed at 38DIV (Fig. 
2.6a).  
 
Figure 2.6: Functional characterization of astrocytic population in neurospheroids. (a) qRT-PCR 
analysis of glutamine synthetase (GS) gene expression; fold increase in gene expression of 
neurospheroids at day 24 and 38 normalized for NT2 undifferentiated cells. (b) Extracellular glutamate 
(Glu) clearance. Neurospheroids were incubated with5 mM Glu for 72 h and Glu concentration was 
measured at 0, 24, 48 and 72 h; medium without cells was used as control. (c) Extracellular glutamine 
(Gln) concentration. Neurospheroids were incubated with only medium (control) or medium with 5 
mM Glu for 72 h and Gln concentration was measured at 0, 24, 48 and 72 h. In (a), (b) and (c) results 
are mean ± SD of three independent experiments;***indicate significant difference with P < 0.001 by 






Moreover, when differentiated neurospheroids were challenged with medium 
containing Glu (5 mM), clearance of the metabolite was observed for 72 h (Fig. 
2.6c), with an average Glu uptake rate of 0.385 ± 0.137 mol mg prot−1 h−1; 
concomitantly, increased Gln concentrations were detected in cell supernatant for 
72 h (Fig. 2.6d), with a seven-fold increase in Gln secretion rate in Glu challenged 
neurospheroids (0.092 ± 0.026 against 0.013 ± 0.007 mol mg prot−1 h−1). Altogether, 
these results indicate that neurospheroids were capable of Glu internalization, and 
Gln efflux, suggesting the activity of Glu and Gln transporters, as well as of GS in 
astrocytes within neurospheroids. 
3.3. Neurotoxicity assays  
The applicability of the human 3D neural cell model generated in a scalable 
stirred culture system to feed high-throughput neuro-toxicity studies was 
evaluated. As a proof of concept, differentiated neurospheroids were used to feed 
96-well plates for neurotoxicity assays with toxic compounds: tBHP, an oxidant 
(Holownia et al., 2009), Acr, a prototypical neurotoxicant (Lopachin and Gavin, 
2012) and chloramphenicol, described as neurotoxicant (Grill and Maganti, 2011; 
Ramilo et al., 1988) and recently suggested to be astrotoxicant (Woehrling et al., 
2011). Cellular viability was evaluated as first endpoint for IC50 determination. 
Initially, in order to set-up assay conditions, a calibration curve was performed 
distributing 0–100 neurospheroids per well; linearity was observed between 5 and 
20 neurospheroids per well (Fig. 2.2). To validate the assay setup in 96-well plates a 
general oxidant compound was used. Neurospheroids were exposed to 0.008–2 
mM tBHP, for 48 h and a dose-response curve was generated based on cellular 
viability evaluation (determined IC50 of 246 ± 1 µM, Fig. 2.7a).  





Figure 2.7: Neurotoxicity assays – functional and gene expression endpoints. (a) Dose-response 
curve of 0.008 - 2 mM tert-buthyl hydroperoxide (tBHP) induced lesion for 48 h, determined by Presto 
blue assay. (b) FM-1-43 dye assay performed for 3DIV (undifferentiated aggregates) and 38DIV 
(differentiated neurospheroids) with and without acrylamide incubation (2.47 mM) for 72 h. (c) qRT-
PCR analysis of GFAP, βIII-tubulin and synaptophysin gene expression; Relative gene expression of 
neurospheroids after incubation with acrylamide (0.10 and 2.47 mM)and chloramphenicol (1 and 4.31 
mM) for 72 and 48 h (respectively) normalized to negative control; data are mean ± SD of three 
independent cultures; asterisks indicate significant difference to negative control, with P < 0.001 by 
one-way ANOVA analysis with Tukey’s post multiple comparison test. 
Dose-response curves were obtained for Acr and chloramphenicol (Fig. 2.2b 
and 2.2c). Overall, the inter-assay coefficient of variation (%CV) was of 15.8 ± 
3.51%, for 12 independent experiments, indicating that evaluation of toxicity using 
differentiated neurospheroids was a reproducible and robust assay setup. The IC50 
and a subtoxic concentration in which cellular viability was affected less than 5% 
were selected for gene expression and functional endpoints. 
3.3.1. Acrylamide neurotoxicity 
Differentiated neurospheroids were exposed to Acr in concentrations ranging 
between 1 µM and 1 M for 72 h and cellular viability was affected in a dose-





curve of Acr presented a plateau around 40% of cellular viability and the deter-
mined IC50 was 2.47 ± 0.45 mM. Evaluation of gene expression of specific cell-
makers was used as endpoint (Laurenza et al., 2013). Differentiated 
neurospheroids were distributed in 6-well plates, incubated with Acr at IC50 and 
one subtoxic concentration (2.47 and 0.10 mM, respectively) and recovered for 
qRT-PCR analysis. Exposure to 2.47 mM Acr led to a significant decrease in gene 
expression of the evaluated neuronal and astrocytic markers (30.3 ± 4.2, 22.7 ± 3.3 
and 42.3 ± 13.5% of control for βIII-tubulin, synaptophysin and GFAP, respectively, 
Fig. 2.7c). The subtoxic concentration of 0.10 mM Acr did not affect gene 
expression of cytoskeletal neuronal marker βIII-tubulin and the astrocytic marker 
GFAP; noteworthy, for synaptophysin a significant decrease in gene expression 
(80.4 ± 7.2% of control, Fig. 2.7c) was observed, indicating that expression of this 
pre-synaptic marker was affected before further cellular effects could be detected. 
In order to determine if the toxicant impaired synaptic functionality, the ability of 
Acr (2.47 mM)-treated neurospheroids to respond to depolarizing stimuli was 
evaluated. This stimulus triggered a smaller decrease in fluorescence intensity of 
differentiated neuro-spheres exposed to Acr than differentiated neurospheroids 
without treatment (Fig. 2.7b) and comparable to undifferentiated aggregates. The 
data obtained suggested that Acr affected synaptic activity of neurons and that this 
assay could be used as a functional endpoint for neurotoxicity evaluation. 
3.3.2. Chloramphenicol neurotoxicity 
Differentiated neurospheroids were exposed to chloramphenicol in 
concentrations ranging between 39 µM and 10 mM, for 48 h. Cellular viability was 
affected in a dose-dependent manner in concentrations above 0.1 mM (Fig. 2.2c) 
and the determined IC50 was 4.31 ± 0.85 mM. Upon exposure of neurospheroids to 
the IC50 concentration (4.31 mM), gene expression of both βIII-tubulin neuronal 
and GFAP astrocytic markers was affected (31 ± 16.7 and 7.3 ± 1 % of negative 
control, respectively, Fig. 2.7c). Exposure to a subtoxic concentration (1 mM) was 
sufficient to induce dramatic changes in expression of astrocytic GFAP, but only 




minor changes in the neuronal βIII-tubulin (35.4 ± 0.7 and 80.1 ± 18.4 % of negative 
control, respectively, Fig. 2.7c). These results indicated that the changes in gene 
expression induced by chloramphenicol treatment were dose-dependent, with 
higher impact on astrocytic GFAP; therefore these can be used as sensitive 
endpoints for chloramphenicol-mediated toxicity, particularly in astrocytes. 
4. Discussion 
In this work we developed a scalable 3D culture strategy using stirred 
suspension culture systems for robust and reproducible differentiation of NT2 cells, 
which allow efficient production of high numbers of stable neurospheroids 
containing not only mature and functional human neurons but also astrocytes, in a 
50% less time-consuming process when compared with the 2D culture systems 
(Goodfellow et al., 2011). This was accomplished having as starting point a protocol 
forNT2 neuronal differentiation in stirred suspension culture systems previously 
developed in our laboratory (Serra et al., 2009, 2007), which increased 10-fold the 
final yields of NT2 neurons, favoring cell–cell interactions and promoting an 
increased synchrony in response of undifferentiated cells to RA (Tonge et al., 2010). 
Herein, an extended culture time was introduced to obtain neurospheroid 
enrichment in functional astrocytes, as well as mature neurons, modeling more 
consistently the basic CNS unit and increasing neurospheroid reliability on 
neurotoxicity assessment. The applicability of the human 3D neural cell model 
generated to feed high-throughput neurotoxicity studies was evaluated by using 
neurospheroids obtained to feed multi-well plates. From one 125 mL culture, we 
are able to feed more than one hundred 96-well plates (typically 10 
neurospheroids/ well). Moreover, the use of a scalable culture system allows easy 
scale-up if higher numbers of neurospheroids are required for even higher 
throughput. Therefore, our differentiated neurospheroids production process, in 
combination with automated measurement of fluorescence-based endpoints, is 





system described herein allowed obtaining differentiated neurospheroids by 
38DIV; these neurospheroids were composed mainly of GFAP+ cells (77.5 ± 4.9% of 
total cells), βIII-tubulin+/MAP2+ neurons and few nestin+ cells, with the different 
cells types homogeneously distributed through the neurospheroids. Similarly, 
astrocytes greatly outnumber neurons in vivo, depending on the brain region, often 
10:1 (Allen and Barres, 2009). Moreover, differentiated neurospheroids 
composition was kept stable for at least 12 additional DIV (up to 50DIV, not 
shown), allowing to start several assays during this time interval with reproducible 
results. Notably, the proportion of GFAP+ cells in the neurospheroids was 
maintained between different batches, indicating a small batch-to-batch variation 
in differentiation efficiencies. Neurospheroid concentration and size (Fig. 2.1b) 
were also maintained through different batches, highlighting the reproducibility 
and robustness of the process. βIII-tubulin+ neurons were detected early in culture, 
around10DIV, while GFAP+ astrocytes were only detected by 31DIV. This is in line 
with in vivo prenatal neural development where neurogenesis is followed by 
astrocytic differentiation and also with ESC in vitro differentiation that generate 
neurons in the first month and astrocytes after 2–3 months (Hu et al., 2010). 
Together, these results indicate that the order of neuronal and astrocytic 
differentiation of NT2 cells resembles those in normal brain development and 
therefore this model could also be applied to developmental neurotoxicity studies. 
Importantly, NT2 cell differentiation has the advantage of being a much simpler 
and less time-consuming process than ESC or NSC differentiation (Gupta et al., 
2012; Schwarz, 2007), as it requires only RA as differentiation factor, thus providing 
a more amenable and cost-effective cell model to be used in high-throughput 
platforms. Excitatory glutamatergic neurons and inhibitory GABAergic neurons, the 
main neuronal phenotypes in brain, were detected in differentiated 
neurospheroids. Furthermore, detection of MAP2+ neurons, and the increase in 
synaptophysin gene expression during differentiation, with accumulation of 
synaptophysin+ vesicles detected in a punctate pattern along neuronal processes 




suggest that neuronal maturation occurred within neurospheroids. The ability of 
neurospheroids to respond with exocytosis of vesicles to depolarizing stimuli 
confirmed that mature neurons with functional synapses were present within 
neurospheroids, presenting the ability of synaptic vesicle fusion with the plasma 
membrane and neurotransmitter release. Concerning astrocytic differentiation, 
expression of S100-β was detected earlier than GFAP, probably because this 
calcium-binding protein is present in neural precursor cells committed to the 
astrocytic lineage (Donato et al., 2009). The presence of GLT-1 along differentiation 
suggest that astrocytic maturation occurred within neurospheroids since it is the 
predominant Glu transporter in astrocytes, being responsible for 90% of total Glu 
uptake by all excitatory aminoacid transporters in adult brain (Kim et al., 2011). 
Furthermore, astrocytic maturation was confirmed by the ability of neurospheroids 
to perform Glu uptake from the extracellular media and Gln production upon Glu 
challenge. These results suggested the presence of functional Glu transporters, 
which are the main mediators of Glu clearance by astrocytes; active GS, which is an 
astrocyte-specific enzyme responsible for conversion of Glu into Gln (Zou et al., 
2010); and Gln efflux into the extracellular space via Gln transporters. These are 
essential steps of the well-described Gln–Glu cycle, involved in supply of Gln to 
neurons (Amaral et al., 2011; Zou et al., 2010). Furthermore, the Gln secretion rates 
after Glu challenge (0.092 ± 0.026 µmol mg prot−1 h−1) were in line with those 
previously determined for primary cultures of pure astrocytes (0.049 ± 0.005 µmol 
mg prot−1 h−1; Amaral et al., 2011), which might be explained by the high astrocyte : 
neuron cell ratio observed in differentiated neurospheroids. The developed cell 
model was validated for neurotoxicity assays by evaluating the response of 
neurospheroids to exposure to Acr and chloramphenicol, previously described as 
neurotoxicants (Grill and Maganti, 2011; Lopachin and Gavin, 2012; Ramilo et al., 
1988). Acr is a widely used industrial chemical with proved neurodegenerative 
effects in humans, with nerve terminals being described as a primary site of Acr 





with an IC50 of 2.47 mM, within the range of previously reported for murine cells 
and animal studies; IC50s of 2.68 and 1.90 mM were reported for differentiated 
PC12 and primary cultures of cerebellum cells, respectively (Gartlon et al., 2006) 
and average LD50 values of 160.8 mg/kg (i.e., 2.26 mmol/kg; Hoffmann et al., 
2010), for rodents. Acr affected synaptophysin gene expression, which was 
significantly decreased in Acr-treated neurospheroids even at subtoxic 
concentrations, while changes in commonly used toxicity endpoints such as 
cytoskeletal genes expression (βIII-tubulin) and cellular viability (Laurenza et al., 
2013; Stern et al., 2013) could not be detected at these concentrations. 
Furthermore, the response of Acr-treated neurospheroids to depolarizing stimuli 
decreased to levels similar to those of undifferentiated aggregates, indicating loss 
of ability of synaptic vesicles to fuse with plasma membrane and perform 
exocytosis. Altogether, our results suggest that Acr neurotoxicity mechanism 
involves impairment of synaptic activity, in particular presynaptic function. This is in 
line with previous reports that showed that Acr inhibits proteins involved in 
synaptic vesicle cycle, as N-ethylmaleimide-sensitive factor and some SNARE 
proteins (Barber and LoPachin, 2004) and consequently interfere with membrane 
fusion processes and impairs neurotransmitter release (Exon, 2006; Lopachin and 
Gavin, 2012). Moreover, our results suggested that gene expression analysis of the 
neuronal marker synaptophysin can be used as a high sensitive endpoint for 
neuronal toxicity. Chloramphenicol is a widely used broad spectrum antibiotic 
known to be neurotoxic (Grill and Maganti, 2011; Ramilo et al., 1988). We observed 
that chloramphenicol affects cellular viability, with an IC50 of 4.31 mM, which is 
within the range of the LD50 previously reported for rodents – 2270 mg/kg (i.e., 
7.02 mmol/kg; Hoffmann et al., 2010). Concerning specific neural markers, 
chloramphenicol affected neuronal βIII-tubulin but not synaptophysin gene 
expression and, to a major extent, astrocytic GFAP gene expression. Altogether, our 
results suggested that chloramphenicol toxicity mechanism involves impairment of 
cytoskeletal proteins βIII-tubulin and GFAP. Although chloramphenicol 




neurotoxicity mechanisms are not well known, this is in line with a previous report 
that described that chloramphenicol induces cytoskeletal injury, including 
degeneration of neurofilaments in neuronal cells and, more significantly, GFAP in 
astrocytic cells, being more toxic to astrocytes than to neurons (Woehrling et al., 
2011). Moreover, our results suggested that gene expression analysis can be used 
as a high sensitive endpoint to distinguish between neuronal and astrocytic toxicity. 
Cell viability within neurospheroids was affected by the oxidant tBHP (Holownia et 
al., 2009), in a dose-dependent manner. In brain, oxygen free radicals are 
constantly produced and can damage neural cells and oxidative stress is known to 
be involved in most neurodegenerative diseases (Federico et al., 2012). Therefore, 
our model can also be used as model to neurodegeneration-related oxidative 
stress. Overall, our results showed that human NT2-derived differentiated 
neurospheroids are compatible with multi-well plate assay formats for high-
throughput neurotoxicity evaluation campaigns, with clear advantages in terms of 
relevance when compared with standard 2D culture systems (Hill et al., 2008; 
Moors et al., 2009). Taking into account the typical workflow of high-throughput 
assays (from cell counting and seeding, to data acquisition and analysis), all steps 
are amenable to be performed in automated high-throughput screening platforms 
applying recent advances in robotic systems for high-throughput campaigns 
(Fennema et al., 2013; Trumpi et al., 2014). Moreover, complementary to cellular 
viability, the specific endpoints implemented – gene expression and functionality, 
presented high sensitivity, allowing early detection of disturbed neuronal or 
astrocytic functions and their correlation with mechanisms of toxicity. The use of a 
larger set of known neurotoxic test compounds, such as methylmercury or 
hydroxyurea (Mundy et al., 2009), as well as the performance of neuroprotection 
assays will provide additional validation of the relevance and robustness of this 
3Dhuman brain in vitro cell model for neurotoxicity evaluation. For repeated dose 





multi-organ chip platforms, which will allow long-term cultures in miniaturized 
controlled environments (Materne et al., 2015).  
5. Conclusion 
Differentiation of NT2 cell line using stirred suspension culture systems with 
integration of a maturation step allowed obtaining a 3D co-culture enriched in 
mature and functional human neurons and astrocytes, homogeneously distributed 
throughout neurospheroids, modeling more consistently the CNS composition. This 
efficient and robust scalable culture strategy generates large numbers of human 
differentiated neurospheroids, providing an amenable and cost-effective cell 
model. Moreover, the feasibility of using this culture strategy to feed high-
throughput neurotoxicity studies was demonstrated by the determination of the 
neurotoxicity of several toxicants. The implementation of specific endpoints such 
as gene expression analysis of cell-specific markers and functional assays allowed 
detection of specific neuronal and astrocytic effects of tested compounds with 
improved sensibility. 
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Central nervous system drug development has registered high attrition rates, 
mainly due to the lack of efficacy of drug candidates, highlighting the low reliability 
of the models used in early-stage drug development and the need for new in vitro 
human cell-based models and assays to accurately identify and validate drug 
candidates. 3D human cell models can include the different tissue cell types and 
represent the spatiotemporal context of the original tissue (co-cultures), allowing 
the establishment of biologically-relevant cell-cell and cell-extracellular matrix 
interactions. Nevertheless, exploitation of these 3D models for neuroprotection 
assessment has been limited due to the lack of data to validate such 3D co-culture 
approaches. 
In this work we combined a 3D human neuron-astrocyte co-culture with a cell 
viability endpoint for the implementation of a novel in vitro neuroprotection assay, 
over an oxidative insult. Neuroprotection assay robustness and specificity were 
evaluated. The applicability of Presto blue, MTT and CytoTox-Glo viability assays to 
the 3D co-culture was evaluated. Presto Blue was the adequate endpoint as it is 
non-destructive and is a simpler and reliable assay. Semi-automation of the cell 
viability endpoint was performed, indicating that the assay setup is amenable to be 
transferred to automated screening platforms. Finally, the neuroprotection assay 
setup was applied to a series of 36 test compounds and several candidates with 
higher neuroprotective effect than the positive control, Idebenone, were identified. 
The robustness and simplicity of the implemented neuroprotection assay with 
the cell viability endpoint enables the use of more complex and reliable 3D in vitro 







There is an increased social, clinical and economical need for new therapies 
targeting central nervous system (CNS) neurodegenerative diseases. CNS drug 
development slowed down since 1990 and high attrition rates have been 
registered, with CNS drugs more likely to fail in late-stage clinical trials than others 
(Kesselheim et al., 2015). The most common reason for failure was the lack of 
efficacy, highlighting the low reliability of the models used in early-stage 
development and the need for new preclinical in vitro cell-based models and assays 
to accurately identify and validate new drug candidates (Astashkina and Grainger, 
2014; Kesselheim et al., 2015). 
Human neural in vitro models typically consist of 2D cultures of neuronal-like 
cells, such as neuroblastoma cell lines (Choi et al., 2011; Del Barrio et al., 2011) or, 
more recently, pluripotent stem cell-derived neurons (Avior, Sagi, & Benvenisty, 
2016). However, to achieve a significant level of mimicry of the in vivo tissue, cell 
models must include the different tissue cell types and be able to represent the 
spatiotemporal context of the original tissue.  
Human in vitro 3D models allow the establishment of biologically relevant cell-
cell and cell-extracellular matrix interactions, which recapitulate the tissue 
microenvironment (Edmondson, Broglie, Adcock, & Yang, 2014). In the last years, 
3D models have undergone rapid development and gained increased attention as 
complementary tools for pre-clinical research which bridge the gap between 
animal models and human clinical trials (Breslin and Driscoll 2013; Astashkina and 
Grainger 2014). Nevertheless, exploitation of these 3D models for neuroprotection 
assessment has been limited due to the lack of validated, robust and user-friendly 
assays. 
Cell viability assays have been developed and widely used in standard 2D 
cultures as simple and robust endpoints (Burroughs et al., 2012). The most 
commonly used cell viability assays are based on cell metabolic activity, such as 
tetrazolium- and resazurin-based methods. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-




diphenyltetrazolium bromide) is an endpoint tetrazolium-based assay that 
quantifies the cellular metabolic activity through the formation of blue formazan 
crystals after the cleavage of the tetrazolium ring by mitochondrial 
dehydrogenases; such crystals can then be solubilized and quantified in cell lysates 
(Riss et al., 2004). Assays based on tetrazolium reduction that originates water-
soluble tetrazolium salts, such as MTS, XTT and WTS are also commercially 
available. Nevertheless, all of these assays are toxic to the cells (Riss et al., 2004). 
Resazurin-based methods quantify the cellular metabolic activity by measuring the 
fluorescence of the water soluble, non-toxic resofurin. This compound is formed 
through the metabolization of resazurin by live cells and diffuses from the cells into 
the surrounding medium; therefore cell lysis is not required and cell cultures can be 
maintained after the measurement (Riss et al., 2004; Sonnaert, Papantoniou, 
Luyten, & Schrooten, 2014). Alternatively, cell viability can be evaluated by plasma 
membrane integrity assays that include trypan blue or nucleic acid staining, by ATP 
determination or by assays that measure the activity of an intracellular enzyme 
that has been released from cells with damaged membrane integrity (Niles, 2007); 
these latter can be lactate dehydrogenase (LDH), or cytosolic, lysosomal or 
transmembrane-bound proteases whose activities are measured using luminogenic 
peptide substrates. However, the use of these assays in 3D cultures for drug 
screening requires its validation. 
Herein we describe the implementation of an assay setup for neuroprotection 
evaluation in a 3D human co-culture of neurons and astrocytes over an oxidative 
insult. We describe the evaluation of several cell viability assays and semi-
automation of the endpoint as a proof-of-concept that the neuroprotection assay 
setup is amenable for high-throughput screening platforms. We have used a 
scalable 3D human neuron-astrocyte co-culture previously developed, based on the 
3D differentiation of the pluripotent embryonic carcinoma-derived NTera-2/ clone 
D1 (NT2) cell line into neurospheroids, in an agitation-based culture system 





model to feed high-throughput screening platforms and to evaluate human 
neuronal and astrocytic toxicity with improved sensitivity due to the functional 
neuron-astrocyte metabolic interactions (Simão et al., 2016; Terrasso et al., 2015). 
Finally, we have applied the neuroprotection assay setup implemented in this 
work to a series of 36 compounds, where several candidates with higher 
neuroprotective effect than the positive control, Idebenone, were identified. 
2. Materials and Methods 
2.1. Cell culture and 3D neural differentiation 
Undifferentiated NTera-2/ clone D1 (NT2) cells from the American Type 
Culture Collection (ATCC) were routinely propagated in 2D culture systems (Brito et 
al., 2007); 3D neural differentiation was performed in an agitation-based culture 
system as previously described (Terrasso et al., 2015). Briefly, undifferentiated NT2 
cells were inoculated as a single cell suspension in 125 mL spinner vessels equipped 
with a ball impeller (Wheaton) in DMEM, 10% (v/v) fetal bovine serum (FBS) and 
1% (v/v) penicillin-streptomycin (P/S; all from Life Technologies). After 3 days of 
aggregation, neuronal and astrocytic differentiation was induced by addition of 10 
μM RA, with a 50% media exchange every 2-3 days for 21 days. Following this 
period, a neurospheroid 3D neuron-astrocyte co-culture was obtained and 
maintained in DMEM, 5% (v/v) FBS, 1% (v/v) P/S up to day 50 and applied in 
neurotoxicity assays between days 38 and 50 of culture. 
2.2. Cell viability endpoint 
Presto blueTM cell viability assay (Life Technologies) was performed following 
the manufacturer’s instructions. Briefly, Presto blue cell viability reagent was 
diluted 1:10 in culture media and incubated with neurospheroids for 40 min. at 
37ºC and 5% CO2. The fluorescence intensity was evaluated using a FluoroMax®-4 
spectrofluorometer, with excitation and emission wavelengths of 580/ 595 nm, 
respectively.  




A stock solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma-Aldrich) 5mg/ mL in PBS was diluted 1:10 in culture media 
and incubated with neurospheroids for 3 hours, at 37ºC and 5% CO2. Afterwards, 
blue formazan crystals were dissolved in dimethyl sulfoxide (DMSO), for 15 min. at 
RT, under shaking conditions, and the absorbance was read at 570 nm. 
CytoTox-GloTM Cytotoxicity Assay (Promega) was performed accordingly to 
manufacturer’s instructions. Briefly, CytoTox-Glo TM cytotoxicity assay reagent was 
added to the neurospheroids and incubated for 15 min. at RT, in an orbital shaker. 
Afterwards, the lysis reagent was added and further incubated for additional 15 
min. in agitation before luminescence measurement. 
2.3. Semi-automation of cell viability endpoint 
Semi-automation of cell viability endpoint was performed using a Hamilton® 
Microlab STARlet workstation (Hamilton) equipped with 8 independent pipetting 
channels, a reagent container carrier, a plate carrier (5 positions) and a disposable 
tip carrier (5 trays with 5 racks). The workstation has an integrated plate storage 
module with 64 positions and a Biotek Synergy 2 multimode microplate reader 
controlled by a computer using the MicroLab Star software. A program for the 
automation of the steps of (1) addition of Presto blue reagent, (2) transfer of 
medium from assay plate to fluorescence reading plate and (3) fluorescence 
reading was implemented. 
2.4. Neurotoxicity and neuroprotection assays 
Neurospheroids were collected from spinner vessels between days 38 and 50 
of culture, where aggregate diameter was kept stable, typically with approximately 
180 μm, distributed in 96-well plates at 10 neurospheroid/ well and incubated in 
DMEM, 5% (v/v) FBS, 1% (v/v) P/S, before carrying out neurotoxicity or 
neuroprotection assays. Six wells were used per test condition and the culture 
medium was used as an untreated control. Cell viability, evaluated by the Presto 





Grupo Tecnimede) was evaluated for concentrations between 0.01 nM-100 μM. 
Thirty-six (36) test compounds were evaluated for their neuroprotective effects on 
3D neuron-astrocyte cultures over an oxidative insult. The test compounds were 
added to the cultures under different regimens: 24 or 48 h pre-incubation, 24 or 48 
h pre-incubation followed by 48 h of co-incubation together with tert-butyl 
hydroperoxide (tBHP) or chloramphenicol, 48 h co-incubation, 48 h co-incubation 
followed by 24 h post-incubation (Fig. 3.1). tBHP- and chloramphenicol-induced 
insults were performed by exposure to its half maximal inhibitory concentration 
(IC50; 280 μM and 4.3 mM, respectively) for 48 h (Terrasso et al., 2015). Negative 
(medium), insult and test compound neurotoxicity controls have been performed. 
Cell viability was accessed before exposure to test compound, before tBHP insult 
and 48h after insult. Final cell viability was calculated as a percentage of cell 
viability before insult. 
 
Figure 3.1: Schematic workflow for the addition of test compounds in neuroprotection assay over 
tBHP insult in 3D human neuron-astrocyte co-culture. Schematic workflow for regimens of test 
compounds addition for neuroprotection evaluation: tBHP insult (light grey), incubation with test 
compound (dark grey) and co-incubation of tBHP and test compound (stripes). 
2.5. Immunofluorescence microscopy 
3D neuron-astrocyte co-cultures were collected at day 38 and processed for 
immunofluorescence staining, accordingly to (Terrasso et al., 2015). Briefly, the 
neurospheroids were fixed in 4% (w/v) paraformaldehyde (Sigma) solution in PBS 
with 4% (w/v) sucrose and processed directly for immunostaining. The primary 
antibodies used for cell characterization were anti-βIII-tubulin (Millipore) and anti-




glial fibrillary acidic protein (GFAP, DAKO). The secondary antibodies used were 
goat anti-mouse IgG-AlexaFluor 488 and goat anti-rabbit IgGAlexaFluor 594 (Life 
Technologies). Cell nuclei were counterstained with 4',6-diamidino-2- phenylindole 
(DAPI, Life Technologies). Preparations were visualized using a point-scan confocal 
(Leica SP5) microscope. Merge between channels, maximum z-projections, and 
orthogonal projections, as well as linear brightness and contrast adjustments of the 
images were created using the ImageJ software version 1.47 m 
(http://rsbweb.nih.gov/ij/).  
2.6. Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism 5 software. 
Neurotoxicity and neuroprotection data are mean ± SD from at least three 
independent experiments performed with six replicates. D'Agostino & Pearson 
omnibus normality test was performed to test if the data follows a normal 
distribution. One-way ANOVA analysis with Tukey’s post multiple comparison test 
was performed to assess statistical differences between samples and controls in 
neuroprotection assays. P ˂ 0.001 was chosen as the level of significance. 
3. Results  
3.1. Neurospheroids cultured in 96 well plates are amenable 
for cell viability and neuroprotection assays 
For the implementation of a viability readout in neurospheroids (Fig. 3.2a, b) 
we have evaluated three different viability assays: a resazurin-based cell viability 
assay (Presto BlueTM) and MTT, which measure cell metabolic activity based on 
resazurin reduction and on tetrazolium salt formation, respectively, and CytoTox-
Glo, which measures cell death based on the activity of an intracellular protease in 







Figure 3.2: Cell viability assays in 3D human neuron-astrocyte co-culture. Immunofluorescence 
microscopy of 3D human neuron-astrocyte co-culture. βIII-tubulin (green) and DAPI (blue) (a);GFAP 
(red) and DAPI (blue) (b); scale bars: 100 μm. (c) Calibration curves performed for the cell viability 
assays Presto blue (blue; data in relative fluorescence units (RFU)), MTT (green; Abs 570nm) and 
CytoTox-Glo (grey; data in relative luminescence units (RLU)). 5 to 20 neurospheroids were distributed 
per well and incubated for 72 h before carrying out the viability assay; data are mean ± SD of at least 
two independent experiments per aggregate number, all with six technical replicates.  
Differentiated neurospheroids, composed of neurons and astrocytes (Fig. 3.2 
a,b), were generated in stirred-tank culture system as previously described 
(Terrasso et al., 2015). Neurospheroids were distributed in 96-well plates at 
increasing concentrations, ranging from 5 to 100 neurospheroids/ well. For the 
three cell viability methods, signal intensity correlated linearly with the aggregate 
number (Fig 3.2c) from 5 to 20 aggregate/ well. Nonetheless, the coefficients of 
determination (r2) were higher for Presto Blue (0.92) and MTT (0.91) assays than 
for CytoTox-Glo (0.60; Fig 2c). Moreover, higher standard deviations were obtained 
for the latter, indicating higher intra-assay variability, compared with the Presto 
Blue and MTT assays. This might have been due to a heterogeneous aggregate lysis, 




a step required in CytoTox-Glo assay for data normalization. Thus, the Presto Blue 
assay was chosen to measure the cell viability in the neuroprotection assays.  
For the implementation of the neuroprotection assay, we have chosen tBHP as 
the neurotoxic agent, a widely used oxidative lesion inducer in neuronal cultures 
(Choi et al., 2011; Kaja et al., 2012). The incubation of neurospheroids with 280 μM 
of tBHP for 48h resulted in approximately 50% reduction of cell viability, measured 
by Presto Blue (Fig 3.3a,b).  
 
Figure 3.3: Idebenone neuroprotective effect over tBHP insult in 3D human neuron-astrocyte co-
culture. (a) Idebenone (100 nM) neuroprotective effect over the tBHP insult in 3D human neuron-
astrocyte co-culture evaluated at several regimens: 24 or 48 h pre-incubation, 24 or 48 h pre-
incubation and 48 h co-incubation, 48 h co-incubation, 48 h co-incubation and 24 h post-incubation. 
(b) Idebenone (12.5–100 nM) neuroprotective effect over the tBHP insult in 3D human neuron-
astrocyte co-culture evaluated at 24 h pre-incubation. Cell viability was determined 48 h after insult, 
relatively to cell viability before insult, by Presto blue assay; data are mean ± SD of at least three 
independent experiments; * indicates significant difference (P < 0.001) to negative control (no tBHP 
insult and no test compound), # indicates significant difference (P < 0.001) to insult control (tBHP) by 
One-way ANOVA analysis with Tukey's post multiple comparison test. 
This loss in cell viability was mitigated by a pre-incubation with 100 nM of 
Idebenone (Fig 3.3a), an analogue of the prototypical anti-oxidant co-enzyme Q10 
(Erb et al., 2012), but not by the incubation of the same Idebenone concentration 
during or after the induction of the insult (Fig 3.3a). Moreover, Idebenone showed 
a dose-dependent neuroprotection in the 24 h pre-incubation assay layout, with a 
significant difference from insult control at 50 nM (Fig. 3.3b). Idebenone was not 





The specificity of the neuroprotective effect of Idebenone over the oxidative 
insult was evaluated by testing the effect of the compound on a different type of 
insult. Chloramphenicol, an antibiotic proposed to have neurotoxic effects was 
chosen. Nevertheless, the mechanisms by which it causes neurotoxicity are not 
fully described (Wiest, Cochran, & Tecklenburg, 2012). Incubation with 4.3 mM of 
Chloramphenicol for 48h resulted in approximately 50% reduction in cell viability 
(Fig. 3.4). 
 
Figure 3.4: Idebenone neuroprotective effect over the chloramphenicol insult in 3D human neuron-
astrocyte co-culture. Idebenone (100 nM) neuroprotective effect over the chloramphenicol (4.3 mM) 
insult in 3D human neuron-astrocyte co-culture evaluated at several regimens: 24 or 48 h pre-
incubation, 24 or 48 h pre-incubation and 48 h co-incubation, 48 h co-incubation, 48 h co-incubation 
and 24 h post-incubation. Cell viability was determined 48 h after insult, relatively to cell viability 
before insult, by Presto blue assay; data are mean ± SD of three independent experiments; * indicates 
significant difference (P b 0.001) to negative control (no chloramphenicol-induced insult and no test 
compound) and # indicates significant difference (P b 0.001) to insult control (chloramphenicol) by 
One-way ANOVA analysis with Tukey's post multiple comparison test. 
Idebenone (100 nM) was not able to revert this loss in cell viability in any of 
the regimens evaluated (Fig. 3.4), contrary to what was observed over a tBHP 
insult. 
As a proof-of-concept that the implemented assay setup is amenable to be 
transferred to high-throughput screening platforms, the Presto blue cell viability 
assay was semi-automated. The Hamilton® Microlab STARlet workstation was used 
to read the cell viability endpoint semi-automatically and thus evaluate the 
neuroprotective effect of Idebenone with 24h pre-incubation. The cell viabilities 




measured were not significantly different when using the manual or semi-
automated methods, for all controls and Idebenone (Fig. 3.5).  
 
Figure 3.5: Semi-automation of Presto blue cell viability endpoint. Idebenone (100 nM) 
neuroprotective effect over tBHP-insult in 3D human neuron-astrocyte co-culture evaluated at 24 h 
pre-incubation performing the final step of Presto blue assay and fluorescence reading manually 
(standard) or semi-automated (SA; using the Hamilton® Microlab STARlet workstation). Cell viability 
was determined 48 h after insult, relatively to cell viability before insult, by Presto blue assay; data are 
mean ± SD of at least three independent experiments; * indicates significant difference (P b 0.001) to 
negative control (no tBHP insult and no test compound), # indicates significant difference (P b 0.001) 
to insult control (tBHP), ns indicates no significant difference by One-way ANOVA analysis with 
Tukey's post multiple comparison test. 
We showed that all steps of the Presto blue viability assay are amenable to be 
performed on the workstation and that it was possible to conclude likewise about 
the neuroprotective effect of Idebenone. This demonstrates the feasibility of 
transferring the neuroprotection assay to an automated platform.  
3.2. Evaluation of the neuroprotective effect of test-
compounds over tBHP insult 
The implemented assay setup was applied to evaluate the neuroprotective 
effect of a series of 36 test-compounds, ranging from chemically synthesized 






Figure 3.6: Neuroprotective effect of chemically synthesized test compounds over the tBHP insult in 
human neuron-astrocyte co-culture. The average cell viability is plotted against the test compounds 
tested at 5 μM with 24 pre-incubation. Cell viability 48 h after insult, relatively to cell viability before 
insult, determined by Presto blue assay; data are mean of at least three independent experiments. 
The threshold of a hit compound was set as ≥65% cell viability. 
The positive hits (cell viability ≥ 65%) were further tested in different 
incubation regimens and in dose-response validation assays. For Nicotinamide and 
Linezolid (compounds 1 and 2 in Fig. 3.6, respectively) the results are presented in 
Fig. 3.7, where non-toxic concentrations of both compounds were used (Fig 3.7 a-
d).  
Nicotinamide and Linezolid were assayed at 1 and 5 μM and displayed 
neuroprotective effect in pre-incubation regimens only, with no significant 
differences between the two concentrations tested (Fig. 3.7 a-d). A significantly 
higher neuroprotection was detected in 24 h pre-incubation in comparison to 48 h 
pre-incubation. Nicotinamide and Linezolid were further tested at lower 
concentrations (1 nM and 1 pM) and there were no significant differences between 
all tested concentrations (Fig. 3.7e and f), although a slight decrease in cell viability 
was observed at such lower concentrations. 





Figure 3.7: Nicotinamide and Linezolid neuroprotective effect over the tBHP insult in 3D human 
neuron-astrocyte co-culture. (a, b, c and d) Neuroprotective effect over tBHP insult in 3D human 
neuron-astrocyte co-culture evaluated at several regimens: 24 or 48 h pre-incubation, 24 or 48 h pre-
incubation and 48 h co-incubation, 48 h co-incubation, 48 h co-incubation and 24 h post-incubation. 
(a) and (b) Nicotinamide, 1 and 5 μM, respectively. (c) and (d) Linezolid, 1 and 5 μM, respectively. 
Nicotinamide (e) and Linezolid (f) (1 pM, 1 nM, 1 μM, 5 μM) neuroprotective effect over tBHP insult in 
3D human neuron-astrocyte co-culture evaluated at 24 h pre-incubation. (a–f) Cell viability was 
determined 48 h after insult, relatively to cell viability before insult, by Presto blue assay; data are 
mean ± SD of at least three independent experiments; * indicates significant difference (P b 0.001) to 
negative control (no tBHP-insult and no test compound), # indicates significant difference (P b 0.001) 
to insult control (tBHP) and *** indicates significant difference (P b 0.001) by One-way ANOVA 






In this work we describe the implementation of a new in vitro assay setup 
combining a 3D human neuron-astrocyte co-culture with a cell viability endpoint 
for screening of neuroprotective compounds. We have shown that this assay is 
amenable to be transferred to high-throughput platforms. 
There is a need for human cell-based models in early-stage drug development 
which can accurately identify and validate new drug candidates. We evaluated the 
applicability of Presto blue, MTT and CytoTox-Glo viability assays to evaluate the 
cell viability of a 3D human neural co-culture. For this, we took advantage of the 3D 
human neuron-astrocyte co-culture previously developed by us in an agitation-
based culture system (Terrasso et al., 2015) which yields large numbers of 
differentiated neurospheroids, in a scalable culture system. These are mainly 
composed of glial cells (approximately 80 % of total cells) and neurons, 
homogeneously distributed throughout the neurospheroids. Aggregate size 
increased during retinoic acid-induced differentiation period (until day 24), up to an 
average diameter of approximately 180 μm and was kept stable during the 
remaining culture time, with low batch-to-batch variation. The application of the 
3D culture system for NT2 neural differentiation allowed reducing in 50% culture 
time and increasing 2.4-fold and 10-fold the final yields of astrocytes and neurons, 
respectively, in comparison with the standard 2D cultures. Moreover, in 2D co-
cultures neurons bundle in small aggregates on top of astrocytes, so cell-cell 
interactions are minimized, while the 3D culture favours cell-cell and cell-
extracellular matrix interactions, closely recapitulating target tissue environment 
and increasing neurospheroids reliability in neurotoxicity assessment (Hopkins, 
DeSimone, Chwalek, & Kaplan, 2015; Picollet-D’hahan et al., 2016; Schmidt et al., 
2016; Woehrling, Hill, & Coleman, 2010). Thus, the 3D co-culture used herein 
represents an amenable and cost-effective human neural cell model for 
neurotoxicity and neuroprotection studies. Moreover, the presence of functional 
human astrocytes provides an extra layer of complexity to this model, with impact 




on the response to neurotoxic and neuroprotective chemicals, as many of these act 
via astrocytes (Gupta et al., 2012; Sofroniew & Vinters, 2010). 
Presto blue was the chosen cell viability assay to be used as an endpoint in the 
neuroprotection assay as it is a non-destructive assay that can be used to evaluate 
viability at several time points in the same sample. This allows the data to be 
normalized relatively to the total cell number in each well and consequently 
minimize the variability of the replicates, which is generally higher in 3D culture 
assays than in 2D cultures. Moreover, it is simpler than the MTT assay as the dye 
could be directly added to the culture and the fluorescence is evaluated in the cell 
supernatant, with no need for crystal solubilisation as in MTT. The CytoTox-Glo 
assay requires an additional lysis step and consequently optimization steps are 
required to implement it when using 3D cell cultures. 
We designed a neuroprotection assay setup that allows the screening of test 
compounds in different regimens of addition (pre-, co- and post-incubation with 
the insult), in a single 96-well plate. The neuroprotection assay setup was based on 
the induction of an oxidative lesion over the 3D human neuron-astrocyte co-
cultures, using the oxidant tBHP (Choi et al., 2011; Kaja et al., 2012). The 
neuroprotective effect of the test-compounds over the tBHP insult was assessed 
based on cell viability compared with the positive and negative controls. In the 
human brain, reactive oxygen species (ROS) are constantly produced and are 
involved in protein misfolding and glial cell activation, leading to apoptosis and 
neurodegeneration (Federico et al., 2012). Oxidative stress is known to be 
implicated in most neurodegenerative diseases, such as Alzheimer’s disease and 
Parkinson’s disease (Yan, Wang, & Zhu, 2013). Therefore, reliable methods to 
evaluate novel neuroprotective compounds that can suppress ROS-induced 
neuronal damages might provide novel insights on chemicals that could be 
promising therapeutic molecules for numerous neurodegenerative disorders. For 
the assay validation, we have used Idebenone, an antioxidant benzoquinone, short-





control for neuroprotection over the tBHP insult. We have evaluated the 
robustness and specificity of the assay setup. The antioxidant function of 
Idebenone is dependent on its two-electron reduction to Idebenol, catalyzed by the 
cytoplasmic NAD(P)H:quinone oxidoreductase (Jaber & Polster, 2015). It has been 
widely investigated for the treatment of Friedreich’s ataxia, caused by a deficiency 
in the protein frataxin, which is involved in iron metabolism and redox 
homeostasis, where the Idebenone treatment led to a reduction in oxidative stress 
markers (Jaber & Polster, 2015). Consistently with its antioxidant activity, 
Idebenone prevents lipid peroxidation in isolated brain mitochondria, 
synaptosomes and human hepatic cells (Erb et al., 2012). It was also shown to 
protect against ROS-induced damage in several in vitro cultures, as primary cortical 
neurons and immortalized neural cells (Jaber & Polster, 2015). We observed a 
dose-dependent neuroprotective effect over tBHP insult when Idebenone is 
administrated in pre-incubation.  
The specificity of the neuroprotective effect observed for Idebenone over 
tBHP insult was evaluated using a non-oxidative lesion induced by 
chloramphenicol. Chloramphenicol is a known neurotoxic broad spectrum 
antibiotic (Grill & Maganti, 2011; Ramilo, Kinane, & McCracken, 1988). We and 
others have shown that the neurotoxicity mechanism of Chloramphenicol involves 
cytoskeletal injury, including degeneration of neurofilaments in neuronal cells and, 
to a major extent, degeneration of GFAP in astrocytic cells (Terrasso et al., 2015; 
Woehrling, Hill, Torr, & Coleman, 2011). Idebenone did not confer a 
neuroprotective effect over the chloramphenicol insult indicating that the 
neuroprotection observed for tBHP is specific and not an assay artefact.  
Assay automation can significantly increase its throughput and accuracy, while 
decreasing variability (Wingfield, 2009). We have implemented a semi-automated 
procedure for the cell viability assay endpoint in an available Hamilton® Microlab 
STARlet workstation. Our results indicated that it was possible to perform the cell 
viability assay in automated high-throughput screening platforms. Thus, a 3D 




human co-culture can be easily collected from an agitation-based culture system, 
distributed in 96-well plates and subject to neuroprotection assays performed in a 
high-throughput setup. The robustness and simplicity of the neuroprotection assay, 
combined with the easy evaluation of the fluorescence-based cell viability endpoint 
makes this a versatile assay setup suitable for early-stage drug screening. 
As a proof-of-concept, 36 compounds from different origins, ranging from 
chemically-synthetized compounds to natural extracts, have been assayed using 
the neuroprotection assay setup implemented. As an example, the results obtained 
with the first two compounds - Nicotinamide and Linezolid are presented. 
Nicotinamide and Linezolid presented a partial neuroprotective effect when 
applied in concentrations between 1 pM and 5μM. Therefore, these compounds 
are potentially more potent over an oxidative insult than Idebenone, that in our 
assay setup did not present neuroprotective effect bellow the nanomolar range. 
Interestingly, for Nicotinamide and Linezolid, the effect was more pronounced 
when cells were exposed to the compounds 24h before insult than for 48h pre-
incubation regimen; these differences were not observed for any of the other test 
compounds. This effect is not expected to be due to compound half-life, as 
Nicotinamide and Linezolid are stable in aqueous solutions, at 37ºC, for the assay 
period (our unpublished data). The differences observed for the 24 and 48h pre-
incubation regimens may be related with the metabolization of these compounds 
by neural cells or with the mechanism of action of the compounds; additional 
studies are required to further evaluate these hypotheses.  
Nicotinamide (vitamin B3) is the amide form of nicotinic acid (niacin) and is a 
precursor of β-nicotinamide adenine dinucleotide (NAD+), a coenzyme essential to 
the cellular energy metabolism (Klaidman, Mukherjee, & Adams, 2001; Shear et al., 
2015). Moreover, the brain has an active uptake mechanism for Nicotinamide 
(Klaidman et al., 2001). Concomitantly with our results, Klaidman and colleagues 
have shown that the administration of tBHP to Nicotinamide pre-treated animals 





to control groups, indicating an upregulation of their synthesis during oxidative 
stress (Klaidman et al., 2001). Thus, Nicotinamide had already been described as 
playing a protective role in oxidative stress injury and as effectively preventing cell 
damage by free radicals due to their action in reductive reactions and energetics 
(Klaidman et al., 2001; Y. Wang & Zuo, 2015). In neurodegenerative diseases, 
Nicotinamide could affect the regulation of cell survival and death during activation 
of oxidative stress pathways (Y. Wang & Zuo, 2015). Thus, nicotinamide may 
become a promising therapeutic molecule for neurodegeneration. 
Linezolid is a prototypical oxazolidinone antibiotic, highly effective against 
multi-drug resistant Gram-positive bacteria (Bobylev, Maru, Joshi, & Lehmann, 
2016; Kombian & Phillips, 2011; T. Wang, Guo, Dong, & Mu, 2014). This compound 
has been reported to have good CNS penetration, making it a good antibiotic to 
treat CNS infections (Kombian & Phillips, 2011). Use of Linezolid at high 
concentrations or after prolonged treatments has been associated with severe side 
effects that include peripheral, central and optical neuropathies, however, the 
cellular mechanism by which it may alter neuronal function is not yet clearly 
understood (Bobylev et al., 2016; Kombian & Phillips, 2011). In vitro studies showed 
that the exposure of Schwann cells and sensory neurons to low concentration of 
linezolid did not change cell survival, while high concentrations induced toxicity, 
with reduction of axonal length in neurons, by a non-cell-specific toxic mechanism 
that may include mitochondrial dysfunction (Bobylev et al., 2016). It was also 
shown that Linezolid at low concentrations (below 10 μM) had minimal effects on 
excitatory and inhibitory synaptic transmission and on neuronal excitability in 
mammalian CNS; however, at higher concentrations (100 μM) it depressed NMDA 
receptor mediated synaptic response (Kombian & Phillips, 2011). In another study, 
linezolid decreased superoxide dismutase and catalase enzymatic activities 
inducing oxidative stress, in a time- and dose-dependent manner (T. Wang et al., 
2014). Herein we observed that at lower concentrations (1 pM – 5 μM) linezolid 
was not toxic to 3D co-cultures of neurons and astrocytes and that the pre-




treatment with linezolid rescued the reduction in cell viability induced by tBHP. A 
biphasic dose-response characterized by a low dose beneficial effect and a high 
dose toxic effect have been described for some compounds (Calabrese et al., 2007; 
Mattson, 2008). The exposure to low concentrations of a compound that is toxic at 
higher doses could induce an adaptive beneficial effect on the cell and increase its 
resistance to more severe toxic effects caused by higher concentrations of the 
compound or to other types of stress (Calabrese et al., 2007). The molecular 
mechanisms of these responses typically involve the increase of cytoprotective 
proteins, including growth factors and antioxidant enzymes (Mattson, 2008). Thus, 
cells subjected to moderate levels of oxidative stress can respond by enhancing 
their ability to tolerate higher amounts of oxidative stress (Arumugam, 
Gleichmann, Tang, & Mattson, 2006). This could possibly explain the 
neuroprotective effect observed for low concentration linezolid over tBHP-induced 
oxidative lesion. Nevertheless, further studies are required to confirm the 
neuroprotective effect of linezolid and the mechanism by which this compound has 
an antioxidant effect at low concentrations.  
5. Conclusion 
We developed a novel assay setup for neuroprotection evaluation over several 
oxidative insults that are amenable to be transferred to a high-throughput 
screening automated platform. Moreover, the same general protection assay setup 
could be applied to other 3D cell models, using different cell sources and different 
insults affecting humans. The combination of 3D human co-cultures and an easy to 
perform cell viability endpoint with the utilization of an automated high-
throughput screening platform would allow simplifying the application of the more 
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Mucopolysaccharidosis type VII (MPS VII) is an ultra-rare lysosomal storage 
disease caused by deficient β-glucuronidase (β-gluc) activity, which leads to 
accumulation of glycosaminoglycans (GAGs) in many tissues, including the brain. 
Numerous combinations of mutations in the GUSB gene (which codes for β-gluc) 
cause a range of neurological features that make disease prognosis and treatment 
challenging. Currently, there is little understanding of why the MPS VII brain is 
affected. To identify a neuronal phenotype that could be used to complement 
genetic analyses, we generated two iPSC clones derived from skin fibroblasts of a 
MPS VII patient. MPS VII neurons exhibited reduced β-gluc activity and showed 
disease-associated phenotypes, including GAGs accumulation, expanded endocytic 
compartments, accumulation of lipofuscin granules, more autophagosomes, and 
altered lysosome function. Addition of recombinant β-gluc to MPS VII neurons to 
mimic enzyme replacement therapy restored disease-associated phenotypes to 
levels similar to the healthy control. MPS VII neurospheroids showed upregulated 
GFAP gene expression, which was associated with astrocyte reactivity, and 
downregulation of GABAergic neuron markers. Spontaneous calcium imaging 
analysis showed reduced neuronal activity and altered network connectivity in 
patient-derived neurospheroids compared to a healthy control. These results 
demonstrate the interplay between reduced β-gluc activity, GAG accumulation and 
alterations in neuronal activity, and provide a human experimental model for 
elucidating the bases of MPS VII-associated cognitive defects.  




Lysosomal storage disorders (LSD) are caused by intra- and extracellular 
accumulation of undigested macromolecules that induce dysfunction of the greater 
lysosomal system. Among LSD, mucopolysaccharidoses (MPS) are caused by 
deficiency in enzymatic activities that degrade glycosaminoglycans (GAGs). GAGs 
are the most abundant polysaccharides of the extracellular matrix (ECM) and, with 
the exception of hyaluronic acid, are covalently attached to protein moieties to 
form proteoglycans (Batzios et al., 2013). β-glucuronidase (β-gluc, EC 3.2.1.31), is 
found in lysosomes of all nucleated mammalian cell and is involved in the step-wise 
degradation of GAGs by removing glucuronic acid residues. Impaired β-gluc activity 
results in partial degradation and accumulation of chondroitin sulfate, dermatan 
sulfate and heparan sulfate GAGs.  
MPS type VII (MPS VII), a neuronopathic form of MPS is an ultra-rare disease 
with an estimated frequency of ~1:2 000 000 (Montaño et al., 2016). It has an 
autosomal recessive inheritance pattern caused by mutations in GUSB (Tomatsu et 
al., 1990). There are at least 49 disease-associated mutations that contribute to 
hepatosplenomegaly, cardiac valvular abnormalities, recurrent pulmonary 
infections, growth retardation, mobility problems, dysostosis multiplex, facial 
dysmorphia, visual and hearing defects, cognitive defects and/or early death 
(Tomatsu et al., 2009). Most of the ~100 identified MPS VII patients present limited 
vocabulary and mental retardation (Montaño et al., 2016). The most severe 
phenotype is hydrops fetalis, while a mild phenotype displays a late onset and near 
normal intelligence (Tomatsu et al., 2009). Notably, MPS VII patients with similar 
mutations can have variable levels of cognitive impairment, which suggests that 
other factors influence disease severity and confound reliable prediction of disease 
progression. While most mutations underlying MPS VII are known, the mechanistic 
links between reduced β-gluc activity, GAG accumulation and neurological 
anomalies are just beginning to be addressed (Montaño et al., 2016). Human MPS 





lysosomal system cause progressive (instead of immediate) brain 
impairment/dysfunction and may also inspire novel therapies.  
Using induced pluripotent stem cell (iPSC) technology (Lee and Studer, 2010; 
Takahashi et al., 2007), a handful of LSD cell models have been established 
(reviewed in (Borger et al., 2017)), including Gaucher (Tiscornia et al., 2013), Hurler 
(Tolar et al., 2011), Pompe (Higuchi et al., 2014), Sanfilippo B and C (Canals et al., 
2015; Lemonnier et al., 2011) and Niemann-Pick type C1 (Maetzel et al., 2014). 
These patient-derived iPSC were differentiated in 2D cultures into several cell 
types, including brain cells, and recapitulated morphological, biochemical and/or 
functional hallmarks of the disease. LSD patient iPSC engineered to overexpress 
functional enzymes have been also reported (Doerr et al., 2015; Griffin et al., 2015; 
Meneghini et al., 2017). While clearly informative, these cell models lack the 
dynamic events linked to interactions with proteoglycans and hyaluronic acid, the 
main components of brain ECM. This may impact the interactions between neural 
cells and ECM that regulate neural cell fate and functionality (Srikanth and Young-
Pearse, 2014). Thus, there is a need for MPS brain cell models in which the ECM 
and its dynamic remodeling can be taken into account.  
We recently developed a 3D culture strategy, using stirred-tank bioreactors, to 
differentiate iPSC-derived neural precursor cells (iPSC-NPC) into neurons, 
astrocytes and oligodendrocytes. This strategy allows cells to produce an ECM, 
fostering cell-cell and cell-ECM interactions that recapitulate many facet of brain 
cell architecture (Simão et al., 2016, 2014). Using the classic 2D and novel 3D 
culture systems we set out to test whether MPS VII iPSC-NPC and mature neurons 
could be used to understand disease-associated cognitive deficits. We show that 
MPS VII neurons have elevated GAG content, expanded endocytic compartment, 
impaired membrane receptor lysosome-mediated degradation and altered 
functional connectivity. MPS VII neurospheroids were the key to identify disease-
associated phenotypes and cellular defects associated with neurological deficits. 
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2. Materials and Methods 
2.1. iPSC generation 
The Vall d'Hebron Hospital ethical committee of clinical investigation approved 
procedures. The donor’s parents gave written consent. A skin punch biopsy (2 
mm3) under local anesthesia was taken from MPS VII donor, biological samples 
were free of pathogens.  Skin biopsies were cultured in AmnioMaxTM basal medium 
containing AmnioMaxTM C-100 Supplement (Invitrogen), 10% fetal bovine serum 
(FBS) (Gibco) and a mixture of penicillin-streptomycin-Amphotericin B (Lonza). 
Dermal fibroblasts that emerged from skin biopsies were expanded 12 days later. 
Then medium was switched to fibroblasts medium (DMEM-GlutaMAX, 10% FBS, 
sodium pyruvate, MEM non-essential amino acids and antibiotics (Gibco). For 
reprogramming, fibroblasts were treated with FGF at 10 ng/mL and ascorbic acid 2-
phosphate at 1 mM (Sigma) for 12 days prior to infection. Ecotropic retroviral 
vectors expressing 4 transcription factors (Oct4, cMyc, Sox2 and Klf4) described by 
Yamanaka (Takahashi et al., 2007). Vectors were produced in Plat-E cells (Morita et 
al., 2000) and used to infect fibroblasts pre-treated with VSV-G vesicles containing 
mCAT1 receptor to improve human cell infection with murine virus (Mangeot et al., 
2011). One week later, infected-fibroblasts were expanded and fibroblast medium 
was switched to human embryonic stem (ES) cells medium (HES; KnockOutTM 
DMEM, 20% KnockOutTM Serum Replacement, MEM non-essential amino acids, 
GlutaMAXTM, 2-mercaptoethanol, Gibco). HES medium was supplemented with 500 
µm valproic acid sodium salt (Sigma) and 10 ng/ml FGF2 (Peprotech) for 3 weeks to 
increase reprogramming efficiency and maintain cells undifferentiated (Huangfu et 
al., 2008). A total of 20 ES-like colonies were picked for each specimen 20-35 days 
later. BJ1-FGF2 (provided by I-Stem) and HFF1 (ATCC) cells were used as feeders. 
iPSC were mechanically passaged weekly, and medium was changed daily. Rock 
inhibitor Y-27632 at 10 µm (Calbiochem) was added to the medium at the first 
passages to improve single cell survival and cell attachment to feeder cells. Three 





control were used. Two MPS VII clones (cl. 8 and cl. 13) were further characterized. 
Mycoplasma test (MycoAlert® Detection Kit, Lonza) was routinely performed. 
2.2. Characterization of iPSC lines 
Alkaline phosphatase (AP) activity was detected by a colorimetric assay 
following manufacture indications (SIGMA FAST™ BCIP/NBT tablets). Expression of 
pluripotent cell surface markers (SSEA-3, TRA-2-49 and NANOG) were assayed in 
iPSCs grown on HFF1 feeders layer by immunohistochemical assays (see below). 
RT-qPCR was done as previously described (Cereso et al., 2014). Gene expression 
was normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  
In vitro differentiation towards the three germ layers was performed by 
embryonic body formation. Briefly, iPSCs were detached from feeder cells with 
collagenase type IV at 1 mg/mL (Invitrogen) and cells were grown in suspension for 
7 days in HES media. For further differentiation, cells were plated into 0.1% gelatin-
coated plates (Sigma). Then, 14 days later, cells were fixed with 4% 
paraformaldehyde (PFA) (EM grade, PKS) in PBS for 15 min and expression of tissue 
specific markers for endoderm (α-fetoprotein), mesoderm (smooth muscle actin), 
and ectoderm (βIII-tub) were assayed by immunofluorescence (see below).  
For teratoma formation, CB17/lcr-Prkdcscid/lcrlcoCrl Fox Chase SCID Congenic 
mice (Charles River Laboratories) were used. Eight-week old mice were 
anesthetized with xylazine (5-10 mg/kg): ketamine (100 mg/kg) mix. Cell injections 
were intra-testicular and under the kidney capsule (Peterson et al., 2011; 
Prokhorova et al., 2009; Zhu et al., 2014) with 106 cells resuspended into 10 µl of 
DMEM/F12 (Gibco) and 10 µl of Matrigel (BD) (Prokhorova et al., 2009). Eight 
weeks after injection, tumors were removed and fixed in 4% neutral buffered 
formalin (Diapath) at room temperature (RT) for 24 to 48 h. Samples were 
processed, included in paraffin and stained with hematoxylin/eosin at the RHEM 
histology platform (IRCM, Montpellier). Histological analysis was performed by a 
pathologist. The protocol followed for teratoma formation takes into account 
standardization rules (Müller et al., 2010). All animal experiments were conducted 
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following protocols previously approved by the Comité National de Réflexion 
Ethique sur l’Expérimentation Animale and by the Ministère de l’Enseignement 
Supérieur et de la Recherche (France).  
For karyotyping, iPSC clones were grown on Matrigel (BD Biosciences) and 
treated during their exponential phase of cellular growth with 0.1 µg/ml colcemid 
(Karyomax Invitrogen Gibco). Karyotyping was done by CHROMOSTEM (CHRU, 
Montpellier). 
2.3. iPSC cells differentiation into neural precursor cells  
NPCs were generated and subsequently differentiated into neural cells from 
the iPSC lines as described previously (Chambers et al., 2009). Briefly, iPSC were 
mechanically dissociated from feeder-layer and small groups of iPSC were grown in 
suspension for 48 h in N2B27 pro-neural medium (1:2 DMEM:F12, 1:2 Neurobasal, 
N2, B27 without vitamin A, 2-mercaptoethanol and gentamicin, Gibco). To further 
differentiate cells into neuroepithelial (NEP)-rosettes, cells were seeded into 16 
µg/ml poly-L-ornithine at (Sigma) and 2 µg/mm laminin (Sigma) (POLAM)-coated 
glass plates and medium was supplemented with 200 ng/ml Noggin (R&D Systems) 
and 10 µM SB431542 (Tocris) to induce neuroectoderm cell differentiation as 
previously described (Chambers et al., 2015, 2009). NEP-rosettes appeared 
between days 8-12, then were mechanically selected and expanded twice each 8-
12 days obtaining a neural rosette-enriched culture. Noggin and SB431542 were 
removed from the medium once NEP-rosettes were formed and during the last 
round of expansion. When cells reached to confluence NEP-rosettes were 
differentiated into NPCs. Briefly NEP-rosettes were enzymatically dissociated with 
0.05% trypsin/EDTA (Gibco), expanded into POLAM-coated plates in pro-neural 
medium supplemented with FGF2 at 10 ng/ml and EGF at 10 ng/ mL (PeproTech) 
prompting NPC self-renewal. NPCs were expanded for 5 passages obtaining a 
homogeneous and phenotypically stable cell population. NPCs were cryopreserved 





(Sigma). NPC self-renewal and ability to generate neurons were retained after 
thawing. 
2.4. iPSC-derived NPC differentiation in 2D cultures 
For neuronal differentiation, NPCs were plated into POLAM-coated glass plates 
and cultured in neural induction medium (pro-neural medium supplemented with 
10 ng/mL BDNF, 10 ng/mL GDNF, 10 ng/mL NT-3 (all from PeproTech) and 100 µM 
cAMP (Sigma-Aldrich)). Half of the medium was weekly replaced with fresh media. 
For immunofluorescence studies cells were plated into POLAM-HCl treated glass 
coverslips as previously described (Gaspard et al., 2009)). 
2.5. iPSC-derived NPC differentiation in 3D cultures 
NPCs were expanded as monolayers and 3D neural differentiation was 
performed in software-controlled stirred-tank bioreactors (DASGIP, Eppendorf), 
accordingly to Simão et al. (2016). Briefly, NPCs were inoculated as single cells at 4 
x 105 cell/mL in pro-neural medium supplemented with 5 ng/mL FGF2, 5 ng/mL EGF 
and 5 µM Y-27632 ROCK-inhibitor (Merck-Millipore). Cell culture parameters were: 
pH 7.4, 15% DO and temperature 37ºC. An initial stirring of 70 rpm was used. 
Perfusion was initiated at day 2 after inoculation, when the cells have aggregated 
into compact neurospheres. A dilution rate of 0.33 day-1 was used. The retention of 
cells in the perfusion was performed using a 20 µm pore stainless steel sparger. 
Neural differentiation was initiated 1 week after inoculation by changing the 
medium to neural induction medium and induced for 3 weeks. 
2.6. Lysosomal enzymes activities in cell extracts 
Enzymatic activities were measured as previously described (Vitner et al., 
2010). Briefly, cells were lysed using 1% Triton X-100, 10 % glycerol, 20 mM Tris-HCl 
pH 7.5 and 150 mM NaCl supplemented with a protease inhibitor cocktail (Roche). 
Cellular lysates were subjected to three cycles of freeze and thaw and centrifuged 
for 15 min at 15,000 g at 4ºC. Protein content of cell lysate was quantified using the 
Micro BCATM Protein Assay Kit (Thermo Scientific). Enzymatic reactions were 
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performed in 48-well plates with 20 µl of protein extracts and 100 µl of reaction 
buffer (100 mM sodium acetate, pH 4.8 containing 10 mM of enzyme substrate) for 
1 h at 37ºC. Substrates for β-gluc and for β-hexosaminidase (β-hex) were 4-
methylumbelliferyl-β-d-glucuronide and 4-methylumbelliferyl-N-acetyl-β-d-
glucosaminide (both from Sigma-Aldrich), respectively. Enzymatic reactions were 
stopped by adding 500 µl of 200 mM sodium carbonate pH 10, and fluorescence 
intensity was measured at 450 nm using Tecan Infinite® M200 Microplate Reader. 
Standard curves were performed using serial dilutions of 4-methylumbelliferyl (4-
MU; Sigma-Aldrich). Enzyme activity is expressed in nmol 4-MU/ µg protein/h. 
2.7. Immunofluorescence 
For indirect immunofluorescence, NPCs and neurons were fixed with 4% PFA 
(EM grade, PKS) in PBS for 15 min at RT and permeabilized with 0.1% Triton X-100 
in PBS at RT for 5 min. Cells were then blocked in blocking solution (BS): 2% bovine 
serum albumin (Sigma) and 10% horse serum in PBS for 1 h at RT. Primary 
antibodies were diluted in BS and incubated overnight at 4ºC, followed by 
incubation with secondary antibodies (Alexa Fluor series from Invitrogen) all 
diluted 1:500 in BS for 1 h at RT. Samples were then mounted with fluorescent 
mounting medium (Dako) containing DAPI at 10 ng/µl (Sigma). Primary antibodies 
used are: SSEA-3, TRA-2-49, Nanog, α-fetoprotein, smooth muscle actin, βIII-tub, 
Nestin, Sox2, OTX1-2, GFAP, LAMP1, CAR, NeuN, Tbr1, Brn2, vGLUT, and PSD95. 
Phalloidin Red (Sigma) to probe for F-actin was used at 1:500 in BS, 1 hour at RT. 
Images were taken using Leica LSM780 and Zeiss SP5 confocal microscopes, with 
20X/0.8 Plan-Apo, 40X/1.3 oil-DIC Plan-Apo or 63X/1.4 oil-DIC Plan-Apo objectives. 
Image analysis was performed using Fiji Software. 
2.8. Glycosaminoglycans quantification  
Neurospheroids were collected at days 7 and 28 of culture and lysed in papain 
extraction reagent (0.2 M sodium phosphate buffer, pH 6.4, containing 100 mM 





3 h at 65ºC. After centrifugation at 10,000 g for 5 min., sulfated GAG content was 
determined in the supernatants using the Blyscan Sulfated Glycosaminoglycan 
Assay (Biocolor) according to manufacturer’s instructions. 
2.9. Protein extraction and Western blot  
For protein extraction, cells were washed once with PBS and incubated with 
lysis buffer (1% Triton X-100, 10 % glycerol, 20 mM Tris-HCl pH 7.5 and 150 mM 
NaCl) supplemented with protease inhibitor cocktail (Roche) for 10 min at 4ºC. 
Cellular lysates were centrifuged for 15 min at 14,000 rpm at 4ºC. Supernatants of 
total protein extracts were quantified using BCA (Pierce) or Bradford reagent 
(BioRad). Proteins were denatured in SDS-containing loading buffer for 10 min at 
95ºC. Proteins were separated in SDS-PAGE and transferred to PVDF membrane. 
The membrane was probed with anti-p62, anti-LC3-I/II, anti-β-tubulin, anti-EGFR, 
anti-CAR and anti-actin antibodies. 
2.10. RNA extraction and qRT-PCR 
Real-time quantitative PCR analysis (RT-qPCR) was performed as described in 
Brito et al. (2012). Briefly, total RNA was extracted with High Pure RNA Isolation kit 
(Roche) and quantified using a NanoDrop 2000c (Thermo Scientific). Reverse 
transcription was performed with Transcriptor High Fidelity cDNA Synthesis kit 
(Roche), using anchored-oligo (dT)18 primer. qRT-PCR analysis was performed in a 
LightCycler 480 (Roche) according to Light-Cycler 480 SYBR Green I Master Kit 
(Roche) instructions. Primers were used at 5 µM, in 20 µL reactions; each sample 
was performed in triplicates. See Table 1 for list of primers. Cycles threshold (Ct’s) 
and melting curves were determined using LightCycler 480 software, version 1.5 
(Roche), and results were processed using the 2-ΔΔCt method for relative gene 
expression analysis (Brito et al., 2012; Livak and Schmittgen, 2001). Changes in 
gene expression were normalized using the housekeeping gene RPL22 (coding for 
ribosomal protein L22) as internal control. 
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Table 4.1: List of primers used in MPS VII cells qRT-PCR analysis 
Target Forward (5’ 3’) Reverse (5’ 3’) 
SOX2 GGGAAATGGGAGGGGTGCAAAAGAGG TTGCGTGAGTGTGGATGGGATTGGTG 
OCT4 GACAGGGGGAGGGGAGGAGCTAGG CTTCCCTCCAACCAGTTGCCCCAAAC 
NANOG CAGCCCCGATTCTTCCACCAGTCCC CGGAAGATTCCCAGTCGGGTTCACC 
LIN28 AGAGTAAGCTGCACATGGAAGGGT TATGGCTGATGCTCTGGCAGAAGT 
trSOX2 TAAAGCAGCGTATCCACATAGC GCCATTAACGGCACACTGC 
trOCT4 TAAAGCAGCGTATCCACATAGC TCACCACTCTGGGCTCTC 
cMYC TAAAGCAGCGTATCCACATAGC CGGAAACGACGAGAACAGTTG 
trKLF4 TAAAGCAGCGTATCCACATAGC ACCACCTCGCCTTACACATG 
hMYC GCGTCCTGGGAAGGGAGATCCGGAGC TTGAGGGGCATCGTCGCGGGAGGCTG  
PCNA CGGAGTGAAATTTTCTGCAAG TTCAGGTACCTCAGTGCAAAAG 
nestin TAAGGTGAAAAGGGGTGTGG GCAAGAGATTCCCTTTGCAG 
βIII-tubulin GGGCCTTTGGACATCTCTTC CCTCCGTGTAGTGACCCTTG 
Synaptophysin 
(SYP) TTTGTGAAGGTGCTGCAATG GCTGAGGTCACTCTCGGTCT 
VGluT-1 GTTCTGCTGCTCGTCTCCT ATGAGTTTCGCGCTCTCTCC 
TH AGCCCTACCAAGACCAGACG GCGTGTACGGGTCGAACTT 
GAD67 ACCAGAAAACTGGGGCTCAA GCAGGTTCTTGGAGGATTGC 
GFAP AGAGAGGTCAAGCCAGGAG GGTCACCCACAACCCCTACT 
GLT-1 CCAGGAAAAACCCCTTCTCC TCTTCCAGGCAACGAAAGGT 
GUSB GGCTACCTCCCCTTCGAG GTTGAAGAACTGCGGCAGC 
RPL22 CACGAAGGAGGAGTGACTGG TGTGGCACACCACTGACATT 






2.11. Cell treatment for protein degradation assays  
NPCs at 80% of confluence were incubated with 200 ng/mL EGF (PeproTech) or 
200 ng/mL FKCAV for 15 min at 4ºC allowing ligand-receptor binding. To synchronize 
ligand-receptor internalization, ligand-containing medium was replaced by fresh 
pre-warmed medium. Then cells were incubated at 37ºC allowing ligand-receptor 
internalization. At indicated times proteins were extracted and subjected to 
western blotting. 
2.12. Calcium fluorescence imaging 
For calcium fluorescence imaging experiments in 2D cultures, neuronal cultures 
were grown on glass coverslips coated with POLAM to prevent cells detaching or 
moving during imaging experiments. Prior to imaging, cells were loaded with 5 µM 
acetoxy-methyl-ester Fura-2 (Fura-2 AM, Invitrogen) for 45 min in Tyrode solution 
(physiological saline) containing 0.5% Pluronic acid at 37°C. Imaging experiments 
were performed at 22°C using an IX70 Nikon microscope equipped with a 20X 
objective. The cultures were excited alternatively at 340 and 380 nm and light 
emission at 510 nm was used to determine the fluorescence ratio (F340/F380) that 
reflect the intracellular calcium concentration. Images were acquired every 3 
seconds for 10 to 15 min. Calcium signals attributable to neuronal cells were 
measured by switching the standard Tyrode solution to a 60 mM KCl/Tyrode 
solution to depolarize the cells and to activate voltage-dependent calcium 
channels. 1,4-dihydropyridine-derivative (5 µM) (Nimopidine (Alomone Labs) was 
used to specifically block L-type calcium channels, a marker of neuronal activity. All 
the imaged cultures were ultimately treated with 10 µM ionomycin (Sigma) to 
validate cell viability. Image analysis was performed using MetaFluor Imaging 
software (Molecular Devices) using the region of interest (ROI) analysis method. 
Three neuronal cultures/neuron sources were analyzed.  
For calcium imaging experiments in 3D cultures, neurospheroids were collected 
after 3 weeks of differentiation and incubated with 1x Fluo-4 DirectTM calcium 
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reagent (Invitrogen) for 30 min at 37 ºC, 5% CO2, and 3% O2, followed by 15 min at 
RT. Samples were then imaged live using a spinning-disk confocal microscope 
(Nikon Eclipse Ti-E, confocal scanner: Yokogawa CSU-x1). Image analysis was 
performed using FluoroSNNAP – Fluorescence Single Neuron and Network Analysis 
Package, an open-source software developed in MatLab for automated 
quantification of calcium dynamics of single cells and network activity patterns 
(Patel et al., 2015). 
2.13. Synaptic vesicle trafficking assay  
Synaptic vesicles trafficking assays were based on (Gaffield and Betz, 2006). 
Neurospheroids were plated in POLAM-coated glass coverslips and incubated with 
5 mM HEPES-NaOH, pH 7.4; 10 mM glucose; 2.5 mM CaCl2; 1 mM MgCl2; 100 mM 
KCl; 37 mM NaCl (referred to as 100 mM KCl buffer) for 5 min. Afterwards, 100 mM 
KCl buffer was removed and neurospheroids incubated with 10 M FM-1-43 dye 
(Invitrogen) in 5 mM HEPES-NaOH, pH 7.4; 10 mM glucose; 2.5 mM CaCl2; 1 mM 
MgCl2; 5 mM KCl; 37 mM NaCl (referred to as 5 mM KCl buffer) for 15 min. 
Neurospheroids were washed for 1 min with 5 mM KCl buffer with ADVASEP-7 
(Sigma), followed by three washes with 5 mM KCl buffer. Exocytosis was stimulated 
with 100 mM KCl buffer and samples were visualized live using a fluorescence 
microscope (Leica DMI6000) in order to monitor the decreasing of fluorescence 
intensity overtime. Fluorescence intensity was measured using ImageJ software 
version 1.47q (http://rsbweb.nih.gov/ij/). 
2.14. TEM on ultrathin sections and toluidine blue stained 
thin sections 
Neurons were differentiated from NPCs and grown for 6 and 9 weeks in 60 mm 
POLAM-coated glass dishes as described above. Cells were fixed with 2.5% 
glutaraldehyde in cacodylate buffer (0.1 M pH 7.1-7.4) for 2 h at 4ºC and washed 
three times with cacodylate buffer (0.1 M pH 7.1-7.4). Then cells were collected 





h at room temperature, dehydrated with ethanol and embedded in EPON. Thin 
(250-1000 nm) and ultrathin (80 nm) sections were obtained with ultra-microtome 
Leica EM UC6. 500-1000 nm-thick sections were stained with toluidine blue and 
images were acquired with Leica DM6000B upright microscope. Ultrathin sections 
were then contrasted with uranyl acetate. Images were acquired with JEOL-JEM-
1011. Images were analyzed using ImageJ software. 
2.15. Experimental design and statistical analysis 
Data are mean ± SD of, at least, 3 independent experiments and were analyzed 
with GraphPad Prism 6 software. One-way ANOVA followed by Tukey’s post-hoc 
multiple comparison analysis was used (* p < 0.05, *** p < 0.001).  
For 3D cultures, analysis of neurospheroids from different stirred-tank bioreactor 
cultures are considered biological replicates, while analysis of different 
neurospheroids sampled from the same bioreactor culture are considered technical 
replicates. 
3. Results 
3.1. Generation and characterization of human MPS VII iPSC 
We generated iPSC from dermal fibroblasts of an MPS VII patient who was 
diagnosed at 3 years old based on decreased β-gluc activity and increased GAG 
storage (Chabas et al., 1991). At the time of skin biopsy, the MPS VII patient was 27 
years old and had severe mental retardation. The homozygous point mutation that 
induced a Leu to Phe change at amino acid 176 in β-gluc was consistent with a 
severe MPS VII phenotype (Chabas et al., 1991; Tomatsu et al., 2009). Primary 
cultures of dermal fibroblasts were established. MPS VII patient fibroblasts had 
approximately 2% of β-gluc activity compared to the fibroblasts from the healthy 
individual (Fig. 4.1a).  





Figure 4.1: Generation and characterization of human MPS VII iPSC. (a) β-gluc enzymatic activity 
(expressed in nmol 4-MU/µg of protein/h) in control and MPS VII patient’s fibroblasts. (b) Gene 
expression analysis of control (white) and MPS VII (grey and black) IPSC-like colonies; gene expression 
relative units of the retroviral-derived reprogramming vectors (exogenous) and endogenous 
expression levels (endogenous). (c) Representative colonies of control and MPS VII iPSC stained for 
alkaline phosphatase (AP) and the pluripotency-associated markers SSEA-3, Tra-2-49 and Nanog (all in 
red) and DAPI (blue); scale bars 200 µm (AP) and 100 µm (SSEA-3, Tra-2-49 and Nanog). (d) Karyotype 
of MPS VII iPSC. (e) Immunofluorescence microscopy of control and MPS VII iPSC differentiated in 
vitro and stained for the endoderm, mesoderm and ectoderm markers α-fetoprotein (green), smooth 
muscle actin (SMA, green) and βIII-tubulin (Tuj1, green), respectively; scale bars 100 µm. (f) Control 
and MPS VII iPSC differentiated in vivo by teratoma formation, stained with hematoxylin and eosin, 
showing potential to differentiate into endoderm (intestinal epithelium), mesoderm (cartilage) and 





Fibroblasts were reprogrammed at passages 2-4 with retroviral vector-
mediated production of OCT4, cMYC, SOX2 and KLF4 (Takahashi et al., 2007). 
Following 3-4 weeks of culture, 20 compact PSC-like colonies emerged. These 
colonies were mechanically selected, expanded for at least 10 passages and tested 
for the expression of pluripotency markers.  
Due to the scarcity of MPS VII patients, consequence of the MPS ultra-rare subtype, 
we characterized 2 MPS VII iPSC clones (#8 and #13) independently. iPSC clones 
from healthy individuals (a gift from the Institute for Stem Cell Therapy and 
Exploration of Monogenic diseases, France) were used as controls. Alkaline 
phosphatase activity (Fig. 4.1b) and expression of the transcription factor NANOG, 
the tumor-related antigen TRA-2-49 and the stage-specific embryonic antigen 
SSEA-3 (Fig. 4.1b) are consistent with pluripotency. The MPS VII iPSC clones had a 
normal karyotype after more than 20 passages (Fig. 4.1c). The ability of iPSC to 
differentiate into the three different germ layers was assessed by in vitro 
embryonic body (EB) formation and in vivo teratoma formation. After EB 
formation, expression of tissue-specific markers for mesoderm (α-smooth muscle 
actin), endoderm (α-fetoprotein) and ectoderm (βIII-tubulin) was demonstrated by 
immunofluorescence analyses (Fig. 4.1d). The presence of germ layers derivatives 
was also confirmed in teratomas by hematoxylin and eosin staining and histological 
analyses (Fig. 4.1e). Together these data demonstrate that these clones harbored 
characteristics indicative of bona fide iPSC. 
3.2. Generation and characterization of human MPS VII iPSC-
NPC 
NPC were differentiated from control and MPS VII (cl. 8 and cl. 13) iPSC by the 
dual SMAD inhibition protocol (Chambers et al., 2009). This involves induction of 
neuroepithelial cell (NE)-rosettes from iPSC and NPC generation. NE-rosettes 
appeared 8-12 days after induction and a homogeneous, expandable and 
phenotypically stable NPC population, as judged by the uniform co-expression of 
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the neural progenitor markers Nestin and Sox2, was obtained after few passages 
(Fig. 4.2a).  
 
Figure 4.2: Characterization of human MPS VII iPSC-NPC and neurons in 2D cultures. (a) 
Immunofluorescence microscopy of control and MPS VII iPSC-NPC stained for NPC markers nestin 
(green) and Sox2 (red; first panel), scale bars 50 µm; nestin (green) and forebrain and midbrain 
progenitor marker Otx1/2 (red; second panel; and neuronal and astrocytic βIII-tubulin (Tuj1, green) 
and GFAP (red), respectively, DAPI (blue; third panel), scale bars 100 µm. (b) β-gluc enzymatic activity 
(expressed in nmol 4-MU/µg of protein/h) in control (black) and MPS VII (white) iPSC-NPC, non-
treated (N.T.) and treated with recombinant β-gluc (rβ-gluc). (c) Representative images of control and 
MPS VII neurons stained for βIII-tubulin (Tuj1, green) and NeuN or cortical markers Tbr1 or Brn2 (red), 
respectively in first, second and third panels, scale bars 100 µm; (d) pre-synaptic protein vGLUT1 
(green), post-synaptic protein PSD95 (red), βIII-tubulin (Tuj1, grey) and DAPI (blue), scale bars 100 µm; 
inserts (right) show synapsis formation at higher magnification, scale bars 5 μm. 
Expression of the transcription factor OTX-1/2 was also consistent with 





markers (βIII-tubulin and GFAP), suggestive of the potential of NPCs to differentiate 
into neurons and astrocytes, were also detected (Fig. 4.2a). 
NPC generated from control and MPS VII iPSC showed self-renewal capability 
and ability to generate cells with neuron-like morphology for at least 18 passages, 
indicating they were bona fide NPC. No differences in self-renewal capability or 
viability were observed between NPC derived from healthy and MPS VII iPSC (not 
shown). Of note, a stromal feeder-free system was used to differentiate iPSC into 
NEP-rosettes and NPC. Therefore, there was no exogenous β-gluc in the media, 
demonstrating that β-gluc deficiency did not interfere in the first stages of 
neuroectodermal differentiation. β-gluc activity in MPS VII NPC was 50-fold lower 
than that in control NPC, confirming deficient β-gluc activity, and in line with that 
observed for MPS VII fibroblasts (Fig. 4.2b). To mimic enzyme replacement therapy 
(ERT), recombinant β-gluc (rβ-gluc) was added to NPC cultures and led to a >500-
fold increase in β-gluc activity in MPS VII NPC, which was then similar to that of 
control NPCs (Fig. 4.2b). Together these data demonstrate that NPC with decreased 
β-gluc activity were generated from MPS VII iPSC. 
3.3. Neural cells differentiated from MPS VII iPSC-NSC 
recapitulate disease features 
To identify possible cellular defects in MPS VII brain cells, control and MPS VII 
(cl. 8 and cl. 13) NPC were further differentiated using 2D and 3D culture strategies 
(Fig. 4.3), as these approaches could impact neural differentiation and cellular 
functions.  
 
Figure 4.3: Schematic experimental workflow for differentiation of neural cells from control and 
MPS VII iPSC-NPC in 2D (top) and 3D (bottom) culture systems. For 2D differentiation, iPSC-NPC were 
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plated and neural differentiation was induced by exposure to BDNF, GDNF, NT-3 and cAMP for 9 
weeks. For 3D differentiation iPSC-NPC were inoculated in a stirred suspension culture system, with 
reduced concentrations of growth factors EGF and FGF, and aggregated for 1 week, followed by 
induction of neural differentiation with BDNF, GDNF, NT-3 and cAMP for 3 weeks. 
For 2D differentiation, NPC were cultured in neuronal induction medium (NIM) 
and differentiated into neurons within 3 weeks as determined by the expression of 
the neuronal markers βIII-tubulin and NeuN (Fig. 4.2c). Moreover, Tbr1+ and Brn2+ 
neurons were observed, indicating the capability of MPS VII NPC to give rise to 
neurons with cortical characteristics (Fig. 4.2c). Pre-synaptic (vGLUT1) and post-
synaptic (PSD95) protein co-localization, suggestive of synapse formation and 
neuronal maturation, was achieved 7 weeks post-differentiation (Fig. 4.2d). iPSC-
derived neurons presented membrane potentials of -50 mV and had voltage-
dependent K+ channels consistent with synapse functionality (not shown).  
For 3D differentiation, NPC were inoculated as single cells in stirred-tank 
bioreactors, allowed to aggregate for 1 week, and then cultured in NIM for 3 
weeks. With this strategy, obtained neurospheroids contain a mix of neural cells 
and allow accumulation of endogenous ECM components (Simão et al., 2016, 
2014). Control and MPS VII neurospheroids maintained high cell viability along 
culture time (Fig. 4.4a) and spheroid size was stable after the aggregation period 
(Fig. 4.4b).  
NPC proliferation, evaluated by the percentage of EdU+ cells, decreased along 
culture time suggesting differentiation towards a post-mitotic neuronal lineage 
(Fig. 4.4c). Concomitantly, downregulation of proliferation (PCNA) and NPC (nestin) 
markers was observed along culture time (Fig. 4.4d), with no differences between 
control and MPS VII cells. These data are in line with 2D differentiation, indicating 







Figure 4.4: Characterization of MPS VII neurospheroids. (a) Representative images of control and 
MPS VII neurospheroids cell viability at day 7 and 28 by live/ dead assay using fluorescein diacetate 
(FDA) for stainig of live cells (green) and propidium iodide (PI) for dead cells (red). (b) Control (black) 
and MPS VII (grey) neurospheroid diameter profile along culture time. (c) Percentage of EdU+ cells in 
control (black) and MPS VII (grey) neurospheroids along culture time. (d) Gene expression analyses of 
control (black) and MPS VII (grey) neurospheroids; fold-changes (normalized to undifferentiated cells) 
of proliferation (PCNA) and NPC (nestin) markers. Data are mean ± SD of 3 (control) and 4 (MPS VII; 2 
with MPS VII-cl.8 and 2 with MPS VII-cl.13) independent cultures. (e) Immunofluorescence confocal 
microscopy of control and MPS VII neurospheroids stained for astrocytic GFAP (red), neuronal βIII-
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tubulin (green) and DAPI (blue); scale bars 20 µm. Gene expression analyses of control (black) and 
MPS VII (grey) neurospheroids; fold-change (normalized to undifferentiated cells) of: (f) βIII-tubulin, 
(g) the synaptic vesicle marker synaptophysin, (h) glutamatergic (VGluT1), dopaminergic (TH) and 
GABAergic (GAD67) neuronal subtypes markers, (i) astrocytic markers GFAP and GLT1. Data are mean 
± SD of 3 (control) and 4 (MPS VII; 2 with MPS VII-cl.8 and 2 with MPS VII-cl.13) independent cultures. 
Asterisks indicate significant difference: * P < 0.05, *** P < 0.001. 
Neuronal differentiation in 3D was confirmed by gene expression and 
detection of βIII-tubulin+ cells within neurospheroids by day 28 of culture (Fig. 4.4e 
and 4.4f). Importantly, gene expression of the pre-synaptic vesicle marker 
synaptophysin (syn) was significantly lower in MPS VII neurons (Fig. 4.4g), 
suggesting that synaptic dysfunction occurs. The presence of glutamatergic, 
dopaminergic and GABAergic neuronal subtypes was suggested by the upregulation 
of vGluT1, TH and GAD67 mRNAs, respectively (Fig. 4.4h). Moreover, a significantly 
(p <0.05) lower (4-fold) level of GAD67 gene expression was detected in MPS VII 
neurospheroids by day 28 (Fig. 4.4h), suggesting decreased numbers of GABAergic 
inhibitory neurons. An increase in astrocytic differentiation within 2D and MPS VII 
neurospheroids was consistent with the time-dependent increase in gene 
expression of GFAP and GLT-1, which codes for a glutamate transporter. Notably, 
significant higher GFAP gene expression was observed in MPS VII neurospheroids 
(Fig. 4.4i), while no differences in GLT-1 were observed, suggesting that the number 
of potential astrocytes was not affected. Together, these results indicate that GFAP 
mRNA enrichment was not directly related to astrocyte differentiation or numbers, 
but rather a characteristic of MPS VII.  
β-gluc activity in extracts of MPS VII neurons (2D) and neurospheroids (3D), 
showed up to 50-fold lower levels compared to control neurons (Fig. 4.5a and 
4.5b). After treatment with rβ-gluc, the activity was restored to levels similar to the 
control (Fig. 4.5a) suggesting that rβ-gluc reached the lysosomes in MPS VII 
neurons, as previously observed for NPC (Fig. 4.2b). These results are in line with 
the low enzymatic activities found in MPS VII patient fibroblasts (Fig. 4.1a) and 
iPSC-NPC (Fig. 4.2b). Nevertheless, GUSB mRNA levels were stable along culture 






Figure 4.5: MPS VII neural cells recapitulate known disease features. (a) β-gluc enzymatic activity 
(expressed in nmol 4-MU/µg of protein/h) in control (black) and MPS VII (white) neurons, non-treated 
(N.T.) and treated with rβ-gluc. (b) β-gluc enzymatic activity in control (black) and MPS VII (grey) 
neurospheroids at day 7 and 28. (c) Gene expression analysis of control (black) and MPS VII (grey) 
neurospheroids; fold-change (normalized to undifferentiated cells) of GUSB. (d) GAGs storage in 
control and MPS VII neurons by toluidine blue staining at 6 and 9 weeks; scale bars 5 μm. (e) GAGs 
quantification in control (black) and MPS VII (grey) neurospheroids by Blyscan Sulphated 
Glycosaminoglycan assay. (f) β-hex enzymatic activity (expressed in nmol 4-MU/µg of protein/h) in 
control (black) and MPS VII (grey) neurospheroids at day 7 and 28. Data are mean ± SD of 3 (control) 
and 4 (MPS VII; 2 with MPS VII-cl.8 and 2 with MPS VII-cl.13) independent cultures. *** P < 0.001. 
GAG accumulation, secretion and presence of enlarged intracellular vesicles 
are the main histological hallmarks and biomarkers for MPS VII (Montaño et al., 
2016). We first investigated whether MPS VII neurons accumulate GAGs and harbor 
extended vesicles. By toluidine blue staining, we found more and bigger non-
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staining vesicles in MPS VII neurons versus control neurons (Fig. 4.5d). In MPS VII 
neurospheroids, total GAG content almost doubled that of controls and this 
increase was already observed by day 7 of culture and maintained up to day 28 
(Fig. 4.5e). This phenotype in human MPS VII neurons resembles that observed in 
mice (Ariza et al., 2014; Karolewski and Wolfe, 2006) and canine (Cubizolle et al., 
2013) MPS VII brain. Additionally, in several MPS one can detect increased 
expression of other genes coding for lysosomal enzymes via the transcription factor 
EB (Sardiello et al., 2009). β-hexosaminidase (β-hex) is one lysosomal enzyme 
whose production and activity are elevated when the greater lysosomal system is 
perturbed. Notably, we observed a 1.7-fold increase in β-hex activity in the MPS VII 
neurospheroids, both at days 7 and 28 (Fig. 4.5f). Similarly, increased β-hex activity 
had been reported in MPS VII mouse and dog brains (Ariza et al., 2014; Cubizolle et 
al., 2013). Together, these data demonstrate that we generated human iPSC-
derived MPS VII neurons that harbored the histological hallmarks of MPS VII 
pathology. 
3.4. TEM reveals anomalies in the endocytic compartment 
of MPS VIII neurons 
Transmission electron microscopy (TEM) was used to examine differences in 
the endocytic compartment between control and MPS VII neurons at 6 and 9 
weeks of culture. In culture conditions that mimic the suboptimal conditions in the 
MPS VII brain, control neurons had a slightly high autophagy activity as indicated by 
the presence of double membrane structures (Fig. 4.6).  
Consistent with the immunofluorescence studies, control neurons contained a 
well-defined endocytic compartment with amphisomes and multivesicular bodies 
(Fig. 4.6a and 4.6c), while MPS VII neurons harbored expanded endocytic 
compartments that were heterogeneous and formed clusters (Fig. 4.6b and 4.6d). 
TEM confirmed the presence of lipofuscin granules and micro-vacuolation of 
neuronal cell cytoplasm with fusion between homotypic vesicles, indicating defects 





4.6d). These data identify pathological changes in human MPS VII neurons, which 
may impact learning and memory disabilities observed in MPS VII mice and some 
MPS VII patients. 
 
Figure 4.6: Transmission electron microscopy (TEM) of MPS VII neurons. Ultrastructure of control (a, 
c) and MPS VII (b, d) neurons at 6 (a, b) and 9 (c, d) weeks of culture. Black arrows in (a) show well-
defined endocytic compartment with amphisomes and multivesicular bodies in control neurons, while 
MPS VII neurons harbor expanded and heterogeneous endocytic compartments that formed clusters. 
Red arrows in (b) indicate fusion between homotypic vesicles in MPS VII neurons. Scale bars 2 μm (top 
panels) and 0.5 μm (bottom panels). 
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3.5. Functional alterations in the greater lysosomal system 
of MPS VII neurons 
We next asked if other aspects of the greater lysosomal system were altered in 
MPS VII NPC and neurons. Lysosomes fuse with autophagosomes to degrade long-
lived proteins, organelles and pathogens. The autophagosome marker, LC3-I/II and 
the adaptor molecule p62/SQSTM1, which label molecules to be delivered to 
autophagosomes, were used to probe steady-state autophagy levels. The amount 
of LC3-I/II and p62/SQSTM1 were similar in control and MPS VII NPC ± rβ-gluc, 
suggesting that autophagy was not unbalanced in MPS VII NPC (Fig. 4.7a).  
 
Figure 4.7: Lysosome function alteration in MPS VII NPC and neurons. Autophagy basal levels in 
control and MPS VII NPC (a) and neurons (b). P62 and LC3-I/ II were analyzed by western blot of 





representative experiment of 4 independent experiments. (c) Control and MPS VII NPC lysosome 
ability to degrade membrane proteins internalized by endosomes assayed by an EGFR degradation 
assay. EGFR content analyzed by Western blot. Data from one representative experiment of 2 
independent experiments. (d) Immunofluorescence confocal microscopy of control and MPS VII NPC, 
after induction of CAR degradation, stained for Lamp1 (green), CAR (extra- and intracellular domains, 
red) and DAPI (blue). CAR localized at the membrane, internalized into lysosomes (LAMP1 and CAR co-
localization, 30’) and degraded (120’). (e) Lysosome ability to degrade CAR assayed in control and MPS 
VII NPC, non-treated (non-treat.) and treated with rβ-gluc. CAR content analyzed by Western blot. 
Data from one representative experiment of 2 independent experiments. (f) Lysosome ability to 
degrade membrane proteins internalized by endosomes assayed by an EGFR degradation assay in 
control and MPS VII neurons, non-treated (N.T.) and treated with rβ-gluc. EGFR content analyzed by 
Western blot. Data from one representative experiment of 5 independent experiments. (g) Control 
and MPS VII neurons lysosome ability to degrade CAR, non-treated (N.T.) and treated with rβ-gluc. 
CAR content was analyzed by Western blot. Data from one representative experiment of 5 
independent experiments. 
While cytosolic LC3-I levels were similar in MPS VII and control neurons, LC3-II 
basal levels were increased in MPS VII neurons compared to controls, and restored 
to control levels when rβ-gluc was added to the medium (Fig. 4.7b). These results 
suggest a defect in autophagosome-lysosome fusion (autophagosome maturation) 
or a dysfunction of lysosomal protein degradation in MPS VII neurons. 
In addition to intracellular degradation of host proteins, lysosomes also play a 
role in the regulation of signaling pathways by degrading cell surface receptors. 
Epidermal growth factor (EGF) signal transduction requires EGF receptor (EGFR) 
engagement, internalization of the EGF-EGFR complex into endosomes and 
degradation of EGFR in lysosomes, while EGF signaling endosomes reach the 
nucleus. We therefore addressed the function of endo-lysosomal system 
determining if EGFR is degraded in MPS VII NPC and neurons. EGFR levels in cell 
extracts at basal levels (time 0) and after recombinant EGF treatment (0.5, 4 and 24 
h) were analyzed by immunoblotting. EGFR levels decreased over time in control 
and MPS VII NPC, with a 60 - 75% loss at 24 h, indicating that lysosomes functioned 
properly for EGFR degradation (Fig. 4.7c). To address lysosomal function using 
another cell surface protein, receptor-mediated endocytosis and lysosomal 
degradation was assayed for coxsackievirus and adenovirus receptor (CAR) 
(Loustalot et al., 2016). We previously showed that the canine adenovirus type 2 
fiber knob (FKCAV) binds CAR (Seiradake et al., 2006) and induces its lysosome-
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mediated degradation in neuronal cells (Salinas et al., 2014). Importantly, EGFR and 
CAR occupy different microdomains in the plasma membrane: EGFR is globally 
spread while CAR is enriched in lipid rafts (Salinas et al., 2014), and therefore 
different internalization routes are used. MPS VII NPC were incubated with FKCAV. 
CAR internalization and degradation were followed by immunofluorescence of CAR 
and LAMP1. In resting conditions, CAR was preferentially found at the cell 
membrane that contacts other NPC. Thirty minutes post-incubation with FKCAV, 
CAR was internalized and co-localized with LAMP1. At 2 h, CAR levels decreased 
compared with resting conditions, indicating its degradation both in control and 
MPS VII NPC (Fig. 4.7d). CAR levels were also quantified by immunoblotting (Fig. 
4.7e). Control and MPS VII NPC ± rβ -gluc degraded CAR to a comparable extent 
(Fig. 4.7e). These data suggest that MPS VII NPC lysosome-mediated degradation is 
not notably altered and that lysosomes function properly in terms of autophagy 
and receptor degradation. 
Because neurons use specific signaling pathways related to membrane 
remodeling, axonal growth and synapses plasticity, these pathways could be more 
susceptible to metabolite accumulation and perturbations of the endo-lysosomal 
system. Thus, levels and processing of EGFR and CAR were also evaluated in MPS 
VII neurons. We found that the levels of EGFR after EGF treatment were reduced in 
control, MPS VII and rβ-gluc treated MPS VII neurons (Fig. 4.7f). Moreover, ERT had 
no effect in EGFR levels, further indicating that there were no alterations in EGFR 
degradation due to MPS VII pathology. CAR levels diminished after FKCAV treatment 
in control neurons (Fig. 4.7g), while in MPS VII neurons were unchanged, indicating 
an alteration in the endo-lysosomal pathway. Of note, CAR levels were diminished 
in rβ-gluc-treated MPS VII neurons similar to control neurons (Fig. 4.7g). These data 






3.6. Network alterations in MPS VII neurons 
MPS VII neuron functionality was assessed by imaging cytosolic calcium (Ca++) 
concentration using the ratiometric fluorescent dye, Fura-2, which monitors Ca++ 
entry through voltage-gated Ca++ channels in neurons. Upon KCl-induced 
depolarization, approximately 50% of the cells exhibited signals in both control and 
MPS VII cultures (Fig. 4.8a).  
 
Figure 4.8: MPS VII neuronal activity and MPS VII neurospheroids calcium (Ca++) imaging analysis. 
(a) Ca++ release in control and MPS VII neurons, upon KCl induction and reduction of Ca++ signaling 
upon inhibition with nimodipine. (b) FM-1-43 fluorescence decay in control (black) and MPS VII (grey) 
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neurospheroids at day 28. Data are mean ± SD of 3 independent cultures. (c) Percentage of cells per 
number of spontaneous Ca++ events in 300 seconds for control (black) and MPS VII (cl. 8 grey; cl. 13 
light grey) neurospheroids. (d) Visual representations of neural networks from control and MPS VII 
neurospheroids reconstructed using FluoroSNNAP; circles show the position of cells in culture, yellow 
circles represent functionally connected nodes and red lines represent the functional connectivity of 
pair-wise neurons. (e) Ca++ events peak amplitude, rise time and fall time in control (black) and MPS 
VII (cl. 8 grey; cl. 13 light grey) neurospheroids. Network properties: Connectivity index (f) and Global 
synchronization index (g) in control (black) and MPS VII (cl. 8 grey; cl. 13 light grey) neurospheroids. 
Data are mean ± SD of 3 (control) and 4 (MPS VII; 2 with MPS VII-cl.8 and 2 with MPS VII-cl.13) 
independent cultures. Asterisks indicate significant difference: * P < 0.05, *** P < 0.01, *** P < 0.001. 
The effectiveness of nimodipine, a L-type Ca++ channel blocker, to inhibit Ca++ 
signals in depolarizing conditions further demonstrated the presence of 
differentiated neurons in both conditions (Fig. 4.8a). These data indicated that after 
7 weeks in culture MPS VII neurons were functionally similar to control neurons. In 
MPS VII neurospheroids synaptic functionality was initially assessed by imaging KCl-
induced synaptic vesicle exocytosis. Control and MPS VII neurospheroids 
responded similarly to the depolarizing stimuli, indicating no differences in total 
synaptic vesicle trafficking (Fig. 4.8b). Next, Ca++ fluorescence imaging was used to 
evaluate the differences in spontaneous neuronal activity between control and 
MPS VII neurons and alterations in neuronal network functional connectivity within 
MPS VII neurospheroids. MPS VII neurospheroids had significantly lower neuronal 
activity than control, with 8.5% (MPS VII cl.8) and 10.0% (MPS VII cl.13) of cells 
presenting one spontaneous Ca++ event, compared to 18.4 % in control 
neurospheroids, and with a higher percentage of cells that did not present 
spontaneous Ca++ events during the monitoring time (Fig. 4.8c). 
To characterize MPS VII neuronal networks, connectivity was evaluated using 
FluoroSNNAP software, which allows one to infer functional connectivity between 
neurons using the temporal correspondence of Ca++ events. These analyses 
generate maps of neuronal interactions where one can quantify the connectivity 
indexes for each active cell (Patel et al., 2015). Representative connectivity maps of 
control and MPS VII neurospheroids are provided in Fig. 4.8d. The average peak 





significantly (p < 0.05) smaller than in control neurospheroids, while no significant 
differences were found in rise and fall times (Fig. 4.8e). 
In control network structures, most of the cells established several connections 
with other cells (Fig. 4.8d). By contrast, connections were formed only between 
some of the cells in MPS VII network, leaving the remaining cells weakly connected 
or disconnected (Fig. 4.8d). Concomitantly, the average connectivity index for 
active cells was significantly (p <0.001) lower in MPS VII neurospheroids (Fig. 4.8f). 
A similar pattern was observed for the global synchronization index, which was also 
significantly (p <0.001) lower in MPS VII networks (Fig. 4.8g), further indicating 
alterations in MPS VII neuronal networks. Together, these results demonstrate that 
MPS VII neurospheroids have less active cells with smaller Ca++ peak amplitudes, 
the cells are weakly connected and poorly synchronized, which may impact the 
MPS VII brain network topology and functionality. 
4. Discussion 
One of our primary, long-term, goals at the core of our studies is to identify 
quantifiable neuronal phenotype that could complement genetic analyses to help 
us predict the severity of MPS VII-associated cognitive anomalies. This is because 
GUSB heterogeneity, in combination with other genetic or environmental factors, 
causes a range of pathological features that make prognosis, and in turn 
recommending treatment options, challenging. We reasoned that the current pace 
of technological improvements in cellular reprograming and directed 
differentiation will allow one to rapidly and inexpensively generate neural cells 
from many cell types. The unique functions of neural cells could then be probed for 
MPS VII-associated defects.  
Here, we used human MPS VII iPSC-derived neural cells, cultured in 2D and 3D 
culture systems, to try to identify neuronal defects. We found that ERT, in this case 
supraphysiological levels of β-gluc activity, was not necessary for fibroblast 
reprogramming, iPSC generation or expansion. The requirement for ERT is similar 
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to that described for MPS IIIC iPSC (Canals et al., 2015), but in contrast to that 
reported for MPS IIIB and Pompe disease iPSC (Higuchi et al., 2014; Lemonnier et 
al., 2011). Generating NPC is primordial during normal brain development. Despite 
limited β -gluc activity, a homogeneous, expandable and phenotypically stable 
population of NSCs was obtained. These in vitro data are consistent with the clinical 
manifestation of MPS VII, and with early brain development of MPS VII mouse and 
dogs, which appears histologically normal (Ariza et al., 2014; Cubizolle et al., 2013; 
Karolewski and Wolfe, 2006). These data suggest that deficiency in β-gluc activity 
may not have a discernable impact on initial stages of neural development. A 
caveat is that during fetal development maternal β-gluc would be present for 
uptake in brain cells until the fetal blood brain barrier is formed. 
We then asked whether some aspects of neural cell homeostasis could be 
perturbed by decreased β-gluc activity. We show that MPS VII neurons 
differentiated in 2D cultures formed functional synapses. Similar differentiation 
patterns were observed during 2D differentiation of control and MPS VII neurons 
indicating that reduced β-gluc activity did not affect the onset of the neuronal 
differentiation of MPS VII NPC in this culture system. Differentiation of MPS VII NPC 
in a 3D culture system revealed downregulation of proliferating cells, prototypic 
NPC gene expression, and upregulation of neuronal βIII-tubulin, consistent with the 
ability of MPS VII NPC to undergo neuronal differentiation. Neuronal differentiation 
was consistent with the expression of synaptophysin and markers of glutamatergic, 
dopaminergic and GABAergic neurons. Notably, GAD67 gene expression was lower 
in MPS VII neurospheroids, suggesting that there was a reduction in GABAergic 
neuronal differentiation. GABA is the main inhibitory neurotransmitter within the 
brain and GABAergic neurons are involved in several physiological functions, 
including stabilization of neuronal activity. A balance between excitation and 
inhibition ensures the normal functioning of the neuronal networks (Błaszczyk, 
2016), so decreased GABAergic neurons could potentially lead to neuronal 





more than other cells types in a MPS VII mouse model and in other LSD, such as 
MPS I, and GM1 and GM2 gangliosidosis (Parente et al., 2012; Walkley, 1998; 
Walkley et al., 1991). Concomitantly, a 8-fold down-regulation in OTX1-2, a 
transcription factor that controls neuron subtype identity and the fate of 
GABAergic neurons, was found in the brain of a MPS VII mouse model (Parente et 
al., 2012) and in human MPS IIB brain the density of GABAergic neurons in the 
cerebral cortex was markedly reduced when compared with age-matched controls 
(Hamano et al., 2008).  
Despite decreased synaptophysin gene expression in MPS VII neurospheroids, 
functional synapses were equivalent to controls. However, it is possible that this 
approach, and/or our culture conditions were not optimized to detect subtle 
differences in neuronal functionality during the depolarization assays. More 
specifically, overall fluorescence of the neurospheroids was quantified in medium 
optimized for culturing and maintaining healthy neuronal cells, and therefore this 
environment poorly recapitulate the environment in the MPS VII brain. Detecting 
alterations in GABAergic neurons synaptic activity may require a 
“stressed/challenging” environment. For example, astrocytes provide neurotrophic 
support, help synchronize neurotransmitter metabolism and release and regulate 
the extracellular milieu. Thus, alterations in astrocyte function can be a major 
contributor to neurodegeneration and/or cognitive defects (Phatnani and Maniatis, 
2015; Sofroniew and Vinters, 2010). Notably, higher GFAP mRNA levels were found 
in MPS VII neurospheroids. Similarly, in recent studies performing transcriptome 
analyses of the MPS VII mouse brain, thirteen astrocyte-specific mRNAs (including 
GFAP) were upregulated (Parente et al., 2016, 2012). Upregulation of GFAP is the 
hallmark of astrocyte reactivity in response to an insult or injury in the CNS (Ben 
Haim et al., 2015; Phatnani and Maniatis, 2015). An increase in the number of 
GFAP+ astrocytes was also found in the cerebral cortex of MPS II and IIIB patients 
(Hamano et al., 2008). Mediators of innate immunity, such as lipopolysaccharide 
(LPS) and other toll-like receptor (TLR) ligands, as well as neurodegenerative 
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diseases, are able to trigger reactive astrogliosis to different extents (Phatnani and 
Maniatis, 2015; Sofroniew and Vinters, 2010). Of note, GAG breakdown products 
are structurally similar to LPS, the canonical ligand of TLR4 (Ballabio and 
Gieselmann, 2009; Xing et al., 2015). Therefore, GAGs accumulation could activate 
TLR4 signaling pathway inducing a pro-inflammatory response. Priming of microglia 
via the TLR4 pathway has been demonstrated in the mouse MPS IIIC brain (Ausseil 
et al., 2008) and MPS VII mice presented elevated levels of p-STAT1-Ser727 and p-
STAT3-Tyr705, consistent with TLR4 activation (Metcalf et al., 2009). Further 
exploring the astrocytes in 3D MPS VII neurospheroids could help us determine if 
they are activated through a TLR pathway.  
In addition to intracellular degradation of host proteins, lysosomes also play a 
role in the regulation of signaling pathways by degrading cell surface protein 
receptors. Our data suggested that lysosomes function properly in terms of EGFR 
degradation both in MPS VII NPC and neurons and CAR degradation in MPS VII NPC, 
but not in MPS VII neurons. As neurons use specific signaling pathways related to 
membrane remodeling, axonal growth and synapse plasticity, these could be more 
susceptible to metabolite accumulation and perturbations of the endo-lysosomal 
system. These data suggest that signaling pathways following similar internalization 
routes like CAR, which is lipid microdomain-, actin-, and dynamin-dependent 
(Salinas et al., 2014), may be affected in MPS VII neurons. Importantly, these 
alterations in MPS VII neurons were restored by ERT. 
The functional and networking alterations in MPS VII neurons are ideal starting 
points to understand MPS VII cognitive defects. A consequence of lower 
connectivity and poor synchronization could be related with the decrease in 
GABAergic neurons. There is a strong interplay between Ca++ levels and GABA, as a 
GABAergic neuron decline is initiated by abnormal increased intracellular Ca++ 
levels (Błaszczyk, 2016). Moreover, as the balance between excitation and 
inhibition ensures the normal functioning of the networks, a decrease in GABAergic 





in MPS VII neuronal activity and network functional connectivity is, to the best of 
our knowledge, the first report of in vitro functional impairment that may 
recapitulate the mechanisms underlying brain dysfunction and cognitive 
impairment in MPS VII patients. The deregulation of Ca++ levels and GABA levels 
further link LSD and Parkinson’s disease, which shared genetic, clinical and 
neuropathological features (Beck, 2016). Furthermore, these observations are 
important to provide new insights in the relation between alterations in the 
network in MPS VII disease and GAG’s accumulation and its impact in impaired 
cognition. Now that quantifiable readouts have been identified, future studies are 
needed to include iPSC-derived neurons from a cohort of MPS VII patients to 
identify inter-individual differences to be correlated with patient’s mutations and 
to provide mechanistic insights on whether disease phenotype is affecting neural 
differentiation and neuronal network functionality. This could represent a step 
towards improved post-natal diagnosis and therapeutic strategies to prevent/ 
reverse MPS VII -associated cognitive defects. Given the similarities between MPS 
VII and other MPS and LSD, our study has broad implications. 
In summary, we identified MPS VII-associated perturbations through 
differentiation of iPSC into NPC and neurons. Our study provides an iPSC-based 
model that reproduces the major biochemical and histological features of the MPS 
VII, especially neuronal phenotypes. This provides a platform upon which the 
cellular processes responsible for brain dysfunction in MPS VII can be further 
elucidated and used for testing and optimizing therapies. 3D neurospheroid culture 
systems combined with neuronal connectivity assays have the potential to assess 
neurological defects in other LSD and neurodegenerative diseases with variable 
phenotypes. 
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Brain diseases represent a major social and economic burden worldwide and 
are expected to rise dramatically with the increase in life expectancy (DiLuca et al., 
2014; Harper, 2014; Rosemann, 2015). Most neurological disorders have no 
effective treatments that target the pathological mechanisms and halt disease 
progression. Human models that recapitulate phenotypic and functional features of 
the human brain and brain-related pathologies, not only provide new tools to 
accurately identify and validate potential therapeutic targets and drug candidates, 
but can also give insights into the mechanisms of disease onset and progression. 
The work developed herein aimed at exploiting 3D differentiation of human 
stem cells to develop, characterize and interrogate 3D neural cell models for 
disease modeling and drug discovery. The focus was on the recapitulation of 
phenotypic and functional features of human brain tissue, namely the 
establishment of functional neuron-astrocyte interactions. These models would 
have applications in drug screening and disease modelling fields. The overview of 
the work developed in this thesis is summarized in Fig. 5.1, where the aims and 
achievements for chapters 2-4 are described.  
 
Figure 5.1: Schematic representation of the major aims of the thesis and the achievements of each 
chapter (2-4). NT2 – Ntera2/ clone D1 cell line; MPS VII – Mucopolysaccharidosis type VII; iPSC-NPC – 





When developing new models aiming at recapitulating specific features of the 
tissue of origin, the balance between complexity and heterogeneity and the desired 
application should be taken into account. Simple and robust models, with less 
expensive protocols and that fit into high-throughput test setups are better suited 
for drug testing applications. In turn, more complex models may be required for 
mechanistic research, as well as target discovery and validation. These should aim 
to mimic specific physiological and pathophysiological brain features, such as the 
interactions between several cell types and the microenvironment, and disease-
related molecular pathways. Several 3D culture strategies have been employed to 
recapitulate important features of the brain tissue, including tissue-specific cellular 
organization (Birey et al., 2017; Lancaster et al., 2013; Ranga et al., 2016), neuron-
astrocyte interactions (Simão et al., 2016a; Terrasso et al., 2015) and cell-ECM 
interactions (Simão et al., 2018). We employed agitation-based culture systems to 
develop scaffold-free culture strategies for PSC aggregation and neural 
differentiation. The stirring increases the frequency of cell-cell interactions, 
allowing cells to self-assemble and form aggregates, and enhances mass and gases 
transfer coefficients, which are function of the agitation speed (Kinney et al., 2011; 
Sargent et al., 2010). After the initial aggregation period, neural differentiation was 
induced by addition of morphogens or neurotrophic factors. This general culture 
strategy was implemented for NT2 cell line (Chapters 2 and 3) and adapted for 
iPSC-NPC neural differentiation, using health and diseased cells (Chapter 4).  
1.1. 3D human brain cell model for drug screening  
In Chapters 2 and 3 the main focus was (1) the establishment of a robust and 
reproducible strategy for 3D neural differentiation of human NT2 cell line into 
neurons and astrocytes (neurospheroids), allowing the establishment of functional 
neuron-astrocyte interactions; (2) the establishment of endpoints to distinguish 
between neuronal and astrocytic toxicity within neurospheroids; and (3) proof-of-
concept of neurospheroid applicability in drug screening applications. Spinner 





based culture systems, easy to implement in any laboratory, without major 
investment or engineering expertise. Our starting point was the bioprocess already 
implemented in our laboratory for NT2 neuronal differentiation in stirred-tank 
bioreactors (Serra et al., 2009, 2007), using RA as neurotrophic factor. 
Nevertheless, this bioprocess resulted in immature neuronal cells and did not 
include glial cells. Indeed, few works have been able to demonstrate the capacity of 
NT2 cell line to differentiate into the astrocytic lineage, in 2D culture systems (Bani-
Yaghoub et al., 1999; Goodfellow et al., 2011). In vivo, during prenatal brain 
development, neurogenesis precedes gliogenesis (Molofsky and Deneen, 2015). 
Also, during ESC neural differentiation in vitro, neurons appear in culture during the 
first month, while astrocytes take 2-3 months to differentiate (Gupta et al., 2012; 
Hu et al., 2010). Following this rational, the culture time was extended, in order to 
allow astrocytic differentiation, as well as neuronal and astrocytic maturation. As 
described in Chapter 2, after 3 weeks of RA treatment and 2 additional weeks in 
culture, we obtained neurospheroids enriched into mature and functional human 
neurons and astrocytes. The major neuronal phenotypes in the human brain, 
excitatory glutamatergic and inhibitory GABAergic neurons, were detected in 
neurospheroids. Neuronal synaptic maturation and functionality were suggested by 
the presence of synaptophysin-positive vesicles and confirmed by the ability of 
neurospheroids to perform stimuli-induced vesicle exocytosis and neurotransmitter 
release. Astrocytic maturation was suggested by the presence of GLT-1, the 
predominant glutamate transporter in astrocytes. This transporter is responsible 
for 90% of glutamate uptake by excitatory aminoacid transporters in human brain 
(Kim et al., 2011). The ability of neurospheroids to perform glutamate uptake from 
the extracellular media and glutamine production, upon glutamate challenge, 
indicated the presence of functional astrocytes. This suggests that astrocytes in 
culture present: (1) functional glutamate transporters, the main mediators of 
glutamate clearance by astrocytes, (2) active glutamine synthase, the astrocyte-





2010) and (3) glutamine efflux to the extracellular space via functional glutamine 
transporters. These are the main steps of the well-described glutamine-glutamate 
cycle, involved into the supply of glutamine to neurons (Amaral et al., 2011; Zou et 
al., 2010). Concomitantly, in the continuation of this work, we later demonstrated 
by nuclear magnetic resonance (NMR) spectroscopy using 13C-labeled substrates, 
the establishment of neuronal and astrocytic metabolic signatures and of the 
glutamine-glutamate-GABA shuttle within NT2 neurospheroids (Simão et al., 
2016a). These results highlight the relevance of this model for better 
understanding the metabolic crosstalk between human neurons and astrocytes. 
Furthermore, the presence of functional neurons and astrocytes enables modelling 
of neuron-astrocyte interactions and increases the model’s reliability in drug 
screening. Functional human astrocytes provided an extra layer of complexity to 
the model, since these were described to be implicated in many neurodegenerative 
disease processes and impact neuronal response to neurotoxic and 
neuroprotective chemicals (Gupta et al., 2012; Sofroniew and Vinters, 2010). 
Astrocyte impairment has been found to contribute to neuronal dysfunction in 
several neurodegenerative diseases, such as ALS, AD, PD and Huntington’s disease 
(Fraldi et al., 2016; Liu et al., 2017; Oksanen et al., 2017). Astrocytes produce and 
secrete neurotrophic factors, cytokines and chemokines that play both neurotoxic 
(inflammatory) and neuroprotective (immunoregulatory) roles (Choi et al., 2014; 
Phatnani and Maniatis, 2015). In vivo, astrocytes can facilitate the delivery of toxic 
or neuroprotective compounds to neurons. Indeed, several studies demonstrated 
that screens focusing on the direct effect of compounds on neurons overlook 
potentially important activities that act via astrocytes. Generally, astrocyte-
containing in vitro models show increased tolerance to toxicant insult and 
impairment of astrocytic functions, such as maintenance of antioxidant defense 
and cellular energy levels, which can critically influence neuronal survival (Gupta et 





 For a cell platform to be used for in vitro drug screening, it is essential that 
models can be available in large amounts and in consistent quality. Indeed, the 
advantages of the NT2-derived model include the scalability and robustness of the 
culture system, allowing to reproducibly produce high number of differentiated 
neurospheroids, with low batch-to-batch variation. From one 125 mL spinner 
culture, one can feed more than one hundred 96-well plates using the assay setup 
implemented in chapters 2 and 3. The process developed for NT2 neural 
differentiation is also 50% less time-consuming and 10-fold more efficient than the 
2D culture system. Moreover, NT2 3D differentiation is within the same duration 
than PSC neuronal and astrocytic differentiation protocols. Besides, it provides a 
more amenable and cost-effective process, as it only requires RA for neural 
differentiation instead of neurotrophic factors, such as BDNF, GDNF or CTNF, which 
are considerably more expensive. 
 The applicability of the NT2 neurospheroid model for drug testing was 
explored, including neurotoxicity (Chapter 2) and neuroprotection (Chapter 3) 
assessment. Neuronal and astrocytic specific gene expression and functionality 
endpoints were applied to distinguish between neuronal and astrocytic toxicity 
within neurospheroids. These were implemented using two prototypical 
neurotoxicants, acrylamide and chloramphenicol. Acrylamide decreased 
synaptophysin gene expression, even at subtoxic concentrations, while 
chloramphenicol decreased gene expression of neuronal (βIII-tubulin) and, at a 
major extent, astrocytic (GFAP) cytoskeletal proteins. The response of acrylamide-
treated neurospheroids to depolarizing stimuli decreased, indicating loss of ability 
of synaptic vesicles to fuse with the plasma membrane and perform exocytosis.  
 Our data suggested that acrylamide neurotoxicity mechanism involves 
impairment of presynaptic function, interference with synaptic vesicle trafficking 
and changes in the ability of synaptic vesicles to fuse with the plasma membrane 
and perform exocytosis. Supporting this hypothesis, we later showed that 





synthesis (Simão et al., 2016a), indicating an imbalanced glutamine-glutamate-
GABA cycle. This can be due to impairment in synaptic vesicle trafficking, leading to 
loss of cell-cell contacts at synaptic sites. Indeed, nowadays there are 3 hypothesis 
for acrylamide neurotoxicity mechanisms: inhibition of kinesin-based fast axonal 
transport, alteration of neurotransmitter levels, and direct inhibition of 
neurotransmission by interference with membrane fusion processes at the nerve 
terminals (Erkekoglu and Baydar, 2014; Lopachin and Gavin, 2012). The 
consequence of the last is a failure of synaptic vesicles to fuse with their target 
membranes, which results in reduced release of neurotransmitters and eventually 
nerve terminal degeneration (Erkekoglu and Baydar, 2014).  
There are few reports of chloramphenicol neurotoxicity mechanisms, but our 
results are in line with a previous report (Woehrling et al., 2011), and suggest that 
chloramphenicol induces cytoskeletal injury, being more toxic to astrocytes than to 
neurons. Still, in lung and liver cancer cells, chloramphenicol is described to cause 
senescence-associated morphological changes, including changes in the expression 
pattern of cytoskeleton genes (Li et al., 2010, 2005). Similar mechanisms can 
potentially be occurring in neurospheroids.  
 Importantly, the gene expression and neuronal functionality endpoints 
employed allowed early detection of changes in neuronal and astrocytic gene 
expression and disturbed neuronal functions and their correlation with 
mechanisms of toxicity. This suggests that these are sensitive endpoints that can be 
used to distinguish between neuronal and astrocytic toxicity in complex 3D models.  
For the proof-of-concept of the applicability of the NT2 neurospheroids for 
testing the neuroprotective effect of drug candidates an in vitro assay setup, in a 
96-well plate format, was implemented. This combined neurospheroids with a 
tBHP-induced oxidative insult and a fluorescence-based cell viability endpoint. 36 
potential neuroprotective compounds from different origins, ranging from 





Robustness and simplicity of the neurospheroids production process and of 
the neuroprotection assay, combined with the evaluation of cell viability using a 
fluorescence-based endpoint, makes this a versatile assay setup suitable for early-
stage drug screening. Neurospheroids can be easily collected from an agitation-
based culture system, be distributed in multi-well plates with a robotic system and 
employed to test drug candidates. Moreover, the general assay setup developed 
herein for drug testing can be applied to other 3D cell models, using different cell 
sources and different insults.  
 Human neurospheroids can also be applied to feed microfluidic devices, such 
as multi-organ chip platforms, allowing long-term cultures of various cell types 
from different tissues, in a miniaturized controlled environment. The application of 
NT2 neurospheroids developed in this work to feed multi-organ chip microfluidic 
devices was evaluated by co-culturing the neurospheroids with human liver 
microtissues (Materne et al., 2015). Also, a 2-week toxicity assay, with repeated 
substance exposure, showed that neurospheroids can be useful for repeated dose 
applications in these platforms (Materne et al., 2015). Nevertheless, as multi-
organ-chips are technically demanding and present a lower throughput than multi-
well plates, this approach should be more useful in later stages of drug discovery 
pipeline, when few drugs are being better characterized. Besides, multi-well plates, 
by allowing a higher throughput, can be useful in primary screenings, to test a high 
number of drugs. Still, multi-organ chips provide additional in vitro tools that can 
more closely recapitulate systemic application of drugs and be employed to predict 
more accurately drug safety and efficacy in preclinical studies using 3D cell models.  
1.2. 3D human brain cell model for MPS VII disease modeling  
Typically when trying to recapitulate neurological defects the focus is on 
neuronal cells. However, astrocytes have important roles on neuronal cell function 
and on the secretion of ECM components and regulation of the extracellular milieu, 
potentially impacting the development and progression of neurological diseases. 





based culture systems allows the establishment of functional neuron-astrocyte 
interactions (Simão et al., 2016b; Terrasso et al., 2015) and accumulation of 
endogenous ECM and secreted components (Simão et al., 2018). We hypothesized 
that through recapitulation of neuron-astrocyte and cell-ECM interactions within 
neurospheroids, it would be possible to recapitulate pathological features, in which 
impairment of neuron-astrocyte and cell-ECM interactions can be relevant.  
MPS VII is an orphan neuronopathic LSD, caused by a deficiency in β-gluc 
enzymatic activity (Tollersrud and Berg, 2005; Tomatsu et al., 2009), which results 
in an abnormal accumulation of GAGs partially degraded in the lysosomes of many 
tissues, including in the brain (Montaño et al., 2016). Whereas the primary effects 
of the disorder are described, the mechanistic events downstream to GAGs 
accumulation that can lead to more deleterious neuronal effects are still unknown. 
Proteoglycans are one of the major components of brain ECM, thus alterations in 
GAGs can potentially impact neural cell interactions and cell ECM interactions, 
which in turn regulate neural cell functionality (Srikanth and Young-Pearse, 2014). 
Moreover, it was reported that the aberrant behavior of neural cells derived from a 
canine MPS VII model was lost after standard culture in vitro, suggesting that the 
neural microenvironment is critical for disease phenotype (Walton and Wolfe, 
2007). Thus, MPS VII patient-derived iPSC cells were employed to generate 
neurospheroids and test our hypothesis.  
In Chapter 4, the main focus was on (1) the establishment of a neurospheroid 
model differentiated from MPS VII patient-derived iPSC, with the presence of 
several brain cell types and allowing for the recapitulation of neuron-astrocyte 
interactions and (2) to test whether MPS VII neurospheroids could recapitulate 
MPS VII disease hallmarks, which would enable them to be used to understand the 
disease-associated cognitive deficits and try to identify disease-related neuronal 
defects. 
MPS VII iPSC were generated by reprogramming of MPS VII patient skin 





by dual SMAD inhibition protocol (Chambers et al., 2009). Reduced β-gluc activity 
had no significant impact on iPSC-NPC and these did not show major lysosome 
structural alterations. MPS VII neurons, differentiated in 2D, showed several MPS 
VII-associated phenotypes, including GAGs accumulation, expanded endocytic 
compartments, accumulation of lipofuscin granules, more autophagosomes, and 
altered lysosome function. While clearly very informative, this 2D cellular model 
lacked the interactions between neurons and astrocytes and between these and 
the proteoglycans.  
The strategies developed by our group for NT2 neural differentiation, allowing 
establishment of neuron-astrocyte interactions (Terrasso et al., 2015) and for iPSC-
NPC neural differentiation, allowing the accumulation of endogenous ECM and 
secreted components (Simão et al., 2016b; Simão et al., 2018), were used as 
starting point for MPS VII neurospheroids culture. MPS VII iPSC-NPC differentiation 
was induced by mitogen (FGF and EGF) removal and exposure to a membrane-
permeable analogue of cAMP and to the neurotrophic factors BDNF, GDNF and NT-
3. Downregulation of prototypic NPC genes and upregulation of glutamatergic, 
dopaminergic and GABAergic neuronal markers in MPS VII neurospheroids were 
observed. MPS VII neurospheroid cultures recapitulated disease-associated 
molecular hallmarks, mainly GAGs accumulation. Interestingly, MPS VII 
neurospheroids revealed an upregulation in GFAP, and a downregulation in 
GABAergic inhibitory neuron markers. This upregulation in GFAP in MPS VII 
neurospheroids can be related with an increase in GFAP-positive astrocytic cells or 
associated with astrocytic reactivity. Since astrocyte-specific glutamate transporter 
GLT-1 gene expression is similar between control and MPS VII neurospheroids we 
hypothesized that the GFAP upregulation is associated with astrocytic reactivity. 
Supporting this hypothesis, in recent studies performing transcriptomic analysis of 
the MPS VII mouse brain GFAP was highly upregulated (Parente et al., 2016). GFAP 
upregulation is the hallmark of astrocyte reactivity (Ben Haim et al., 2015; Phatnani 





in brains of AD and ALS patients before clinical symptoms (Carter et al., 2012; 
Philips and Robberecht, 2011) and in animal models of the same neurological 
disorders (Maragakis and Rothstein, 2006; Olabarria et al., 2010). Mediators of 
innate immunity such as lipopolysaccharides (LPS) and other Toll-like receptor (TLR) 
ligands are able to trigger reactive astrogliosis to different extents. GAGs 
breakdown products are structurally similar to LPS, the canonical ligand of TLR4 
(Ballabio and Gieselmann, 2009; Xing et al., 2015). Therefore, GAGs accumulation 
in MPS can activate TLR4 signaling pathway, eliciting pro-inflammatory cytokine 
production (e.g. TNF-α and IL-1β) and inducing a pro-inflammatory response 
(Ballabio and Gieselmann, 2009; Simonaro et al., 2010; Xing et al., 2015). Indeed, 
priming of microglia via TLR4 was demonstrated in MPS IIIC (Ausseil et al., 2008) 
and MPS VII mouse brains (Metcalf et al., 2009). Further studies are required to 
confirm that astrocytes within MPS VII neurospheroids are reactive and if this 
occurs through activation of TLR4 pathway by accumulation of GAG breakdown 
products. Increasing one layer of complexity to the MPS VII neurospheroid disease 
model, adding MPS VII iPSC-derived microglial cells to the culture could contribute 
to give insights on astrocyte and microglia reactivity in MPS diseases, as usually 
both cell types become reactive. Probably, this model would also better 
recapitulate the disease phenotype.  
The evaluation of neuronal connectivity by spontaneous calcium imaging 
revealed disturbances in the functional connectivity of the MPS VII neurospheroid 
neuronal network. These alterations can possibly be related with the decrease in 
GABAergic neurons, as these are involved in the stabilization of neuronal activity, 
through the maintenance of the balance between excitation and inhibition 
(Błaszczyk, 2016). The maintenance of this balance, together with the calcium 
homeostasis, ensures the correct functioning of neuron-astrocyte networks. 
Calcium-GABA interactions were used to adjust the fast electrical neuronal activity 
to the slower cell biochemical and metabolic processes (Błaszczyk, 2016). To 





calcium influx. This can be done directly, by increased GABA inhibition and 
reduction of GABA receptors and calcium channels or indirectly, via astrocytes 
(Allaman et al., 2011). These are activated by the neurotransmitters released within 
neuronal networks and inhibit the influx of calcium ions into the presynaptic 
neurons via GABA. Thus, if GABA concentration decreases, neurons become more 
excitable (Allaman et al., 2011) and this excitability of the neuronal network is 
adjusted through the elimination of neurons with excessive activity, initiating 
neurodegeneration (Błaszczyk, 2016). Our data is the ideal starting point to 
understand MPS VII-associated cognitive defects, providing insights into the 
interplay between reduced β-gluc activity, GAG accumulation and alterations in the 
neural network. The iPSC-derived MPS VII 3D neurospheroids provide a platform to 
further elucidate the molecular and cellular processes responsible of MPS VII-
associated brain dysfunction. These can also be used for testing and optimizing 
new therapies. Moreover, the 3D neurospheroid culture combined with the 3D 
neuronal connectivity assay are new tools with potential to assess other LSD and 
neurodegenerative diseases with variable phenotypes, contributing to better 
understand the cellular changes induced by the disease itself or by novel 
therapeutics. Lysosomes are nowadays viewed not only as degradative and 
recycling centers, but also as important organelles to maintain brain homeostasis. 
Additionally, lysosomal dysfunction has been increasingly associated with age-
related pathologies, like AD and PD neurological disorders (Carmona-Gutierrez et 
al., 2016; Fraldi et al., 2016). Thus, insights from the mechanisms of neuronal 
degeneration in LSD, such as MPS VII, can contribute to unveil new knowledge 
related with these mechanisms in other neurological disorders.  
2. Challenges and future opportunities  
 The work developed in this thesis describes the development and application 
of 3D human neural cell models for disease modeling and drug discovery. This work 





human neural cell differentiation and neural cell model development and 
ultimately providing model systems for the disease modeling and drug discovery 
fields. 
 In recent years, the rise of 3D models derived from PSC, and the 
implementation of characterization tools adapted to 3D cultures, triggered an 
exponential evolution in the neural cell models toolbox. Despite the significant 
improvements, the lack of efficient neural differentiation protocols that provide 
mature cells able to form the functional neuronal networks present in the adult 
tissue in vivo, remains one bottleneck. Still, there is no evidence indicating whether 
the neural maturation stage attained in vitro is enough to reflect disease 
pathogenesis and/ or to mimic the drug response of neural cells. 
 In the last years, the cerebral organoids methodology emerged (Lancaster et 
al., 2013) and, nowadays, there are several groups working on this and making 
efforts to improve the differentiation protocols and further characterize them 
(Camp et al., 2015; Qian et al., 2017; Quadrato et al., 2017). Cerebral organoids 
have proven their utility to study human brain development and developmental 
diseases, as various brain regions are present in those models (Kelava and 
Lancaster, 2017). However, for drug screening applications the differentiation 
protocols need to be further improved in order to generate more homogeneous 
cultures, with low intra-batch and batch-to-batch variations. Furthermore, the 
validity of cerebral organoids to address microenvironment-related questions 
remains uncertain, due to the use of a heterologous matrix (Matrigel) that poorly 
resemble the brain ECM, and that may introduce confounding effects. Taking this 
into consideration, for drug discovery or to study diseases where ECM is involved, 
or has important roles in disease progression, neurospheroids appear as a better 
option. Another alternative are the defined synthetic 3D matrices that are under 
investigation (Ranga et al., 2016) and can be further explored to recapitulate the 





 Importantly, 3D models should not be viewed as platforms to replace animal 
models, but instead as complementary in vitro tools to find more effective drugs 
before going to animal models or to address specific aspects that cannot be 
addressed in animals due to the differences between species. This will reduce the 
number of animals used and the attrition rates observed in drug discovery 
pipelines. It must also be recognized that the utility of 3D cell models need to be 
further explored and thoroughly validated to attain definitive conclusions on their 
physiological relevance and correlation with the in vivo situation. Furthermore, the 
establishment of novel models in drug discovery and drug testing pipelines requires 
extensive validation studies, including evaluation of robustness, specificity and 
reproducibility of the assays. Additional data demonstrating robust in vivo and in 
vitro correlations are needed to enhance confidence and ensure widespread use of 
the 3D models for drug testing in the future. 
 In the future, models would be complex in its morphology while still 
maintaining reproducibility, thus coming closer to the in vivo features. Further 
optimization of the existing models is still required, to recapitulate in the models 
the functional interactions of the three neural cell lineages (neurons, astrocytes 
and oligodendrocytes). Additionally, immune microglia cells should also be 
incorporated in the models, since these contribute directly to brain physiology and 
microenvironment, both in health and pathological conditions. Moreover, 
mimicking the brain vascular networks, and ultimately, the blood brain barrier, will 
not only overcome the oxygen and nutrients/ chemicals supply to the 3D tissue-like 
structures, but also influence the drug response. In this context, 3D models still 
have a lot to evolve until fully replicating the complex in vivo environment, with 
multiple and functional cells types surrounded by the ECM and the vascular 
network, while reproducing organ function, which up to now has been impossible 
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